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Antibody responses to infection with herpes simplex virus (HSV) and
human immunodeficiency virus type 1 (HIV) formed the core of the work
described in this thesis. Several techniques, including some developed
during the course of the work, were used to study the targets of
antibody elicited by infection. In particular, sera from patients
taken around the time of seroconversion for antibody to HSV and HIV
were tested by a range of assays in order to make a critical
comparison of their sensitivities and specificities.
Immunoblotting (IB) and radioimmunoprecipitation (RIP) assays were
used to study sera from patients with primary genital HSV infection of
both types. The tests proved to have different sensitivities in that
the IB assay detected antibody to a tegument protein in the acute
phase sera, although, predominant reactivity with a herpesvirus
glycoprotein, gB, was found in the RIP assay. Furthermore, antibody at
an earlier stage of infection was found in this latter assay. The
discrepancy was investigated by the development of new tests for
antibody. The first was a non-denaturing version of the IB assay.
Despite the methodological similarities between this test and the
conventional IB assay, essentially similar results to the RIP assay
were obtained by this new method. This underlines the importance of
denaturation of antigen in the performance of such tests. However, it
was the poor solubility of capsid proteins and possibly certain
glycoproteins in the non-denaturing detergents used in the modified IB
and RIP assays that prevented the detection of antibody to a wider
range of proteins. A further test, that was not dependent on the
solubilisation and separation of proteins for specificity, was
developed. In this assay, sera competed with monoclonal antibodies for
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the latter's target antigen. Applying this method to the
seroconversion study, antibody to a wide range of proteins was found
in the acute phase sera, including reactivity to several proteins not
detected in either the conventional IB or in the RIP and modified IB
methods.
The performance of the IB assay for antibody to HIV was compared with
that of several commercially available enzyme immunoassays. Although
the results from the different tests were substantially in agreement,
in some patients, antibody at an earlier stage in the seroconversion
was detected by the IB method. Serological assays were also used to
investigate the course of disease in a cohort of haemophiliacs. These
patients had received a single batch of HIV-contaminated clotting
factor, and had become infected. Since the time of exposure was known,
and frequent sera were taken from all of the patients for other
reasons, it was possible to reconstruct the seroconversion events by
retrospective testing. In particular, it was possible to measure the
time to seroconversion, and to estimate the duration of the
antigenaemia that accompanied the primary infection. Follow-up studies
of the same patients were carried out with a view to correlate
serological measurements, such as loss of antibody to core proteins,
and reappearance of antigenaemia, with clinical progression to AIDS,
or AIDS-related complex. Although all of the patients who are unwell
have lost antibody to core proteins, and the majority are
antigenaemic, there remain several patients with similar findings but
who have remained well. Further studies are needed to establish
whether there is a difference in prognosis between these patients and
the other group of well patients who have high levels of antibody to
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The aim of the work described in this thesis was to investigate
serological responses to viral infection. Both herpes simplex virus
(HSV) and human immunodeficiency virus (HIV) cause chronic infections
and have developed different methods for evading the immune system.
HSV exhibits the phenomenon of latency followed by periodic
recrudescence. The site of latent infection by HSV is the cell body of
sensory neurones. Latency of HSV is maintained by poorly understood
regulatory mechanisms that suspend the rapid lytic replicative cycle
of HSV observed in vitro,. During reactivation, HSV exploits the
remarkable morphology of nervous tissue by moving from the cell body
along the axon to infect the site of innervation of the neurone.
Pre-existing immunity, either cell-mediated or humoral, is often
unable to prevent localised infection of the skin and shedding of
virus. Neither specific immunity nor drug treatment with antiviral
agents affect HSV in its latent phase, and this makes medical
treatment of HSV a major challenge.
The method by which HIV infects individuals and persists despite
demonstrable immunological responses is not known. Even more
importantly, it is not known how or why certain individuals progress
to AIDS from the asymptomatic stage. The site of infection of HIV is
not entirely clear; at present it seems probable that there is a
reservoir of infection in macrophages. It has also been suggested that
HIV may be able to exhibit latent infection in such cells. In the
absence of synthesis of viral proteins for long periods, infected
macrophages may avoid immunological destruction and the mobility of
these cells could result in the wide dissemination of HIV infection
throughout the body. It would appear unlikely that a vaccine could
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prevent AIDS from developing in those already infected with the virus,
although it is entirely possible that it could prevent primary
infection. Drug treatment of HIV infection shares similar problems to
that of HSV infection; the currently used drug of choice only affects
HIV during active virus replication, and appears unable to eradicate
infection permanently. ,
Understanding the pathogenesis of infection by these two viruses, and
the relationship they have with the immune system of the infected host
is important for immunisation and medical treatment. Study of this
subject involves clinical, immunological and virological data to build
up a picture of the relationship between the viruses and their host.
A review of this background data is presented in chapters 1 to 4. The
two viruses have been considered separately, although there are many
important parallels and differences between them to make a comparison
interesting. The large amount of previous published work about these
two viruses, in particular, has necessitated a long introduction that
does no more than summarise many of the areas of current research into
the two viruses. Chapters 1 and 3 describe the clinical features of
infection with HSV and HIV respectively, and then proceed with
virological aspects, including the structure and composition of the
two viruses, their replicative cycle and their interaction with the
cells thay infect. Chapter 2 considers the pathogenesis of HSV
infection, and then reviews in detail the immune response to primary
infection, during reactivation, and during experimental immunisation
of experimental animals. Chapter 4 reviews the laboratory markers of
HIV infection and then considers several theories for the causation of
disease.
xi
Chapter 5 outlines preliminary work leading up to the project and the
aims of the proposed work. The section "Development of Methods" has
been included since a significant proportion of the work was
developmental. The "Results" section that follows covers the




HSV causes a spectrum of disease in humans, from clinically inapparent
to fatal conditions. First exposure to HSV leads to primary infection,
so called because it occurs in the absence of any specific immunity
and may be diagnosed by demonstrating a rise in titre of HSV antibody.
Following primary infection, HSV becomes latent in the central nervous
system but may periodically reactivate and lead to shedding of
infectious virus. Such reactivations may be clinically inapparent.
However, localised inflammation and vesicle formation may occur. This
symptomatic reactivation is called a recrudescence. It may be
distinguished from a primary infection, which it may resemble
clinically, by serology. In the case of recrudescences, there is
generally no rise in antibody titre.
The term "herpes" was used originally to describe the cutaneous
manifestations of several diseases, but later was restricted to those
with vesicle formation. As knowledege advanced, firstly the poxviruses
and secondly, varicella-zoster virus were distinguished and described
separately. The detection of neutralising antibodies in patients with
regular recrudescences of HSV caused some confusion historically,
since no other viruses were, at that time, known to show the
phenomenon of latency. The discovery of the site of latency of HSV in
sensory ganglia was established on the basis of results of
experimental inoculation of HSV into animals, in whom involvement of
the central nervous system was more apparent.
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For many years it had been noted that genital HSV isolates differed
from those from oral lesions in cytopathic effect during in vitro
passaging. Schneweis, (1962) first established that the virus
recoverable from genital herpes infections was serologically distinct
from the virus causing oral lesions. The latter was called HSV type 1
(HSV-1), while HSV causing genital infection was called type 2
(HSV-2). HSV-2 infection can occur despite previous exposure to HSV-1.
Such an infection is called an initial infection, to distinguish it
from primary HSV-2 infection that occurs without prior exposure, and
which is generally more severe. The association between the site of
isolation and virus type is not absolute, and, in particular, a
proportion of genital infections are caused by HSV-1. The proportion
varies between studies, and appears to be influenced by patient
selection (Smith et al., 1973; Barton et al., 1982; Nahmias &
Roizman, 1973) .
CLINICAL FEATURES OF HSV INFECTION IN MAN
The primary infection may pass entirely unnoticed, or more commonly
may produce relatively trivial symptoms, and rarely may cause severe
disease and systemic involvement. The recurrent infection is usually
trivial, except in immunosuppressed patients. The most frequent sites
of primary HSV-1 infection are the mouth and lips. Single or crops of
vesicles on the gums, tongue or buccal membranes are observed
(gingivostomatitis). Severity has been shown to be partially dependent
on age. As the prevalence of childhood HSV infection falls, increasing
numbers of older children or young adults are affected and they tend
to have more severe symptoms. Severe infection may begin with a sore
throat, malaise, fever (occasionally rigors), extensive generalised
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lymphadenopathy, especially of the neck and rarely splenomegaly.
Extensive ulceration of the gums, hard palate, soft palate and lips
follows. The lesions are exceptionally painful and severely affected
patients have problems swallowing. Lesions generally resolve within
10-14 days untreated.
Recrudescent HSV-1 infection normally affects the lips, skin around
the mouth and around the nose. Recurrent gingivostomatitis is rare.
Approximately a third of patients with evidence of past primary
infection suffer from regular recrudescences. These are often
associated with prior stimuli such as sunlight, emotional upset or
fever. Recrudescences may be preceded by prodromal symptoms such as
tingling, itching or hyperesthesia. Each episode tends to occur in
the same site. The average duration of lesions is around 10 days,
although there may be secondary infection with Staphylococcus aureus
which prolongs the resolution period. Healing is normally complete
with no scarring, since only the superficial layers of the epidermis
are involved. The time between recrudescences tends to increase with
age. In some patients, there may be trigeminal neuralgia, and in
others, progressive hypoaesthesia may occur at the site of the
recrudescence.
Herpetic whitlow is an infection of the fingers caused by HSV. It is
an occupational hazard of dentists and nurses, and tends to occur in
those without prior exposure to HSV. Infection rarely occurs through
intact skin. Primary infection in patients with eczema may be very
much more severe, particularly if they are on concurrent steroid
treatment. Spread of the virus is not effectively checked and there
may be generalised lesions, particularly where the eczema is severe.
Systemic symptoms, such as generalised lymphadenopathy, fever, rigors,
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splenomegaly and hepatomegaly occur to varying degrees. Recurrent
infection may also lead to widespread lesions, but systemic symptoms
are less severe or absent. Severe systemic illness due to HSV occurs
in immunosuppressed patients, in whom common sites of infection are
the lungs and the liver. HSV pneumonia resembles that of other
"atypical" virus lung infections, with marked consolidation. Liver
infection may lead to transient elevation of aspartate transaminase
and alkaline phosphatase levels, but jaundice is rare. Systemic
involvement is thought to occur to a lesser extent in many
immunologically normal patients with primary infection.
Primary infections of the eye are normally unilateral, giving rise to
a follicular conjunctivitis. There may be regional lymphadenopathy and
associated swelling of the eye. Resolution is relatively
rapid (3-5 days), although patients may be left with
corneal opacities from epithelial thickening. Recrudescent lesions are
modified by prior immunity to HSV and follicular lesions are rarely
seen. Instead, there may be dendritic ulceration of the cornea.
Steroid treatment exacerbates the severity of the lesions. Frequent
recrudescence may lead to progressive blindness.
HSV-1 may rarely cause a severe form of encephalitis. It is normally
associated with primary infection; a history of recrudescence makes
the diagnosis less likely. Headaches, personality change, and possibly
fits rapidly followed by neck rigidity, vomiting and neurological
deficits are signs suggestive of HSV encephalitis. Cerebral oedema
precludes the routine testing of cerebrospinal fluid, but when done,
shows normal glucose, raised protein and increased leucocytes,
features typical of viral menigitis and encephalitis. Diagnosis was a
primary concern in the managment of patients with suspected HSV
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encephalitis when treatment with cytotoxic drugs was all that was
available. With the advent of Acyclovir, a relatively non-toxic drug
with marked efficacy against HSV, a case could be made for blind
Acyclovir treatment for all patients with suspected viral
encephalitis. The drug is very safe and its rapid use may reduce the
risks associated with delayed treatment while the diagnosis is
established by virus isolation from brain biopsy. The current poor
prognosis (45% survival) may be confidently expected to improve with
Acyclovir treatment.
Genital infection is closely associated with HSV-2 rather than HSV-1.
It is generally transmitted by sexual intercourse. In the male, there
are cutaneous lesions on the glans, in the coronal sulcus and on the
shaft of the penis. Primary infection is normally accompanied by
systemic symptoms and lesions at other sites of the body. In the
female, there is often extensive and painful infection of the labia
and vagina. Central nervous system involvement is more common in HSV-2
infection and may manifest itself as a transient aseptic meningitis.
This is a benign and self-limiting condition, diagnosed by findings of
raised white cells in the CSF. HSV-2 has rarely been isolated from
meninges or CSF in this condition.
Recrudescent genital infection with HSV-2 is common, although the
frequency and severity declines with time. Recurrence of HSV-1 genital
infections is generally considered to be less frequent than HSV-2. The
severity of genital primary and recrudescent infections may be
sufficient to warrant treatment with Acyclovir. HSV infection may be
acquired by a neonate on vaginal delivery during maternal primary or
recrudescent infection. The prognosis of neonatal HSV infection is
extremely poor, with up to 70% mortality; neurological damage is found
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in a proportion of the survivors. Neonates are commonly unable to
prevent spread of HSV and succumb to generalised disease involving
many organs of the body. Caesarian section is advocated for mothers at
term with evidence of genital infection. Two factors make primary maternaL
infection more serious than recrudescence. Firstly, the lesions are
generally more widespread and infectious during primary infection.
Secondly, the neonate will have acquired HSV antibody from a mother
with recrudescent disease, and there is evidence that such antibody
may be protective.
Patients with impaired immunity are more susceptible to complications
arising from HSV infection. In particular, patients on long term
immunosuppressive treatment following heart, bone marrow and renal
transplants, and patients with advanced AIDS appear to be particularly
at risk from fatal, overwhelming HSV infection. Data on the stimuli
that lead to recrudescence and the increased severity of disease in
newborn and immunosuppressed patients point to a central role for
immunity in the pathogenesis of HSV infection. Normal immune reponses
appear to be necessary for the maintenance of latency, and
recrudescence in a proportion of patients, can be regarded as a
transient failure to contain the disease.
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BIOLOGY OF HSV
Herpesviruses have been isolated from a wide range of vertebrate and
invertebrate species of animals, as well as from yeasts and fungi.
There are at least six distinct human herpesviruses; In addition to
the familiar HSV types 1 and 2, varicella-zoster virus (VZV), human
cytomegalovirus (HCMV) and Epstein-Barr virus (EBV), human
B-lymphotropic virus (HBLV) has been recently discovered (Salahuddin
et al., (1986) and partially characterised. (Josephs et al., 1986).
Features found in all herpesviruses are a linear double stranded
genome consisting of DNA with molecular weights (MWs) ranging from 80
to 160 million daltons; an icosahedral nucleocapsid comprising 162
capsomeres; and a membranous envelope that is acquired on budding
through the nuclear membrane of the infected cell. Herpesviruses,
particularly human herpesviruses, are the most intensively studied of
all virus groups. Reasons for this include the implication of certain
herpesviruses in oncogenesis, the ease with which most herpesviruses
may be isolated and passaged in vitro , the phenomenon of latency
exhibited by many members of the group and finally the desire to
prevent the wide spectrum of medical and veterinary illnesses that
they cause.
STRUCTURE OF THE HERPES SIMPLEX VIRUS GENOME
HSV is a double stranded DNA virus of relatively large size and
functional complexity. The genome of HSV is linear and has a total
length of approximately 150 000 base pairs. HSV is classified as an
alpha herpesvirus, the criteria being broad host range, short
repoductive cycle, rapid spread in tissue culture, destruction of
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infected cells and the establishment of latency in neurones in sensory
ganglia (Matthews, 1982). Beta herpesviruses, typified by CMV, have a
restricted host range in vitro , long reproductive cycle and
syncytial, formation. Gamma herpesviruses, whose prototype is EBV, are
characterised by growth in lymphoblastoid cells, and a slow and
sometimes arrested growth cycle.
The genome of HSV can be described as comprising two covalently linked
segements, the long and short (figure 1). The ends of the two
components are flanked by two types of repeated sequence (Hayward et
al., 1975; Delius & Clement, 1976). To distinguish the these regions,
the following nomenclature has been adopted. The UL and Us regions are
the unique regions of the long and short segements respectively. TRL
and IRl refer to the terminal and inverted (internal) repeats found at
the ends of the long segment, and TRS and IRS are those of the short
segment. The b region is found in TRL and IRU at the two ends of the
long segment; the sequence of bases being inverted relative to each
other. Likewise the short segment is flanked by inverted repeats of
the c regions. These two regions are coding; thus while most
proteins have only one gene, those proteins coded for within the b
or c regions have two gene copies (diploid). Beyond the b and c
regions, at the extreme ends of the genome and in the joint region
between the long and short regions is the a region. This is a
non-coding, heterogeneous sequence of DNA which varies greatly between
HSV-1 and HSV-2 and even between strains of HSV-1 (intertypic and
intratypic variation (Wagner & Summers, 1978). The a sequences at
the ends of the genome have the same orientation, while the a
sequence in the joint region is inverted relative to the other two.
The a sequence at the end of the long sequence may have a variable
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This variation is strain dependent, although the number of copies of
the a sequence in the two areas is not related. The ends of the a
regions themselves have very short (20 base pair) inverted repeats.
Isomerisation is a term to describe the variable orientation of both
UL and Us, the unique long and short regions. For each of the two
orientations of the long segment, there are two possible orientations
of the short segment, making 4 isomers altogether. There is currently
no evidence that there is any biological preference for any of the
possible isomers either in vivo or in vitro (Davison & Wilkie,
1983). Populations of wild type HSV appear to contain equal numbers of
each of the four isomers. The length of restriction enzyme fragments
that straddle the junction between unique and reiterated sequences
depends on the orientation of the unique segments. This accounts for
the previous observation of so-called half-molar and quarter-molar
fragments on restriction enzyme analysis of HSV (Wilkie, 1976; Hayward
et al. , 1975; Skare & Summers, 1977 ).
The significance of the internal repeats in the jcjint region is
unclear. It is an evolutionarily conserved feature of many
herpesviruses and is obviously involved at a fundamental level in the
mechanism by which herpesviruses replicate. The ab and the ac
regions undoubtedly provide sites for recombination, and this would
provide a mechanism by which all four isomers could be produced.
Whether recombination is responsible for isomerisation remains an open
question. A notable feature of herpesviruses is the very wide range in
the G+C content of the genomes; there is some correlation between G+C
content and the alpha, beta and gamma groupings of herpesviruses.
Typically, alpha herpesviruses such as HSV have avery high G+C
content, while the gamma herpesviruses such as EBV have a low content,
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around 35 to 50%. Furthermore, the repeated regions in the genome of
HSV and other herpesviruses consistently have a 10-20% higher G+C
content than the unique regions. The average G+C content of HSV-1 is
67% and HSV-2 is 69%, and the content in the repeated regions may be
85% or more. This is beyond the limit at which coding can be preserved
by nucleotide substitution. The implications and possible reasons for
this are discussed in Honess, (1984).
MORPHOLOGY
In its extracellular form, HSV has four distinct morphological
elements. 1) an electron-opaque core, 2) an icosahedral capsid, 3) an
amorphous tegument surrounding the core, and 4) a lipid envelope
encircling all of the other elements. Viral DNA is found in the core,
and is responsible for the electron-opacity. The DNA has a toroidal
shape and surrounds a spindle of electron-dense material, probably
protein (Furlong et al., 1974). The diameter of the capsid is
approximately 100 nm, and it has a precise geometric structure
containing a fixed number of five- and six-sided elements arranged
similarly to many virus groups (Wildy & Watson, 1963). The tegument is
a poorly defined and variable structural feature of HSV. There appears
to be fibrous material in this area which may be involved in
attachment of the capsid to the outer envelope. The thickness of the
tegument layer appears to be at least partially dependent on the cell
line in which the virus is grown (McCombs et al., 1971). The outer
envelope consists of a typical cellular lipid bilayer, as it is
acquired when the formed capsid buds through nuclear, cytoplasmic or
vesicular membranes on egress from the cell. In common with cellular
membranes, the envelope is sensitive to ether and detergents, a factor
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that makes HSV very susceptible to inactivation experimentally (Spear
& Roizman, 1972). Embedded in the envelope are a number of
virally-coded glycoproteins that are the sites of antibody-mediated
neutralisation and major antigenic determinants of the virus. HSV-1
and HSV-2, the two serotypes, are indistinguishable morphologically.
THE STRUCTURAL PROTEINS OF HSV
It has been variously estimated that the extracellular form of HSV has
between 15 and 33 different polypeptides (reviewed in Spear & Roizman,
1980). Difficulties encountered when attempting to estimate the number
arise from 1) the limited resolution that can be achieved by
conventional methods of protein analysis; 2) different abundances of
the various proteins so that minor species may be obscured; 3)
contamination of purified virus by non-structural, or even cellular
proteins and 4) the presence of precursor and mature forms of proteins
with differing mobilities in the virion. The normal method of analysis
of HSV is separation of proteins on a size basis by polyacrylamide gel
electrophoresis (PAGE); resolution may be improved by 2-dimensional
gel electrophoresis, where separation in the second dimension is by
pKa on an ampholine gradient. Even more protein species may be
detected when this method is used to analyse HSV. Partially
glycosylated forms of glycoproteins are always present in HSV virions,
and this causes some glycoproteins to appear as more than one band,
thus complicating the analysis. There is surprisingly little knowledge
about the composition of the capsid and the tegument, mainly because
of their insolublility in detergents used to disaggregate the virus
prior to analysis. The nomenclature for herpes proteins is based on
three main systems. The first one is a numerical system in which the
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bands that appear on PAGE analysis of HSV virions are numbered VP1 to
VP24, with VP1 being the heaviest and VP24 being the lightest (Spear &
Roizman, 1972). The second system is similar except that radiolabelled
cell-lysate is used instead, in order that some of the non-structural
proteins of HSV may be identified. The problems mentioned above have
diminished the usefulness of both schemes. Newly discovered proteins
needed a number and a suffix to distinguish them from their
neighbours; proteins with precursor forms have been assigned more than
one number; and finally, neither system gives information about
homologies that exist between HSV-1 and -2 proteins. The third system,
used for identifying glycoproteins, is very much more useful, since it
attempts to give one alphabetic designation to each of the
glycoproteins, with a prefix followed by the same letter for precursor
forms. The same letters are used for homologous HSV-1 and -2 proteins,
regardless of any difference in apparent MW between them. A policy of
renaming glycoproteins has been adopted as precursor forms are
identified (eg. gA to pgB) and as new homologies are detected (eg. gF
to gC-2).
The capsid contains at least four proteins, of which the most abundant
species is VP5, commonly called the major capsid protein (MCP) with
about 800-1000 .copies/capsid (Gibson & Roizman, 1972). Full HSV-1
capsids, ie. those containing DNA, appear to contain an extra protein,
VP21 (Gibson & Roizman, 1974). An early report also described the
association of another protein, variously described as VP22, ICP35,
ICP37, ICP35 a-f, the 35 family, or p40, with full, but not empty
capsids (Braun et al., 1984). However, recent work has discounted
this association, and localises p40 in the tegument and not the capsid
(Rixon et al., 1986). It is possible that there are several other
tegument proteins, but they are normally so identified on the negative
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grounds that they are found in purified virus, but not in capsid or in
the envelope. Very little is known about the arrangement and function
of these proteins, although presumably some may have roles in the
attachment of the envelope to the capsid, in packaging of DNA and in
release of viral DNA on infection of the cell (see below).
HSV GLYCOPROTEINS
The glycoproteins encoded by HSV are found in the viral envelope and
have roles in the extracellular phase of the life cycle of HSV. In
order to review the properties of the various glycoproteins, the
following account will pay attention to the position of the gene
encoding each glycoprotein in the HSV genome; its relation to other
genes; the predicted size and structure of the translation product;
glycosylation, and any properties that this may confer; homologies
between equivalent HSV 1 and 2 glycoproteins and with other
herpesviruses, and finally the functions attributable to each
glycoprotein.
GLYCOPROTEIN B
Glycoprotein B is a major constituent of the viral envelope with a
clearly defined role in attachment and penetration of the virus into
the cell (see below). The gene encoding this protein is found in the
region of the genome at 0.37 map units. gB of both HSV 1 and HSV 2
has been sequenced (Bzik et al., 1984; Bzik et al., 1986); overall
there is a high degree of nucleotide sequence homology (85%). Most of
the changes are conservative, occuring at the third nucleotide of the
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codon, and do not affect the final amino acid sequence (synonymous
changes). The amino acid sequence can be predicted to produce a
protein with typical internal, transmembrane and external portions.
There are potentially 9 sites for N-linked oligosaccharide addition.
Comparison of the outer portions of gB-1 and gB-2 indicates the
presence of predominantly type-common potential antibody binding
sites, although minor differences in secondary structure indicate the
possibility of type-specific epitopes. The two proteins cross-react
extensively in serological assays, as do the vast majority of gB
monoclonals so far produced. Of all the herpes proteins, this is the
most conserved, with extensive homologies with those of VZV and bovine
mammilitis virus, both alpha viruses, and with more distant homology
with equivalent proteins of HCMV and EBV (Davison & Scott, 1986;
Pellett et al., 1985). The genes for these homologous proteins lie in
equivalent areas of the genome of the other herpesviruses.
Furthermore, the proteins in other herpesviruses appear to play the
same functional role in attachment and fusion. It is noteworthy that
the two other glycoproteins encoded by the U,_ region (gH-1 and gC)
also have EBV and other herpesvirus homologies, while no homologies
are found between EBV and any of the HSV glycoproteins encoded by the
Us region. It has been shown that antibody to HSV gB cross-reacts with
those of. equivalent proteins of other herpesviruses. This can be
demonstrated unequivocally with bovine mammilitis virus, VZV and other
alphaviruses, (Snowden & Halliburton, 1985; Snowden et al., 1985) but
the evidence for reactivity with EBV and HCMV is less convincing and
requires confirmation (Balachandran et al., 1987).
The predicted MW of gB from the sequence data is lOOKDa.
Experimentally, the MW is found to be around 118KDa, although there
are several bands around this area corresponding to precursor
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(intermediate stages of glycosylation) forms with slightly differing
MWs (Spear, 1976). The apparent MW of gB in HSV infected
ricin-resistant (hence lacking in O-linked glycosylation) CL6 cells is
increased; this indicates that there are O-linked as well as N-linked
oligosaccharides in this protein (Johnson & Spear, 1983). SDS-PAGE in
milder, non-reducing conditions reveals the existence of higher MW
forms of gB,- probably the result of dimer formation (Snowden &
Halliburton, 1985).
GLYCOPROTEIN C
Glycoprotein C of HSV 1 and 2 are encoded in the U,_ region at position
0.63. Both genes have been sequenced and have been shown to share 64%
nucleotide homology. (Frink et al., 1983; Swain et al., 1985). V2V
has a homologous gene sequence, but with no recognised translation
product (Davison & Scott, 1986). The predicted MWs of gC-1 and -2 are
55 and 51 KDa respectively. gC-1 has precursor forms of 85 and 110 KDa
while the mature form of gC-1 is 130 KDa. The MW of gC-2 (formerly
called gF) is 75KDa (via 66 and 68 KDa precursors; Spear, 1976).
Endo-^-N-acetylglucosaminidase treatment of gC-2 removes all
glycosylation, and results in a protein of MW 54 KDa, a good agreement
with the sequence data. The large discrepancy between the predicted
and observed MWs of gC-1 reflects its very high carbohydrate content,
with at least 30KDa of sugars attached via 9 N-linked sites and
extensive addition of O-linked oligosaccharides (Wenske & Courtney,
1983). gC-1 differs from gC-2 in having affinity for the Helix
pomatia lectin (HPA), via an N-acetylgalactosamine residue (Olofsson
et al. , 1981). HSV-1 grown in the presence of tunicamycin, which
prevents N-linked glycosylation, produces gC with an apparent MW of
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lOOKDa. This protein retains its binding ability with HPA but differs
in antigenicity and other properties from the native form. It appears
that gC-1 has two main antibody binding sites. Site I is found in a
part of the protein with relatively little glycosylation, and is most
likely to be of a peptide nature. Site II is found in the most heavily
glycosylated part of the protein and is extremely sensitive to
sialidase-periodate treatment, a process that removes terminal
monosaccharides from oligosaccharides (Sjoeblom et al., 1987). By a
totally different method, (investigation of the sites of
neutralisation of gC monoclonals), Marlin et al., (1985) also found
that there were two distinct antigenic sites.
There is little cross-reactivity serologically between gC-1 and gC-2,
and this is probably because gC-2 lacks the immunodominant
carbohydrate antigenic area of gC-1. gC-1 has been used as antigen in
several type-specific assays in the past, although there was a degree
of misunderstanding about the nature of gC-1 and its relationship to
the glycoproteins of HSV-2. Suchanova et al., (1984) used lectin from
helix pomatia in columns to purify both HSV-1 and HSV-2 proteins
with lectin binding properties. This proceedure purified gC-1 and was
correctly identified. A HSV-2 protein of MW 130 KDa also showed an
affinity for HPA and was assumed to be the HSV-2 counterpart of gC-1.
It was originally called gC-2, whereas, in fact, the true counterpart
did not bind to HPA and was then lurking under the name of gF. gC-1
and "gC-2" were used as antigens in a serological assay to determine
type-specific antibodies in human sera in order to obtain
epidemiological data about past exposure to the two viruses. "gC-2"
was apparently type-specific while gC-1 showed some cross-reactivity.
This data was very hard to interpret and the investigators concluded
erroneously that HPA-purified gC-1 contained minor quantities of
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contaminating cross-reactive proteins. Svennerholm et al. , (1984)
used a similar assay system, and also found cross-reactivity. Attempts
by other investigators to use gC-1 presumably failed for similar
reasons. One feature of the carbohydrate antigen of gC-1 is that it is
only present on the fully processed form of the protein. The
antigenicity of immature gC-1 is presumably dominated by the site I
area, which would, in view of the peptide sequence similarity, be
expected to be partially cross-reactive. "gC-2" was later shown to be
unrelated to gC-1 and was renamed gG. Unlike gC-1, this protein
appears to be entirely type-specific, although a comparable reading
frame was found in HSV-1 and a translation product (gG-1) subsequently
identified (see below).
gC-1, but not gC-2 appears to have C3b binding activity (Friedman et
al. , 1984), although the activity is not related to the higher
carbohydrate content of gC-1. The functional significance of the
activity is not known, although there has been extensive investigation
of this and other possible roles of gC in vitro and in vivo . HSV
deficient in gC production can be readily selected for by in vitro
culture in the presence of gC-specific monoclonals (Marlin et al.,
1985). Such mutants may also arise spontaneously on extensive
passaging. Deficient strains grow rapidly in culture, and several
investigators have found that they have normal pathogenicity in
experimental animals (Johnson et al., 1986). The conclusion to be
drawn from such work is that gC does not play an essential role in HSV
infectivity. However, given that spontaneous mutants deficient in gC
production may arise in vitro , it is a little surprising that no
such mutants have ever been isolated from patients. Another criticsm
of the above conclusion is that it is possible that the function of gC
may be duplicated elsewhere in the genome. Sequence data has indicated
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that there is a gene clearly homologous to that of gC immediately
downstream in the UL region which may have originated by tandem
duplication (Harsden et al., 1987). HSV may therefore be diploid for
the function of gC.
GLYCOPROTEIN D
Glycoprotein D is produced by both HSV 1 and 2 and they are homologous
in sequence, antigenicity and function. The overall nucleotide
homology is 82% (Watson et al., 1982; Watson, 1983), similar to that
between gB-1 and -2. The gene for gD lies in the Us region and has
been called US6, a nomenclature based on numbering the open reading
frames (ORFs) found on sequencing the Us region of HSV 1 (McGeoch et
al., 1985). gD shows no homologies with proteins encoded by other
herpesviruses. In view of the unrelatedness of the Ug of HSV and EBV
and other non-neurotropic viruses, this is not surprising. However,
the Us of VZV, while largely colinear with that of HSV, has 6 rather
than 12 ORF's, and US6 is one of the absent genes. The predicted MW of
gD-1 and -2 is 43 KDa, and both proteins have three potential sites on
the exterior part of the protein for N-linked glycosylation. The
observed MW of gD.of both serotypes is around 59 KDa (Spear, 1976),
and both N-linked and O-linked glycosylation has been demonstrated
(Johnson & Spear, 1983).
gD-1 and -2 cross-react serologically, although there is evidence for
the presence type-specific as well as type-common epitopes. The
protein has been shown to play an essential role in both the
attachment and entry of the virus into the cell (see below).
Antibodies to gD are readily neutralising, and this protein is
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currently a strong candidate for a sub-unit vaccine against HSV
infection. As a result, there have been numerous studies of its
antigenic determinants, with distinctions made between conformational
(resulting from tertiary and quaternary structure, and denaturation
sensitive) and linear (secondary; denaturation resistant) epitopes
(Eisenberg et al., 1985b; Dietzschold et al., 1984). Sites I, III,
IV and VI are conformational epitopes which have been mapped to
distinct areas of the external part of the protein. The localisation
of this type of epitope was not exact, and there was evidence of
cross-reactivity between these four epitopes. This suggests that the
four areas are closely associated, despite the number of residues
separating them. It is possible to build models of the quarternary
structure of gD from this type of data. Several epitopes were linear;
monoclonals reactive with these epitopes also reacted with synthetic
oligopeptides of 10 to 20 amino acids in the same sequence. In
contrast to conformational epitopes, linear epitopes were well
localised. Single amino acid changes in a linear epitope abolished the
reactivity of monoclonals. Where there was intertypic variation
between gD-1 and gD-2 in a linear epitope, single amino acid
substitutions could convert the epitope from HSV-1 to HSV-2
specificity and vice versa (Dietzschold, 1984).
GLYCOPROTEIN E
This protein is encoded by the Us region. The HSV-1 gene has been
identified as US8 and would produce a protein of 59 KDa on translation
(McGeoch et al., 1985). The protein would be predicted to have a
typical membrane protein structure and two sites of N-linked
glycosylation on the external portion of the protein. Sequence data
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from the HSV-2 equivalent is not available although a homologous
protein has been previously reported (Cassai et al., 1975). There is
sequence homology between US8 and an equivalent VZV gene potentially
encoding a hitherto undetected 70 KDa protein (Davison & Scott, 1986).
Like the other HSV glycoproteins, gE is processed extensively after
translation. In addition to N- and 0- linked glycosylation, there is
evidence for extensive sulphation. gE differs from the other HSV
glycoproteins in also being modified by the addition of fatty acids,
as shown by pulse labelling with tritiated palmitate, a fatty acid
residue. The modification was found to take place in the golgi
apparatus and occured after N-linked glycosylation but before 0-linked
glycosylation (Johnson & Spear, 1983). This is further evidence for
the multi-stage modifications of HSV glycoproteins; this has
consequences for theories of egress of the HSV virion from the cell.
gE of HSV-1 has been found to have affinity for the Fc portion of
immunoglobulin G (IgG; Baucke & Spear, 1979). gE was shown to be
unnecessary for HSV growth in tissue culture, since a mutant that
failed to produce several proteins, including gE was able to grow in a
variety of cell lines (Longnecker & Roizman, 1986). This experiment is
unlikely to have any relevance for the in vivo role of gE. If Fc
binding is the role of gE, than in vitro passaging in the absence of
antibody is unlikely to demonstrate it. gE has been shown to play some
role in virus attachment to cells (see below). Baucke & Spear (1979)
used IgG columns to purify gE from a detergent lysate of radiolabelled
HSV-1 proteins prior to analysis. However, a recent report has shown
that there is a second HSV protein with Fc binding properties. This
protein could co-purify with gE-1 (Johnson & Feenstra, 1987), so the
original studies may have to be reinterpreted. Notwithstanding this,
the original report identified three distinct polypetides of MWs in
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the range from 65 to 80 KDa. Partial proteolysis of these fragments
indicated to the investigators that the three species were related,
and it was assumed that the extra bands were precursors, yet with Fc
binding activity. Johnson & Feenstra, (1987) showed that one of the
bands (of MW 70 KDa) had distinct partial proteolysis profiles from
the other two, and presented evidence that the so-named g70 complexed
with gE-1 and that both gE-1 and g70 were required for Fc binding. No
HSV-2 counterpart for g70 was found in these experiments, and it is
possible that gE-2 may bind to Fc without the need to be complexed to
another protein.
The gene for g70 was mapped in the Us, close to the gene for gE-1 by
intratypic recombinants. However this data is preliminary, and it is
not impossible that g70 may in fact prove to be a cellular protein.
g70 was shown to have an unglycosylated MW of 56 KDa. Looking at the
% sequence of HSV-1, there are two ORF'S encoding what would appear
to be so far undiscovered glycoproteins. US5 encodes a protein of 9K,
with a transmembrane region and one external site of glycosylation.
The authors have reservations about the existence of this gene, and it
is too small to correspond to g70. US7 potentially encodes a protein
of MW 41 KDa in its unprocessed form. Lee et al., (1982) transcribed
an mRNA from this gene and translated it in vitro (non-glycosylated)
to a 55 KDa protein. This measurement was made by SDS-PAGE and the
discrepancy could be attributed to its high proline content. It is
therefore entirely possible that US7 does encode g70. The US7 gene has
no homologies with any other HSV-1 gene in the Us segment, thus
discounting the possibility that it represents a tandem repeat of the
gE gene, hence encoding a protein with similar properties to gE. There
is clear homology, however, between US7 and a VZV gene encoding a
hitherto undescribed 39 KDa protein. A report in press (Longnecker et
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al., 1987) will present data on the characterisation of the gene
product of US7, that they have named gl. Whether it is the same as g70
or not should shortly be revealed.
GLYCOPROTEIN G
Glycoprotein G of HSV-1 and HSV-2 are distinct proteins with very
limited homology between them. Until the availabililty of sequence
data there was no indication that they were related to each other,
since they are of different size and there is no detectable
serological cross-reactivity between them. gG-2 has a mature MW of 130
KDa in certain gel systems and was originally been named gC-2 (see
above) on this basis (Spear, 1976). The gene for gG-2 lies in the Us
region and encodes a protein of MW 72 KDa in its unprocessed form
(McGeoch et al., 1987). There is no VZV or EBV counterpart to this
protein. US4 in the region of HSV-1 occupies an analogous place to
the gene for gG-2, but encodes a much shorter protein, with homology
confined to the internal carboxy terminus (McGeoch et al., 1985).
There are only 4 sites for N-linked glycosylation on the external part
of gG-2, but- there is much evidence for extensive 0-linkage.
Serafini-Cessi et al., (1985) showed gG-2 to have more 0-linked
oligosaccharides than any other HSV specified glycoprotein, including
gC-1. As may be predicted, gG-2 has affinity for lectin from helix
pomatia . gG-2 differs from other proteins in other aspects of its
post-translational modifications. Several investigators have detected
a proteolytic cleavage step on processing (Balachandran &
Hutt-Fletcher, 1985; Su et al., 1987) The most recent paper traced
the processing of gG-2 from initial translation through a 104 KDa high
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mannose intermediate form processed on the rough endoplasmic
reticulum. Following this, the protein was cleaved into two fragment
of size 31 and 72 KDa. Further processing by addition of O-linked
oligosaccharides in the golgi apparatus converted the two fragments to
proteins of 34 and 108 KDa respectively. The larger fragment is
derived from the carboxy terminus and is incorporated into the mature
virion. The smaller fragment is water soluble and apparently secreted
into the tissue culture medium.
The mature form of gG-2 migrates anomalously on SDS-PAGE due to its
high glycosylation. The use of gG-2 specific monoclonals led to
agreement that the g92K protein of Marsden et al., 1984, the 124K
protein, named gG, of Roizman et al., (1984) and the lectin binding
130 KDa protein of Suchanova et al., (1984), Svennerholm et al.,
(1984) and Olofsson et al., (1986) were one and the same protein.
gG-1 remained undiscovered until the advent of specific monoclonals
and sequence data of the Us region, since it co-migrates with gD-1.
Richman et al., (1986) described the properties of an HSV-1 protein
reactive with monoclonal antibody LP10. Although originally thought to
be gD-1, the protein was found to label less efficiently with
methionine than gD, to be less sensitive to tunicamycin and to map to
a separate place in the Us region. Frame et al., (1986) produced an
oligopeptide corresponding to a region of the US4 gene and used it to
immunise a rabbit. The antiserum reacted with 56, 48 and 37 KDa
glycosylated proteins of HSV-1. An antiserum prepared from an
oligopeptide (McGeoch et al., 1987), corresponding to an
area of homology between US4 and gG-2 genes, was found to be reactive
not only with gG-2, but also with the same HSV-1 glycoprotein as
described by Frame et al., (1986). It was then possible to name the
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product of US4 as gG-1. US4 is much shorter than the gene for gG-2,
encoding a protein of only 25 KDa. The external part of the protein
has three N-linked glycosylation sites, and there is no evidence that
it has affinity for helix pomatia lectin. Comparison of the CJS4 gene
with the neighbouring US6 gene encoding gD-1, has shown some sequence
homology, and it is postulated that the two genes may have arisen by
tandem duplication. No data has yet been published on possible
homologies between gG-2 and gD-2. There are no VZV or EBV homologues
to gG.
No role has been ascribed to either gG-1 or gG-2, although data on
pathogenicity in animals or man of gG deficient mutants is lacking. On
a speculative note, it is interesting that both HSV-1 and -2 have
proteins with extensive O-linked glycosylation and affinity for
certain lectins. Since different proteins are involved, it is possible
that there has been convergent evolution towards some essential
function conferred by this type of processing. Theories about the
origin of the two distinct types of HSV predict that there might be a
selective advantage for HSV-2 to develop a type-specific
immunodominant protein to circumvent pre-existing immunity to
reinfection by HSV-1.
GLYCOPROTEIN H
This recently discovered protein has so far only been found in HSV-1.
It is present in relatively smaller amounts than the other
glycoproteins and required the use of a specific monoclonal for its
detection. Showalter et al., (1981) first described a 110 KDa
protein, distinct from other HSV proteins reactive with monoclonal
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52D. Buckmaster et al. , (1984) described a similar protein reactive
with LP11. Subsequently the gene encoding the proteins has been found
at 0.3 map units in the UL region of the HSV-1 genome (McGeoch &
Davidson, 1986; Gompels & Minson, 1986). The gene codes for a protein
of MW 90 KDa with a predicted high arginine and proline content, 7
potential N-linked glycosylation sites, typical transmembrane
hydrophobic areas and external hydrophilic loops corresponding to
antibody binding domains. Little is known about its post-translational
processing. The gene has homologies with EBV and VZV genes, in both
cases situated in corresponding positions in the UL segment and in the
same relationship to neighbouring thymidine kinase genes.
Monoclonals reactive with gH-1 have been shown to have neutralising
activity and to be able to block attachment of HSV to cell membranes.
Whereas LP11 (anti-gH-1) inhibits plaque formation when added to
tissue culture cells infected with HSV, neutralising monoclonal
antibodies aginst gB and gD do not do so to the same extent. On this
basis, Buckmaster et al., 1984 and Gompels & Minson (1986) have
postulated a role for gH-1 in maturation and exit functions (see
below).
OTHER GLYCOPROTEINS
gY is a further HSV glycoprotein, but it is not readily detectable by
conventional methods of protein analysis. Some evidence for the
existence of gY was presented in work described by Palfreyman et al.,
(1983), that used 2-dimensional electrophoresis to identify a
glycoprotein that comigrated with gC-1 on the basis of molecular
weight, but could be differentiated from it on the basis of charge.
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This paper also showed the existence of several proteins of MW 50-65
KDa that also were not identified. Marsden et al. , (1987), in a
report to be published, will present data that maps gY to a similar
place in the genome as gC-1.
In the search for further HSV glycoproteins in the UL region of the
genome, the sequence data from VZV (Davison & Scott, 1987) may be of
some use in view of the extensive homologies between the two viruses.
It appears that the prototype orientation of the published VZV
sequence is opposite to the conventional orientation used in
illustrations of the genomic arrangement of HSV (including figure 1).
Surprisingly, a total of 7 potential glycoproteins are found in the UL
region of VZV (UL 5, 14, 15, 31, 37, 39 and 50). Three have clear
homologies: gB with UL31; gH-1 with UL37 and gC with UL14; the rest
are uncharacterised in both VZV and HSV. It is possible that, after
extensive rearrangement of the genome, some of the missing Us genes
encoding VZV glycoproteins have been relocated in the Uu region.
However, a gene adjacent to UL15 (homologous to gC-1) in the VZV
genome (UL16) codes for a glycoprotein. Perhaps this is the homologue
of gY, in view of the recombination data of Marsden et al., (1987)
suggesting the close proximity of the two genes.
A broad area of HSV research, not discussed previously, concerns the
mapping of genes responsible for the syncytial phenotype in vitro .
On the assumption that mutants defective in normal glycoprotein
production may induce syncytium fprmation, mapping of the defects may
help to localise further glycoproteins. There are 8 loci involved in
the syncytial phenotype (reviewed by Spear, 1985; see figure 1). Loci
3, 7 and 6/8 map within the genes encoding gB, gD and gH-1
respectively. Locus 1 maps within a gene encoding what would appear to
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be a glycoprotein, with typical internal and external hydrophilic
regions and a hydrophobic anchor region (Debroy et al. , 1985).
Interestingly, this gene has a homologue in the VZV genome (UL5), also
predicted to encode a glycoprotein, but so far uncharacterised. gC-1
deficient mutants commonly induce syncytium formation but the critical
site of the mutation appears to lie to one side of the gC-1 gene
(Honess et al., 1980). This is further evidence that localises the
position of gY.
There is recent evidence for intermolecular associations between the
glycoproteins. By electronmicroscopy after immunogold labelling of the
different glycoproteins, gB was found to be the main component of long
thick spikes protruding from the envelope (Stannard et al., 1987). It
is probable that these are the spikes observed previously by
conventional staining methods (Wildy & Watson, 1963). gC was
associated with thinner shorter spikes. Future studies that link this
structural observation with individual functions could provide
information about the attachment of HSV to cellular membranes.
PROCESS OF INFECTION
Much of the evidence in the following section comes comes from
ultramicroscopic observations of cultured cells infected with HSV in
vitro . Typically, cells are fixed, stained, and examined by
electron-microscopy. As well as introducing a number of possible
artefacts, the method is also open to the criticism that the infected
cells may not parallel the infection in vivo . Caution is required in
generalising EM findings to the in vivo situation.
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VIRUS ATTACHMENT
Most evidence points to a role for glycoproteins and possibly a
non-glycosylated protein in virus absorption (Johnson et al., 1984).
In contrast to many viruses, including the beta and gamma
herpesviruses, HSV has a very broad host range, and can productively
infect a wide range of mammalian cells. This observation indicates
that if there were a cellular receptor for HSV, it would need to be
ubiquitous, and highly conserved between species. Virus absorption has
been shown to be blocked by high concentrations of heparin (Hochberg &
Becker, 1968), but little else is known about the cellular receptor
for HSV. HSV absorption is not affected by inhibitors of phagocytosis,
and EM evidence also points to direct fusion of the viral envelope
with the cytoplasmic membrane (Morgan et al., 1968). gE has readily
detectable Fc binding activity; such binding is demonstrable on the
cytoplasmic membrane after infection, indicating fusion of the viral
envelope to the outer membrane of the cell (Para et al., 1980) The
latter two lines of evidence came from experiments that used high
multiplicities of infection (moi's); this does not reflect the natural
course of infection in humans so the data should be interpreted with
caution.
Sarmiento et al., (1979) proposed a role for gB in virus attachment
by observing the properties of virosomes, artificial lipid membranes
into which HSV-encoded membrane proteins have been inserted. Virosomes
containing gB fused more readily with uninfected cell membranes than
those without. Antibody to gB reduced the avidity with which virosomes
bound to cell membranes (Johnson et al., 1984). The experiments with
virosomes also provided evidence for the role in viral attachment of
VP14, a 78KDa protein, found in the membrane but not glycosylated.
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Fuller and Spear (1985) investigated the blocking by antibody of
attachment of radiolabelled HSV particles to cell membranes. Briefly,
all polyclonal and some monoclonal antibodies to gB and gD prevented
attachment as did high concentrations of Fc fractions of human IgG.
This latter observation indicates a role for gE in attachment, since
this glycoprotein has Fc receptor binding properties. The ability of
the monoclonals to neutralise HSV was also measured. This did not
correlate with the ability of the monoclonals to prevent attachment
and the authors proposed that antibody may interfere with infection of
the cell after the attachment process. The authors also proposed that
the three implicated glycoproteins, and possibly others made up a
viral attachment structure. The recent EM studies of HSV envelopes
showing different glycoproteins associated with distinct morphological
entities (Stannard et al., 1987) does not concur with this hypothesis
(see above).
VIRUS FUSION
Certain monoclonals to gD neutralise HSV but do not prevent attachment
to uninfected cells. It is possible that gD plays a role in the next
stage of the infection of the cell, that is penetration of the
cellular membrane by fusion (Fuller & Spear, 1985). Temperature
sensitive ( ts ) mutants deficient in gB production have also been
shown to be unable to penetrate the cell membrane although they can
attach to the cell (Sarmiento et al., 1979; Little et al., 1981).
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INTRACELLULAR EVENTS
Cytoskeletal elements draw the capsid towards the nucleus. Capsids
accumulate at nuclear pores and the viral DNA appears to be actively
secreted into the nucleus by a component of the capsid or tegument
(Batterson et al. , 1983). Changes in the appearance of the nucleus
begin very soon after the release of viral DNA. The nucleolus, the
site of ribosome synthesis enlarges and eventually disaggregates. Host
chromosomes become marginated and later may break up. The nucleus
eventually becomes distorted and invaginated to form reduplicated
membranes. The first microscopic evidence of virus replication can be
seen at about 7 to 9 hours after infection. Capsids self-assemble in
the nucleus after synthesis of the component proteins in the
cytoplasm. Viral DNA in synthesised in multi-unit lengths, and cleaved
immediately before encapsidation. There is evidence for the
involvement of p40 (VP22, ICP 35), a phosphorylated structural protein
in this process. The original work suggested that this protein was a
component of full but not empty capsids; furthermore, in the process
it is modified to a form with a different elctrophoretic mobility
(VP22a; Braun et al., 1984). This work has been widely quoted, but
more recent evidence with monoclonal antibodies has not confirmed
these findings (Rixon et al., 1986). The protein is phosphorylated
and exists in multiple forms as determined by both one and two
dimensional electrophoresis. It therefore has the attributes of a DNA




The route HSV takes on egress from the cell is disputed, even in the
in vitro studies. There are at least three theories of egress. The
first theory, (Morgan et al., 1959) proposes that the capsid buds
through the internal nuclear membrane, but then fuses with the extrnal
membrane and enters the cytoplasm, losing its envelope. On reaching
the external cytoplasmic membrane, HSV-encoded membrane proteins
accumulate in areas through which the capsid buds. This theory
accounts for the observation of large amounts of glycoprotein on the
surface of infected cells, but does not account for the observation of
glycoproteins present on the nuclear membrane. It is, of course,
possible that there is inappropiate routing of glycoproteins,
particularly in a damaged cell. This theory suffers from two problems.
Firstly, it would seem unlikely that the viral envelope would be
entirely devoid of cytoplasmic membrane proteins, and secondly, HSV
has not been observed budding through the external nuclear membrane.
Schwartz & Roizman, (1969) postulated the formation of microtubules
connecting the perinuclear space with the extracellular fluid. This
entails the synthesis and post-translational processing of
glycoproteins to take place before migration to the nucleus. While
this is the simplest model of egress, it has certain problems. It
predicts that the eventual viral envelope will be derived from the
nuclear membrane, albeit modified by virally coded proteins. It seems
unlikely, however, that all membrane proteins of cellular origin could
be excluded during this modification process. However, to date, no
cellular proteins have been found in the envelope of HSV or any of the
other human herpesviruses, except as contaminants in the virus
purification process. Another problem is that the proposed
- 31 -
microtubules have not been observed, although it could be argued that
the frequent observation of enveloped HSV particles in what appear to
be secretory vesicles are, in fact, microtubules cut transversely. The
clearest evidence against this theory is the frequent observation of
HSV apparently budding through membranes in the cytoplasm; this should
not occur if the theory was correct.
The most convincing explanation for HSV egress (Johnson & Spear, 1982)
proposes that the capsid buds into the perinuclear space, acquiring an
envelope bearing partially glycosylated HSV glycoproteins. The virus
then migrates to the golgi apparatus, the site of further processing.
The glycoproteins would be embedded on newly produced membrane after
processing, explaining the absence of cellular proteins in the mature
virion. Enveloped virus would leave the cell by means of the well
characterised and physiological secretory pathway associated with the
golgi. HSV infected cells treated with monensin, an inhibitor of
N-linked glycosylation, produced enveloped virus but failed to excrete
it. Secretory vesicles containing several enveloped virus particles
accumulated in the cytoplasm. This hypothesis accounts for many of the
observations of egress in in vitro models of HSV replication. It
remains to . be seen whether this corresponds to the in vivo
situation.
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REGULATION OF HSV REPLICATION
HSV, in common with other herpes viruses, but unlike most other
viruses encodes a very large number of non-structural proteins with
presumed enzymatic and regulatory functions. Much of the evidence
comes from studies of the effects of conditional lethal mutants of the
genes encoding these proteins. It is beyond the scope of this review
to present any more than a brief overview of some of the accumulating
experimental evidence in this area.
GENOME STRUCTURE
The origins of DNA replication in HSV were determined in advance of
sequence data. The evidence came from studies of defective interfering
virus particles. This type of HSV may be obtained by multiple passage
in cell culture at high moi1s (Murray et al., 1975). Virus prepared
in this way comprises a minority of wild type virus that plays a
helper role in the replication of the majority of defective viruses.
The defective genomes are of the same length as wild type genomes
(presumably regulated by packaging) but the majority of the coding
capacity has been lost. Instead there are multiple tandem repeats of
either an area in the middle of the long segment, or within the c
region of the short segment. These so-called type I and type II
repeats were predicted to encompass separate replication origins from
the long and short segments, termed ori,_ and oris (Ciufo & Hayward,
1981). They would have a replicative advantage over wild type virus;
however, the latter would have to be retained in small numbers to act
in a helper role to provide missing functions and structural proteins
for the defective genome. Interestingly, it is very difficult to clone
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fragments of ori,_. Any attempt to do so leads immediately to a 120 bp
deletion. The reason for this deletion became appparent when the area
was sequenced (Gray & Kaerner, 1984). there was a 144 bp palindromic
sequence at the centre of ori L; attempts to clone this failed because
the sequence would form a self-annealed loop and would be excised. The
oris region also revealed a palindromic sequence, but only 45 bp in
length (Stow, 1982). There is extensive homology between oriL and
oris; oris has a small deletion beyond the palindromic area; if it
were hypothetically restored, a 144 bp palindrome would result. Oris
lies very close to l£175K,one of five immediate early proteins, but
the only one to have a clearly defined role.
CLASSES OF REGULATORY PROTEINS
The replication of the structural proteins of HSV involves the
activity of several non-structural proteins with enymatic activity to
regulate transciption and translation. There are at least three
classes of HSV genes, that are trascribed and translated at different
times in the replicative cycle. Immediate early genes are those
transcribed in the first hour of HSV DNA reaching the nucleus of the
cell. Transcription is mediated by a cellular protein, RNA polymerase
II, with maximum rates of synthesis 2-4 hours after infection (Preston
& Newton, 1976). Pre-treatment of cells with cycloheximide, a chemical
that prevents protein synthesis, does not prevent the transcription of
IE genes. Furthermore, cells pretreated in this way also accumulate
abnormally large amounts of IE messenger RNAs (mRNAs), indicating a
possible negative feedback mechanism by proteins synthesised
subsequently in a normal infection. Delayed early (DE) genes are those
that are not transcribed until IE proteins have been produced. The
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maximum rate of transcription of DE genes is at 5-7 hours. Late genes
are either absolutely dependent on DNA replication (true late; TL) or
are translated in small amounts before replication but increase in
abundance after (early/late; EL). Late genes can further be
distiguished from DE genes by their increasing rate of translation
after 7 hours compared with the diminishing rate of production of DE
proteins.
IMMEDIATE EARLY GENES
Five HSV-1 and 2 genes are transcribed in the absence of de novo
protein synthesis on infection of a cell, and have therefore been
identified as IE genes. The products of the genes are IE175K (ICP4),
IE110K (ICPO), IE68K (ICP22), IE63K (ICP27) and IE12K (ICP47). This
nomenclature is based on the apparent MW of the proteins on SDS-PAGE.
Although the HSV 2 homologues of IE175K and IE110K have slightly
different apparent MWs, this is ignored in order to show
relationships. The alternative ICP nomenclature of Roizman is given in
parentheses; the HSV 2 proteins have different designations in this
system. The sequence data of IE175K and IE110K predict a much lower MW
than that observed by SDS-PAGE. The discrepancy- may be partially
accounted for by the hydrophilic nature of many of the residues and
the high proline content of the proteins. All but IE12K are
phosporylated with multiple forms on 2 dimensional electrophoresis
reflecting differently charged species (Ackermann et al., 1984).
Numerous ts mutants of HSV that fail to express IE175K at
non-permissive temperatures have been described (Preston, 1979). DE
proteins are not synthesised, and by shifting to non-permissive
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temperatures late in infection, IE175K was also shown to activate the
transcription of late proteins (Watson & Clements, 1980). More
evidence for the function of IE175K came from transfection experiments
where the isolated IE175K gene is expressed in mammalian cell lines.
IE175K was shown to be able to activate transciption of non-HSV genes,
such as those of adenovirus (Feldman et al., 1982). Furthermore,
IE175K was shown to activate DE and late HSV genes in cell free
systems (Pizer et al., 1986), and did so by a demonstrable affinity
for specific DNA sequences in the promoter regions of such genes
(Faber & Wilcox, 1986). The protein was also shown to have an
inhibitory effect on the transcription of all of the IE genes,
including its own. The specificity of the action of this IE protein
was unexpected, as it had been thought to have general activation
properties, possibly mediated through cellular proteins.
IE110K has a similar composition to IE175K and would be expected to be
able to bind to DNA to influence the rate of transcription. Increased
rates of transcription of DE proteins mediated by IE110K have been
demonstrated in transfection experiments (O'Hare & Hayward, 1985).
Although it had not proved possible to obtain conditional lethal
mutants of this gene, it was possible to artificially truncate the
gene. IE110K deficient mutants grew normally in tissue culture,
although there was evidence that at low moi's, the infectivity of the
virus was compromised (Stow & Stow, 1986). A ts mutant of IE63K was
shown to transcribe DE proteins normally but to be deficient in late
gene transcription (Sacks et al., 1985). No roles have been assigned
to the other two IE proteins. It is notable that VZV, another
neurotropic virus, has been shown to have counterparts to IE175K,
IE68K and IE63K, but not IE110K or IE12K. By contrast, there are no




The major role of DE genes in the replicative cycle of HSV is thought
to be to mediate rapid synthesis of viral DNA. Although cells may
contain the necessary enzymes for DNA replication, enhancement or
reduplication of this function by virally encoded proteins is
essential if the virus is to be able to productively infect cells that
are no longer capable of division, or are in a resting phase of
mitosis. Neurotropic viruses such as HSV spend a large part of their
life cycle in such cells (neurones). This makes it difficult to
determine the roles and requirements of DE and other regulatory
proteins, since the in vitro models require actively replicating
cells. Indeed many of the cell lines used are transformed and may not
be susceptible to many of the regulatory controls of cellular
replication.
The best characterised DE proteins are thymidine kinase (TK), DNA
polymerase, DNA'ase and ribonucleotide reductase. TK is an important
DE protein that is exploited by most currently used antiviral agents.
Acycloguanosine (Acyclovir; ACG) has a specific antiviral effect due
to the broader substrate specificity of viral TK, relative to its
cellular counterpart. Viral TK phosphorylates ACG to
ACG-monophosphate, while cellular enzymes process it further to di-
and tri- phosphate forms. The latter nucleotide is a substrate for the
virally encoded DNA polymerase leading to its incorporation into
replicating viral DNA, causing premature chain termination. Cellular
TK does not phosporylate ACG, nor do cellular polymerases recognise
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the triphosphate form so the drug has a very low toxicity for
uninfected cells. Since the widespread use of ACG and its predecessor,
lododeoxyuridine, much attention has focussed on the possible
mechanisms by which HSV may become resistant. HSV culture in
increasing, initially sub-lethal doses of thymidine analogues in
vitro commonly leads to the evolution of resistant strains deficient
in TK production (Dubbs & Kit, 1965). While these mutants grow in
vitro , they are non-pathogenic in experimental animals for the
reasons discussed above. Less commonly, resistance may be acquired by
changes in the specificities of virally DNA polymerase for ACG, rather
than ablation of function (Coen & Schaffer, 1980). Should these
mutants retain normal replicative abilities, then it is possible that
they may also be fully pathogenic in experimental animals and in man.
ACG resistant HSV has recently been isolated from a bone marrow
transplant patient on long term ACG therapy (I. Smith, personal
communication). The virally encoded DNA polymerase was unable to
metabolise ACG-TP, yet the isolate retained some, but not total,
pathogenicity in experimental animals.
The major DNA binding protein (MDBP) is another DE protein. The name
derives from its observed properties in vitro , but its. precise role
is unclear. It is essential for DNA replication (Lee & Knipe,
1983) and evidence suggests that it operates in conjunction with DNA
polymerase (Chiou et al., 1985). A 136K early protein (ICP6) is a
component of ribonucleotide reductase, the other being a 38 KDa DE
protein (Frame et al., 1985). The regulation of transcription of the
former protein differs from the other DE proteins in that it is not
dependent on IE175K and is transcribed along with the IE proteins.
However, its transcription is not prevented by DE proteins, and the
translation product rapidly accumulates in large amounts in the
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cytoplasm and the nucleus during the DE phase of replication
(Middleton et al., 1982). By contrast, the 38K component has a solely
nuclear distribution and is present in much smaller amounts. The
functional significance of the apparent overproduction of the 136K
protein is not known. Apart from DNA replication, DE gene products
have been shown to prevent further transcription of IE proteins, and
to influence the rate of transcription of late proteins.
LATE GENES
As mentioned previously, there are two classes of late gene, those
that are transcribed from both parental and progeny viral DNA (EL) and
those that can only be transcribed from progeny DNA (TL). There
appears to be little functional significance in the distinction; for
example, the major capsid protein, gD and gB are EL proteins, while gC
is a TL protein. DE genes can be distinguished from both classes of
late gene by observing the effect of DNA replication inhibitors on the
abundances of transcripts of the three classes of gene. While the
level of DE transcripts is not affected, EL transcripts are markedly
reduced and TL are absent. The translation products of the late genes
are primarily structural proteins, although regulatory functions may
be attributed to some.
Specific antibody to gH-1 appears to prevent egress of mature virions
if administered after infection of the cell (Gompels & Minson, 1986).
Several lines of evidence point to role of components of the capsid in
activation of transcription of IE genes, and in shutting off host cell
protein synthesis. However, it is essential to point out the results
of several investigators who found that naked single or double
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stranded DNA of the HSV genome was capable of productive infection on
transfection of a cell (Graham et al., 1973; Sheldrick et al.,
1973). This discounts an "essential role" for capsid proteins in the
initiation of infection. The conditions in which the experiments were
performed were highly unnatural since very large moi's were required
for infection. The duration of the replicative cycle was longer than
that of cells infected with wild type virus. Thus, capsid components
may be necessary for infectivity in vivo .
Shut-off of cellular protein synthesis appears to be mediated at the
level of ribosomal RNA synthesis rather than suppression of synthesis
of non-ribosomal mRNA. The very early swelling and disintegration of
the nucleolus may be an effect of this shut-off. Fenwick & Walker
(1978) mapped a gene product mediating shut-off to an area 0.52 to
0.59 map units by means of intertypic recombinants. Although this
region encodes many proteins, ICP10 was thought to be the most likely
effector of this function. Trans-activation of IE genes was mapped to
a 65K phosphorylated protein, found in relatively large amounts in the
tegument (Campbell et al., 1984). The activity of the protein may be
demonstrated even though the capsid is known not to enter the nucleus.
The protein has no demonstrable affinity for DNA; this consideration
and the low amounts of input protein on infection makes it likely that
the protein operates through a cellular intermediary.
In summary, the biology of HSV is complex. Structurally, the virus is
comprised of a large number of proteins, with diverse properties and
antigenicity. The need for such a wide range of HSV-encoded
glycoproteins is an enigma; conservation of the nucleotide sequence of
genes encoding structural proteins between herpesviruses is evidence
that they play diverse and subtle roles in the infectious process.
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Understanding the method by which HSV takes over a cell and replicates
is hampered by the large range of regulatory proteins produced by HSV
and a fundamental ignorance of the normal metabolic processes within a
cell. Assigning roles to individual proteins is complicated by the
biochemical differences between the normal target cells of HSV in




This chapter discusses the phenomenon of latency, and presents data on
the role of the various arms of the immune system in protection from
primary and recrudescent infection with HSV. In particular, attention
is paid to the immune responses to individual proteins, and the
implications for the proposed HSV vaccine.
PATHOLOGY
Primary and recrudescent infection with HSV cause an intradermal
infection with accumulation of serous fluid containing infectious
virus in vesicles. Typically, vesicles are lined with giant
multinucleated cells with ballooning of the cytoplasm. There is an
inflammatory response to HSV infection, with macrophages, neutrophils
and killer (K) cells identifiable in pathological sections. It is long
established that HSV becomes latent in the cell body of sensory
neurones innervating the area of the primary infection. In animals,
primary infection is prolonged and extended by reactivation of virus.
Simmons & Nash, (1984) describe an animal model of primary and
recrudescent infection in the mouse. Intradermally inoculated virus
replicates in the skin reaching a peak by two days, accompanied by
inflammatory processes. Virus is recoverable from the sensory ganglion
by 2 days, reaching a peak titre by 4 days. Virus, reactivated from
the ganglion becomes detectable in skin adjacent to the site of the
original inoculation at 4 days and inflammatory changes develop
subsequently. In this model, primary infection has two distinct
components, the first being local infection, subsequently followed by
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reinfection of the site by virus from the sensory ganglion.
Immunochemical staining of epithelial sheets from the eyes of mice
inoculated nasally showed that virus appeared in the eye at 3 days,
and provided evidence for zosteriform spread of HSV to the eye
(Shimeld et al., 1986). Bernstein & Starberry (1986) describe the
zosteriform spread of HSV-2 on vaginal inoculation of guinea pigs, as
a model of primary and recrudescent genital infection.
LATENCY
The events leading to the establishment of latency in the neurone are
unclear. HSV DNA can be readily detected in neurones of mice by
southern blotting, at a copy number of 0.15 to 0.015 copies/cell (Rock
& Fraser, 1983). The investigators failed to detect the terminal
sequences of HSV, suggesting that the DNA was either circularised or
in a highly concatamerised form. Puga et al., (1984) presented
evidence that there might be integration of virus sequences into the
cellular DNA. The biological significance of these observations is not
clear since it was not established that the DNA detected represented
viral genomes with potential to reactivate, or whether it was an
artefact resulting from the high doses of virus used to infect the
experimental mice. In fact, Fraser et al., (1981) found normal DNA
sequences with no evidence of circularisation or integration in human
brain tissue.
Efstathiou et al., (1986) described experiments with both mouse
models and human specimens. Linear DNA was found in the ganglia of
mice during the acute stage of infection, but later, only endless,
possibly circularised forms, were found. Follow-up of mice showed that
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the endless form remained detectable for at least 4 months. Their
analysis of cadaver trigeminal ganglia showed that endless forms of
HSV DNA are also to be found in humans. Most recently, Mellerick and
Fraser (1987) confirmed that HSV DNA was not integrated, and provided
some evidence that it was circularised rather than concatamerised.
These findings suggest that HSV could reactivate using the
circularised form as a template for a rolling circle mechanism of
replication.
A recent paper (Stevens et al., 1987) descibes the discovery of an
RNA species with an exclusively nuclear distribution in neurones
containing latent HSV. The sequence of the RNA is complementary (ie
negative sense) to the gene encoding IE110K, and may prevent IE110K
mRNA transcription and hence expression of the regulatory protein. It
is known that mutants deficient in IE110K production grow poorly in
vitro , and it is possible that suppression of this protein in vivo
could block HSV replication.
The immune system has also been shown to play a role in maintainance
of latency. It is clear that immunosupression, either systemic or
local (many of the stimuli that provoke recrudescence, such as pyrexia
and ultra-violet light, appear to affect local cell-mediated immunity)
leads to an increased frequency and severity of recrudescence. A clue
as to how the immune system can prevent recrudescence comes from the
observation that HSV may sometimes be isolated from patients who
either do not suffer from recrudescences, or more commonly, from
patients between recudescences. Regular sufferers of recrudescence
often report experiencing prodromal symptoms such as tingling and
hyperaesthesia but without subsequently developing any cold sores.
Reactivation thus seems to have a variable outcome. Hill & Blyth
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(1976) suggested a plausible hypothesis to explain the prevention of
recrudescence by the immune system. They postulated that HSV
reactivates frequently in all infected people, but brisk and effective
immunity at the site of virus shedding normally prevents lesions
forming. Whereas the majority of individuals are always able to
contain reactivated virus, a minority occasionally fail to do so and
suffer from periodic recrudescences. This hypothesis also accounts for
the observation that many individuals maintain lifelong high titres of
HSV antibody yet never have recrudescences. Repeated reactivation and
exposure to the immune system but without recrudescence in such people
would account for this observation. It is not known what proportion of
people without recrudescences have regular reactivation of HSV.
HOST RESPONSES TO HSV INFECTION
The morbidity associated with HSV infection in man has been a major
factor in current attempts to understand how the body responds to
infection with HSV. Such knowledge is essential if effective
preventive measures against HSV infection are to be developed. Much
research has been concentrated on evaluating which arms of the immune
system are responsible for protection from HSV. More detailed work
that measures immune responses to individual viral components, such as
individual glycoproteins, has been carried out, with the aim of
developing an effective subunit vaccine to prevent primary infection.
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NON-SPECIFIC HOST DEFENCES TO HSV
An intact skin barrier is a major factor in the prevention of
infection. This is illustrated by the increased severity of disease
caused by HSV in patients with eczema and burns. Natural killer (NK)
cells kill target cells in the absence of any known antigenic
stimulation and in the absence of antibody to the target cell. The
method by which NK cells recognise their target is unknown. There is
no apparent major histocompatibility complex (MHC) restriction,
although they are more effective against target cells of the same
species. Killing activity is enhanced by interferon. Bishop et al. ,
(1983; 1986) have presented evidence that there is specific
recognition of gB and gC by NK cells of mice with no prior exposure to
HSV.
Lopez (1981) reviewed a series of experiments that studied the role of
inherited factors in resistance to HSV-1 in mice. There was a dominant
trait in mice that protected them from the intraperitoneal, but not
intracerebral, route of inoculation. Inheritance of this trait
paralleled the inheritance of resistance to bone marrow allografts.
This latter function is thought to be mediated by NK cells, so the
evidence supports the idea that NK cells are important in resistance
to HSV-1 infection. Whether NK function is an important factor in the
human response to HSV infection remains to be established.
Macrophages are involved in many arms of the immune response, but they
also have intrinsic anti-bacterial activity mediated by lectin-like
compounds. It would seem unlikely that there would be any natural
antiviral activity in these cells or in neutrophils that operate in a
similar way. However, procedures that impair macrophage function
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increase the susceptibility of mice to HSV infection inoculated
mtraperitoneally (Zisman et al., 1970). Apart from using an
inappropiate route, these studies are also subject to the objection
that the proceedures may alter interferon levels (see below) and so
increase the NK cell activity. Genetic differences in macrophage
activity affected the resistance of mice to infection with HSV-2. The
Chediak-Hlgashi syndrome is characterised by defective killing by
macrophages, neutrophils and other phagocytic cells. Patients affected
by the disease are susceptible to bacterial infection, but do not
suffer from an increased prevalence or severity of infection by
viruses, including HSV. All three interferons are important mediators
of non-specific immunity to viruses, although the mechanisms by which
they act are not fully understood and is probably multifactorial. Oc- &
interferon are antiviral, while 6~interferon, a T-cell lymphokine,
can modify the activity of various cells of the immune system. The
role of interferons in controlling infection by HSV is unclear. It
would appear unlikely that complement could directly act on virus in
the absence of specific immunity. gC of HSV-1 binds to C3b but its
role in pathogenesis is unclear, nor is it known if this binding is a
primary function of the protein (see chapter 1)
SPECIFIC IMMUNITY TO HSV
Evidence for the importance of specific immunity comes both from
observation of the effects of immunodeficiency states, both acquired
and hereditary, and from experiments with the effector cells, both in
vitro , and in vivo in animals. Interpretation of evidence from both
sources is not without problems, in that apparently simple defects may
have wide effects on other aspects of the immune system.
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Investigating the function of the effector cells eg cytotoxic T cells,
killer cells etc. in vitro has its own problems. Delayed-type
hypersensitivity (DTH) cannot be studied readily in vitro and so
there is very limited information on human DTH responses. Cytotoxic
T-cells (CTCs) can be tested in vitro , but the antigen must be
presented in association with self class I MHC antigens. This
restricts experiments either to syngeneic mice or to human cytotoxic
T-cells where it is possible to culture and experimentally infect
target cells from the same patient. Antibody-dependent cell-mediated
cytotoxicity (ADCC) can be readily studied in vitro since it is
mediated by K cells that are not MHC restricted. All in vitro
experiments suffer from the problem that only one aspect of the immune
response can be studied at a time. Interaction and cooperation between
cells does not occur and findings may not apply directly to the in
vivo situation. In vivo experiments with HSV can only be performed
readily in animal models. The main problems with these experiments is
the artificiality of the situation.
IMMUNE RESPONSES TO ACUTE INFECTION
Many studies have been reported in which HSV is inoculated
peripherally (either footpad or ear pinna) into a mouse and the immune
response measured (Hill et al., 1975; Nash et al., 1980).
Inflammation begins on the first day and becomes maximal within 4-5
days (Simmons & Nash, 1984). Neutralising antibody becomes detectable
after 8 days, with maximal levels between 12-14 days post inoculation
(Knoblich et al., 1983). DTH can be observed within 4 days by
injection of virus in the opposite ear pinna; the response becomes
maximal after 8 days and persists indefinitely (Nash et al., 1980). T
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cells taken from the lymph node draining the site of inoculation show
proliferation on exposure to antigen in mice in vitro . This occurs
from the third day onwards. The proliferation response of helper T
cells becomes maximal several weeks after inoculation and persists
indefinitely. However, cytotoxic T cells are only found for about ten
days after experimental infection of mice.
Although many arms of the immune response operate during primary
infection, it is difficult to determine which of the responses are
important in controlling its severity and spread. It is possible to
study the role of humoral antibody relatively independently of T cell
immunity. Mice treated with anti-IgM from birth lose the ability to
mount an antibody response; all 5 classes of immunoglobulin are absent
while their cellular immunity appears to be unimpaired (Gordon, 1979).
Mice treated in this way showed equal susceptibility to HSV infection
as the control group, with similar rates of clearance of virus from
the site of inoculation (Kapoor et al., 1982a). There was however,
wider spread of virus in the central nervous system, with latency
demonstrable in ipsilateral, adjacent and contralateral ganglia. This
evidence is supported by findings of a normal course of HSV infection
in human subjects with congenital B cell deficiencies. It also
concords with findings with other human viruses. For example, reduced
humoral immunity leads to an increased prevalence of paralysis in
patients infected with poliovirus, presumably because of a failure to
limit spread of the infection. Limiting the spread of HSV infection
may be mediated by antibody alone, antibody and complement or antibody
and K cells. It is not clear at present which of the three
possibilities is effective in vivo .
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In experimental animals, T cell mediated immunity appears essential
for survival of HSV infection. Athymic mice rapidly perish from
disseminated infection on challenge with HSV (Nagafuchi et al., 1979;
Metcalf et al., 1979), and can be protected by transfer of syngeneic
T cells taken from normal mice 7 days after viral challenge (Kapoor
et al., 1982b). Patients with diminished cell mediated immunity also
appear to be at risk from a much more severe primary HSV infection
than normal subjects.
Many methods can be used to evaluate the roles of the different
components of cell mediated immunity. Transfer of various populations
of syngeneic T cell from immunocompetent mice to athymic mice is one
possibility. The donor and recipient mice could have the same class I
and II markers, or they could differ in one or the other.
Cell-mediated cytotoxicity (CMC) is restricted by class I and DTH by
class II. Such studies have given conflicting results on the relative
importance of CMC and DTH (Nash et al., 1981b; Nash & Gell, 1983;
Larson et al., 1983). Further work on T cell responses will need more
careful separation of T cells with different functions. On balance, it
would appear that DTH makes a relatively greater contibution to
immunity from HSV than CMC, although this remains disputed. The target
specificity of T cells is also important; transfection experiments now
allow responses to individual proteins, or protein fragments, to be
studied. This is obviously important in view of the known functional
differences between the various glycoproteins, and the variation in
the susceptibility of HSV to neutralisation by antisera of differing
target specificities.
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Several studies of the antibody response to naturally occuring HSV
infection in man have been described. Neutralising antibodies are
detectable within a month of primary infection and readily
cross-neutralise the type-heterologous virus. Gilman et al., (1980;
1981) describe the results of using a radioimmunoprecipitation (RIP)
assay to investigate the target specificity of human convalescent
sera. The results showed that patients generally had antibody to a
large number of virally-specified proteins but that patients differed
in the range of apparent antibody specificities. Eberle et al.,
(1983) used the western blotting or immunoblotting (IB) method to
identify the targets of antibody in convalescent sera, and found
reactivity with HSV glycoproteins and several capsid components. The
results of Teglbjaerg et al., (1986), who used both methods, are
difficult to interpret, and reveal a major problem of the
identification of bands produced by both assays. Convalescent sera
reacted with the major capsid protein (MCP), ICP6, major DNA binding
protein (MDBP), gB and ICP 20 and 25, in the RIP assay. However, many
more bands were produced, but they were not identified. In the IB
assay, several bands appeared, including MCP, ICPs 6 & 7, MDBP, gB,
ICPs 25 & -36 and gD, and, again, over half were not'identified.
Eberle et al., (1984; 1985) and Bernstein et al., (1984) used the IB
method to study antibody response in primary infection. They found
that the initial antibody response was not to a glycoprotein, but
rather to the tegument protein, p40 (see chapter 1). This was a
surprising result and conflicted with work by Zweerink & Corey,
(1981), Ashley & Corey, (1984) and Ashley et al., (1985) who showed,
using the RIP method, that the initial immune response was confined to
gB, gC-1 and the MCP of HSV-2, although their results differ in
detail. Ashley & Corey (1984) reported also that, in some patients,
the appearance of antibody to gD was delayed, and that this correlated
with a decreased interval to the first recrudescence. Ashley et al.,
(1985) reported that Acyclovir treatment reduced the humoral antibody
response to primary genital HSV infection, and associated this finding
with the clinical observation that patients on such treatment tended
to have earlier and more severe recrudescences than those in the
untreated group.
IMMUNOLOGICAL RESPONSES AND THE ESTABLISHMENT OF LATENCY
As described previously, the establishment of latency involves the
migration of virus up the afferent axon to the nerve cell body in the
sensory ganglion. In this latent state, the immune system is obviously
incapable of eradicating the virus. There have been many studies to
determine which arms of the immune system are responsible for
preventing recrudescence. Recrudescences occur in the presence of high
titres of neutralising antibody; indeed, patients with frequent
recrudescence show, on average, higher antibody titres than patients
with no recrudescences. This data discounts a role of humoral immunity
in the maintenance of latency. Torseth et al., "(1987) demonstrated
that peripheral lymphocytes of patients with previous exposure to HSV
showed a lymphoproliferative response to synthetic gD, gB and gC. The
V-interferon produced by the T cells was quantitated; the level
produced on stimulation with gD correlated with the frequency of
recrudescence. Whether this is a cause or effect remains to be
established. Recrudescence may be influenced by any aspect of
cell-mediated immunity eg. cytotoxic T-cells, antibody dependent
cell-mediated cytotoxicity, by DTH, or by other mechanisms.
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In mice, many immunological functions can be demonstrated following
the resolution of the primary infection. Mice retain a lifelong
lymphoproliferative response to HSV antigen, indicating helper T-cell
recognition. DTH is also permanent, but this function cannot be
transferred to uninfected, syngeneic mice by transfer of spleen cells,
as it could in earlier stages of the infection. Transfer of DTH is
thought to be prevented by suppressor cells that appear after the
primary response to primary infection. Suppressor cells of both B cell
and T cell origin can be demonstrated in the mouse (Nash & Gell, 1983;
Schreier et al. , 1983a). Suppressor T cells appear to comprise at
least two distinct populations with different surface markers. A
notable feature of T suppressor cells is that, while
lymphoproliferative responses are observed in response to type
heterologous virus, suppressor cell activity is type specific (Nash
et al., 1981a)
CTC activity wanes in both mice and humans after primary infection,
and classic MHC-restricted cytotoxicity cannot be demonstrated in
specimens from convalescent patients. A correlation between lymphokine
production and recrudescence has been observed in both guinea pigs and
humans. Guinea pigs vary in their susceptibility to recrudescence; the
lymphocytes of those with frequent episodes show reduced lymphokine
production on challenge with HSV antigen in a lymphoproliferative
assay (Dounenberg et al., 1980). A similar reduction can be observed
with human T cells from patients with frequent recrudescence compared
with controls (Shillitoe et al., 1977; O'Reilly et al., 1977).
However, the production of a lymphokine, macrophage migration
inhibition factor, was normal in patients between recrudescence; a
reduction could be observed during recrudescence (Sheridan et al.,
1982). Another measure of immune function in humans, the T4 (helper)
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to T8 (cytotoxic/supressor) ratio, is also lowered during
recrudescence. At present it is not possible to establish whether
reduced lymphokine production or reduced T4/T8 ratio are the cause or
effect of recrudescence in humans.
VACCINE DEVELOPMENT
One of the aims of studies of the immune response to herpes simplex
virus is to obtain information relevant to development of a vaccine
for HSV. Although recrudescence occurs despite demonstrable cell
mediated and humoral immunity, a vaccine administered before first
exposure to HSV might prevent primary infection, or may prevent the
establishment of latency. Preliminary observations indicate that a
vaccine may be effective. Firstly, restriction enzyme analysis to
differentiate strains of HSV has shown that patients are generally
infected with only one strain, with the implication that the first
infection prevents subsequent infection with other type-homologous
strains. Another general observation concerns the epidemiology of
HSV-2 infection. The reasons for the evolution of two serotypes of HSV
are uncertain. One explanation for the divergence is based on the
observation that recrudescences of genital HSV-1 infection are much
less common than HSV-2. HSV-2 therefore appears better adapted to that
area, and, in evolutionary terms, is more likely to be transmitted.
But another explanation for the difference is that HSV-2 has diverged
antigenically in order to avoid pre-existing immunity to HSV-1
acquired before the onset of sexual activity. The latter hypothesis is
supported by evidence that genital infection with HSV-1 is rare in
patients with previous oro-labial HSV-1 infection; HSV-1 genital
infection is normally primary. If the latter explanation is valid,
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then it would be clear evidence that pre-exposure to HSV can prevent
or modify the outcome of subsequent HSV infection.
The safety of vaccines is paramount, particularly for infections such
as HSV, that are often asymptomatic or trivial. UV irradiated HSV DNA
has been shown to have transforming activity in vitro and in vivo ,
and any vaccine should be guaranteed to be free of any HSV genetic
material. For these reasons, much attention has focussed on the
possibility of a vaccine made by recombinant DNA technology. The
advantages of such a product would be purity, ease of preparation and
safety. However, it is necessary to establish if immunity induced by
individual HSV proteins is sufficient for protection, and which
proteins should be chosen.
To date, most work has concentrated on examination of immunity to
individual HSV glycoproteins, and the protective effect subunit
vaccination has on experimental animals. Potential efficacy of
immunisation can be examined in several ways. 1) measuring
neutralising antibody and cell imediated responses to individual
glycoproteins; 2) determining the protective effects of passively
administered antibody; 3) determining the protective effect of
individual or multiple glycoprotein antigens in both limiting or
preventing primary infection with challenge doses of virus, and
preventing the establishment of latency.
Immunopurified and recombinant gD has been shown to protect mice from
lethal challenge by HSV-1 and -2 (Long et al., 1984; Eisenberg et
al., 1985a). Roberts et al, (1985) have extended this conclusion to
gB and gC, again by using immunopurified glycoproteins. Glorioso et
al., (1984) compared the efficacy of gB, gC and whole virus immunogens
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in protection from challenge by the intraperitoneal amd intracerebral
routes. They found that all three protected mice from viral challenge
by the i/p route, but only the whole virus vaccine protected mice from
l/c challenge. Paoletti et al. , (1984a) made vaccinia recombinants
containing an inserted gene for gD. Such constructs were then
evaluated as possible vaccines. The same investigators (Paoletti et
al., 1984b) found 100% and 80% survival rates in mice challenged after
receiving the vaccine, compared with 45% and 15% in the untreated
groups. Similar results have been obtained by other investigators
(Cremer et al., 1985; Martin et al., 1987). Dix & Mills, (1985)
immunised mice with gD-1, gD-2, gB-1 and gB-2 and measured protection
from challenge with HSV-1 and -2. All four immunogens completely
protected mice from a footpad HSV-1 challenge that killed 70% of the
control group. However, a dose of HSV-2 that killed 90% of the control
group also killed 60 and 90% of the mice receiving the gB-1 and gB-2
vaccines, and 30 and 20% of mice receiving gD-1 and gD-2. The
investigators then dissected out the sacral ganglia, and found
extensive infection of the CNS with contralateral and ipsilateral
infection in the control and gB-1 and -2 recipients, while in those
receiving gD, infection was confined to the ipsilateral ganglia. These
findings indicate that a vaccine could prevent the establishment of
latency.
Antibody elicited by an immunisation could operate either by
neutralisation of virus, by ADCC of infected cells by activated K
cells, or by complement-mediated lysis. Passively administered
antibody has been shown to be protective in mice (Dix et al., 1981;
Balachandran et al., 1982 and others). Monoclonal antibodies have
been extensively investigated for neutralising activity in vitro ,
and it has been demonstrated by several investigators that
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neutralisation of HSV can be achieved by monoclonals against every
glycoprotein so far investigated, even though not all of the proteins
are essential for virus growth in vitro . Similarly immunisation with
individual purified glycoproteins induces the production of
neutralising polyclonal sera (Norrild, 1985). Monoclonal and
monospecific antisera to gD been shown to have the highest
neutralising titres. Neutralisation may not be the mode by which
antibody limits primary infection in a vaccinee, since ADCC operates
at much lower antibody concentrations. Furthermore, antibody
participating in K cell or complement mediated cytolysis need not be
neutralising; only recognition of infected cell membrane components is
necessary to activate the pathways leading to destruction of infected
cells. Kumel et al., (1985) showed that there was no correlation
between in vitro neutralisation by monoclonals and their in vivo
protective effect when passively administered into mice. These
experiments directly point to a role for ADCC by K cells, since the
mice were congenitally deficient in complement activity. These
findings disagree with those of Simmons & Nash, (1984), who found that
only neutralising antibodies protected mice from experimental
challenge.
Cell-mediated immunity induced by vaccination is likely to be more
important in conferring protection, in view of its demonstrably
greater role in limiting natural infection. Chan et al., (1985)
showed that passive transfer of T cells from gB immunised mice to
syngeneic naive mice conferred protection from lethal challenge.
Schreier et al., (1983b) showed delayed type hypersensitivity
reactions in mice protectively immunised with either gD and gC. As
might be expected from the antigenic sites of gD and gC, protection
and DTH was demonstrable against heterologous type virus following gD,
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but not gC, vaccination. Naylor et al. , (1982) showed that the route
of immunisation affected the type of immunity produced.
Intraperitoneal immunisation, in many respects equivalent to
intravenous, elicited an antibody response but no detectable DTH,
while animals immunised subcutaneously showed DTH but no antibody
response. Martin et al., (1987) showed that a gD-vaccinia construct
induced protection from lethal challenge, T cell lymphoproliferative
responses and interleukin-2 production. However, no class I restricted
cytotoxic T cells reactive with HSV were produced even on
re-immunisation with whole HSV virions. The failure to induce CMC was
not MHC related, and did not appear to be the result of an
inappropiate route of inoculation since CMC to vaccinia was readily
detectable. Low levels of CMC to HSV were mediated by T cells bearing
class II antigens, although the significance of this is not clear.
In summary, the available information on subunit vaccines shows that a
protective effect may be elicited in experimental animals, and that
DTH rather than CMC is important in this protecive effect. Results
from trials of such vaccines in humans should shortly be forthcoming.
The data about the protective effect of antibody tends to indicate
that it plays a minor role in the pathogenesis of HSV infection,
possibly related to the late appearance of specific'antibody relative
to the rate at which HSV infects neurones. However, this does not mean
that it is unimportant as an effector of protection by vaccination,
and, in particular, it may localise the infection by rapid complement
and K cell mediated killing of infected cells and neutralisation of
released virus.
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In man, Chen et al. , (1984) describe the efficacy of the "Skinner
vaccine" in protection of the sexual partners of patients with genital
HSV-2 infection. This work has been criticised from an ethical and
safety point of the view, and inadequate selection and monitoring of
the patients in the study make interpretation of the results
difficult. The main problem is that no attempt was made to establish
if the partners had had prior exposure to HSV-2 by serological assays.
In patient selection and claims of efficacy, the investigators did not
consider the fact that up to 50% of genital HSV infection may be
asymptomatic. These criticisms emphasise the need for careful and
thorough trials to establish the efficiacy of any candidate vaccine.
MEASUREMENT OF TYPE-SPECIFIC ANTIBODY TO HSV
The knowledge recently gained concerning the nature of, and
serological response to, HSV glycoproteins has been used in the
development of an assay that can detect and differentiate specific
antibodies to HSV-1 and -2. The motivation is epidemiological and
clinical, in that it often desirable to differentiate past exposure to
HSV-1 from HSV-2, and from infection with both. In a clinical setting,
there are instances where the results of such an assay would have a
bearing on the clinical management of the patient, such as genital HSV
infection during pregnancy, and in the diagnosis of HSV infection
where isolations have proved unsuccessful.
Plummer (1973) reviewed very early attempts to develop a type-specific
assay for HSV. These methods without exception used whole virus, and
usually were found to be inadequate at differentiating sera with
antibodies to both HSV-1 and -2 from monospecific sera. The
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application of gel based methods led to the identification of proteins
that appeared to elicit type-specific antibody. Vestergaard et al.,
(1979) and Jeansson et al., (1979) described the separation of
apparently type-specific antigens by non-immunological purification
methods. Dreesman et al., (1979) and Eberle & Courtney (1981) used
RIP analysis of HSV proteins to identify gC-1 and gC-2 (later found to Ge
gG-2) as type-specific antigens. The proteins were purified and used
in a type-specific assay. Proteins binding to helix pomatia lectin
(gC-1, gG-2) were used in type specific assays (Suchanova et al.,
1984; Svennerholm et al., 1984). Monoclonal antibodies have also been
CL
used to extract gG-2 from a cell lysAte prior to use in a type-specific
assay (Lee et al., 1985).
gC-1 has since been shown to be related to gF (renamed gC-2) and
cross-reactivity demonstrated in one of the two antigenic areas of the
protein (Zweig et al., 1984); it can no longer be condidered as a
candidate type-specific antigen. More recently, the lack of homology
between gG-2 and other HSV proteins has become apparent, and antibody
to this protein would be expected to be type-specific. However, a
cross-reactive oligopeptide serum reactive both with gG-2 and gG-1 has
been described (McGeoch et al., 1987; see chapter 1). Whether this
would lead to cross-reactivity of antibody elicited by natural
infection is unclear, since the antiserum was raised to an
oligopeptide corresponding to a sequence of amino acids near the C
terminus, within the viral envelope.
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CHAPTER 3
The AIDS epidemic has reached alarming proportions, and it is unclear
what will be the eventual outcome in terms of human mortality and
morbidity. Rarely has so much effort been concentrated in fundamental
and applied research to find a cure. It is now clearly established
that AIDS is the terminal stage of infection with a retrovirus, human
immunodeficiency virus (HIV). Preceding clinical disease, there is a
prolonged carrier stage when patients are positive for HIV-specific
antibody and may be infectious but symptom-free. This stage may last
for several years before the onset of AIDS; prospective follow-up
should establish whether HIV infection inevitably progresses, or
whether some individuals are able to keep the disease in check
indefinitely. AIDS, when it does occur, is uniformly fatal and there
have been no reported cases of spontaneous remission of symptoms. HIV
has been isolated from blood, semen, saliva and other secretions of an
infected individual, but, while it has been established that HIV is
commonly transmitted through sexual intercourse, there is currently
little evidence for aerosol spread or infection through intact skin.
Evidence that direct inoculation is required for infection comes from
the strong association of HIV infection with intravenous drug abusers
and haemophiliacs.
This introduction consists of a description of the syndrome
(particularly of illness caused by the virus itself, with relatively
less attention given to the range of disease secondary to
immunosuppression). Further sections will describe the biology of HIV
and the process of infection of a cell. Chapter 4 describes the
laboratory markers of infection and describes the current research
into the immune responses to HIV infection. Finally, a selection of
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the numerous theories of pathogenesis will be reviewed.
DISCOVERY OF HIV
The AIDS syndrome was recognised several years before the discovery of
the virus. Although the primary feature of the syndrome was recognised
to be that of immunosuppression, the distribution of cases suggested
an infectious aetiology, and a virus transmitted in similar ways to
Hepatitis B was suspected as far back as 1982. Particularly suspicious
was the exponential rise in numbers in certain well-defined risk
groups, initially promiscuous male homosexuals in the San Franscisco
area, but later haemophiliacs, drug abusers and heterosexual partners
of any of these. This ruled out the earlier theory that certain
features of the lifestyle of the first group was responsible for the
observed immunosuppression. Human cytomegalovirus (CMV), hepatitis B
(HBV; possibly in association with delta agent) and human
T-lymphotropic virus type 1 (HTLV-1) were all considered as candidates
for the causative agent of AIDS. However all three viruses were
excluded as the primary cause on the basis of cases, particularly
children, in whom evidence for infection with these viruses was
absent. Barre-Sinnoussi et al., (1983) found reverse transcriptase
(RT) activity, suggestive of a retrovirus, in cultures of T
lymphocytes from a patient with persistent generalised lymphadenopathy
(PGL), a condition found in patients in the recognised risk groups for
AIDS. The virus showed a tropism for replicating T-lymphocytes, formed
syncytia with subsequent cell lysis, could be seen budding from the
membranes of infected cells by EM, and showed weak serological
cross-reactivity with HTLV-I by immunofluorescence. On this basis,
Barre-Sinnoussi and colleagues classifed the isolate as a retrovirus,
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and called it lymphadenopathy associated virus (LAV). Two further
detections were subsequently made from patients with AIDS (Vilmer et
U-
al.r 1984). Proof that the three virses isolated were the cause of
A
AIDS was problematic. Gallo et al., (1984) found viral particles and
RT activity in 48 out of 70 T-cell cultures of patients with PGL or
AIDS. Continuous propagation of one isolate was achieved and allowed
large amounts of purified viral antigens to be prepared. Antibody
reactivity with the prepared antigens was found in essentially all of
the patients with AIDS and PGL and also in a proportion of well
patients in the risk groups. Antibody reactivity was not found in
patients in low-risk groups. Finally, retrospective testing of stored
serum collections worldwide showed that seroconversion in AIDS-risk
populations first began to occur about 3 years before the first AIDS
cases were reported (Brun-Vezinet et al., 1984; Chiengsong-Popov et
al., 1984; Safai et al., 1984; Sarngadharan et al., 1984).
CLINICAL FEATURES OF HIV INFECTION
The current Centres for Disease Control (CDC) classification of the
clinical features of AIDS comprises:
Group I ACUTE INFECTION
Group II ASYMPTOMATIC INFECTION
Group III PERSISTENT GENERALISED LYMPHADENOPATHY
(cont'd)
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Group IV OTHER DISEASE:
A) Constitutional disease. Fever more than one month, more
than 10% weight loss, or diarrhoea for more than one
month.





candiadiasis (of oesophagus or lungs),
cryptococcosis, histoplasmosis, infection with
Mycobacterium avium or kansasii, CMV infection,
chronic or disseminated HSV infection, progressive
multifocal leukencephalopathy.
ii) Oral hairy leukoplakia, VZV reactivation of more
than one segment, Salmonella bacteremia,
nocardiosis, tuberculosis, or oral candidiasis.
D) Secondary cancers. Kaposi's sarcoma, non-Hodkin's
lymphoma, primary lymphoma of the brain.
E) Other conditions in HIV infection.
The four principle groups are based on chronology, and patients can
only be reclassified downwards, even with remission of symptoms.
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Patients may, however, fall into several subcategories of group IV.
The classification was designed to remove uncertainty about the
distinction between AIDS-related complex and AIDS, and it separates
illness caused by the virus itself (groups I, II, III, IVa and IVb)
from illness secondary to immunosuppression (IVc and IVd). There
remain some problems. For example, while weight loss may be attributed
to a hypercatabolic state and a direct infection of the intestinal
mucosa by HIV, opportunisic infection with isospora and Cryptosporidia
undoubtedly account for a proportion of the symptoms observed. Weight
loss could therefore be a feature of both groups IVa and IVc.
Following exposure, there is an interval of several weeks or months
during which the patient remains well and seronegative. In a few cases
(group I), there may be an infectious mononucleolosis-like illness,
with fever, rash, malaise and generalised lymphadenopathy for several
weeks. The signs are non-specific and it is unlikely that HIV
infection could be reliably diagnosed on these findings alone.
Information about the seroconversion events has either come from
retrospective examination of patient records where the time of
seroconversion was known, or from prospective studies of risk groups
known to be at risk for AIDS.
After seroconversion, patients may remain symptom-free for several
months to several years (group II). Increasingly, careful clinical
scrutiny of patients after seroconversion reveals minor degrees of
immunosuppression in almost all patients. For example, patients are
more likely to suffer from shingles, a well known marker of mild
deficiency in cell-mediated immunity. Laboratory investigations also
may reveal characteristic changes also seen in the full AIDS syndrome,
such as depressed T-helper cell number and raised immunoglobulin
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levels. Leukopoenia (particularly neutropoenia), anaemia and
thrombocytopoenia have all been described in asymptomatic patients. In
particular, overt thrombocytopoenia, along with other hypersensitivity
reactions, is frequently found on administration of trimethoprim and
related antibiotics.
A proportion of patients develop PGL (group III). PGL is defined as
enlargement of lymph nodes at two or more sites (other than inguinal),
for more than three months with no other identifiable cause. Although
originally considered as a preliminary step before the development of
AIDS, a proportion of cases are considered to be incidental, in whom
PGL is not prodromal to the full AIDS syndrome (Janossy et al.,
1985). PGL may in fact regress either spontaneously or on development
of the full syndrome, while patients may have PGL for several years
with no sign of advancing disease. Patients with PGL may have a
variety of constitutional symptoms, but remain classified in group III
rather than IVa on the basis of severity.
Constitutional disease (Group IVa) comprises fatigue, night sweats,
and malaise of varying grades of severity. Patients appear chronically
ill and often cachectic. Prolonged fevers and involuntary weight loss
of more than 10% are found in severe cases. In Africa, the term "slim"
is used to describe this condition. Patients may also have chronic
diarrhoea, often with malabsorption. Hypersensitivity reactions,
retinal infarcts (cotton wool spots), thrombocytopoenia and
hypergammaglobulinaemia and raised levels of cx-interferon have been
described. In some respects, the features resemble the clinical
features of systemic lupus erythematosis, an autoimmune disease. This
suggests an immune complex aetiology for certain aspects of HIV
pathogenesis.
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Neurological disease (Group IVb) probably comprises at least two
distinct syndromes, that can be distinguished both clinically and
histologically. Progressive encephalopathy is a rapid form of the
disease with an underlying inflammatory component. Patients initially
show episodes of confusion or forgetfulness which evolves within weeks
or months into a marked psychomotor depression, with apathy,
withdrawal, mutism and profound dementia. Ultimately the patient
becomes bedridden, incontinent and unresponsive. A slower course may
be observed in some patients, in whom degeneration of the brain tissue
is the prominent pathological finding. In such patients, subtle
personality changes may develop over several years, often with
profound depression or inappropiate, uncontrollable moods. Patients
become increasingly withdrawn, and eventually enter a vegetative state
similar to the other form of encephalopathy. Involvement of the
peripheral nerves may lead to focal neurological abnormalities.
Secondary infection (Group IVc) by opportunistic organisms is one of
the hallmarks of the full AIDS syndrome, and infection by the 12
organisms listed in part (i) constitutes the CD.C definition of AIDS.
However, infections with the pathogens listed in-part (ii) are also
indicative of profound immunosuppression (see Pinching, (1985) for a
review of the clinical features of secondary infections in AIDS
patients). The pattern of infections is similar, in many ways, to that
observed in patients with congenital or acquired cellular immune
deficiency. Characteristically, organisms that do not normally cause
disease in the normal host ( P. carinii, M. avium,), and those that
cause mild and self-limiting disease (HSV, Toxoplasma gondii,) are
pathogenic in AIDS patients, with severe, disseminated and persistent
disease and poor response to conventional antimicrobial therapy. The
spectrum of opportunistic infection in AIDS patients differs in detail
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from that seen in other patients with other deficiencies in cellular
immunity; infection with Legionella pneumophila, and Listeria
monocytogenes, are characteristically rare in AIDS patients.
Secondary cancers (Group IVd) that comprise the CDC definition of AIDS
are Kaposi's sarcoma, non-Hodgkin's lymphoma and primary central
nervous system lymphoma. There is some evidence for the involvement of
CMV and EBV in the aetiology of Kaposi's sarcoma and non-Hodgkin's
lymphoma. (Safai et al., 1984) The incidence of these tumours
resembles that in other patients with secondary immunodeficiency. In
the latter situation, discontinuation of iatrogenic immunosuppression
is associated with regression of the tumour. This supports the idea
that secondary cancers are primarily opportunist in AIDS patients.
Undoubtedly, new syndromes will be characterised in HIV-infected
patients as the epidemic progesses. In the absence of an animal model
for HIV-related disease, clinical features and associated pathology
remain a primary source of information about the virus. Analogies do
exist, however, between AIDS and visna infection in sheep, and such
comparisons have led to a greater appreciation of the direct effects
of HIV infection compared with those secondary to immunosuppression.
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BIOLOGY OF HIV
Retroviruses are very diverse in host range, structure and
pathogenicity, but share a common method of replication. The genomic
material is in the form of positive sense RNA; on infection of a cell,
it is transcribed to a double stranded DNA copy which migrates to the
nucleus to initiate virus replication. The "reverse" transcription is
mediated by a virally-encoded protein found within the capsid of the
virion. The so-called reverse transcriptase is essential for the
infectivity of the virus and is characteristic of the retrovirus
family. At one time it was thought that this enzyme was uniquely
present in retroviruses, but more recent work has established that it
is found in cauliflower mosaic virus (CaMV), and, in a related form,
in hepatitis B virus. Hull & Covey, (1986) discuss the relationships
between these latter two viruses and retroviruses, and come to the
surprising conclusion that they share sequence and functional features
with each other and with transposable elements of drosophila and
yeast. This data, if corroborated, would significantly broaden the
definition of a virus.
Retroviruses can be divided into three main groups. The best
characterised are the oncogenic retroviruses that cause cancers in
their host species. There are at least two oncogenic retroviruses
known to affect man (human T-lymphotropic virus (HTLV) types I and II)
that cause certain types of T-cell leukaemia. Feline leukaemia virus,
Rous sarcoma virus and Moloney murine leukaemia virus are just some of
the many animal oncogenic retroviruses that have been investigated.
The name oncogenic retrovirus should not be taken to imply that they
all cause cancer by the same mechanism; at least five distinct ways
have been described, ranging from direct transmission of oncogenes to
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the cell they infect, to trans-activation and cis-activation of
normally suppressed cellular genes. There is no evidence that HIV is
oncogenic, and sequence data indicates that it is only distantly
related to this family of retroviruses.
The spumavisuses are the second group of retroviruses. These have been
little studied due to problems with culture, and because they appear
to be non-pathogenic. They have been isolated from several mammalian
species including man. There is a suspicion that a spumavirus is
associated with the very rare de Quervain subacute thyroiditis (Werner
& Gelderblom, 1979).
There are grounds for classifying HIV as a lentivirus, the third group
of retroviruses, characterised by slow, progressive diseases found in
several mammalian species. Visna virus (VV; sheep), progressive
pneumonia virus (PPV; sheep and goats), caprine arthritis encephalitis
virus (CAEV; goat) and equine infectious anaemia virus (EIAV; horse)
are well characterised members of this group. A recently discovered
relative of HIV, HIV-2 has been isolated in Africa from patients with
AIDS, but who were seronegative for HIV by conventional antibody
testing (Clavel et al., 1986).
Kanki et al., (1986) also reported a novel "human" retrovirus from
Africa at the same time as the French group, but it is widely
suspected that the virus they called HTLV-IV was merely a contaminant
from primate isolation experiments. A primate retrovirus (simian T
cell lymphotropic virus type III or simian immunodeficiency virus;
STLV-III or SIV) causes an AIDS-lke disease in macaques, shows close
sequence homology with HIV-2, but to be more distantly related to
HIV-1 (Franchini et al., 1987; Chakrabarti et al., 1987). The SIV
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sequence was found to be essentially identical to HTLV-IV, in contrast
to the variability commonly observed between different isolates of the
same retrovirus. There is now a consensus of opinion that rejects the
claim of a human origin for HTLV-IV.
Figure 2 illustrates the HIV genome (after Rabson & Martin, 1985).
Notable is its much smaller size than the HSV genome (only 9735 base
pairs instead of 150 000), and the relatively fewer open reading
frames (7 or 8 instead of around 50). In contrast to HSV, there is
complete sequence data on several isolates of HIV, and of several
other retroviruses. A major surprise was the discovery of extra open
reading frames as compared with the oncogenic retroviruses. The latter
generally only have three, gag , pol and env (although HTLV-1 and
-II also have a transactivating protein pX). Subsequent sequencing of
VV revealed a similar arrangement to HIV, with three extra genes
encoding presumably regulatory proteins (Sonigo et al., 1985).
PROCESS OF INFECTION
Infection of a cell by HIV is followed by release of positive sense
genomic RNA in the cytoplasm. Reverse transcriptase (RT), present in
the core of the virus, mediates the immediate synthesis of a
complementary strand of DNA. RNA is removed from the DNA copy by endo
H activity present in the RT protein. On completion, RT continues to
produce a double stranded DNA from the newly synthesised negative
sense DNA, and the linear duplex is then transported to the nucleus to
initiate transcription of viral RNAs. The extent of viral DNA
replication in vivo is not known, but since it is mediated by host
cell DNA polymerase, it probably varies between different cell types.







FIGURE2:HIVgenomea dlocationofgenes(baseW is ,1987).Viricompon nts inboxes.
There are two origins for DNA replication, one at the 5' LTR and one
at the the downstream end of the pol gene. Progeny genomes have a
characteristic structure of a complete negative strand and a positive
strand with a nick, corresponding to the junction between strands from
the two initiation sites. The 5' end of the RNA has strong promoter
sites for transcription by cellular RNA polymerase II.
Lytic infection of a cell occurs with the synthesis of structural
proteins encoded by the gag , pol and env genes. There are two
distinct mRNAs produced from the nuclear DNA for this step. Firstly
there are full length transcripts from which the gag and pol proteins
are translated. Initially a polyprotein spanning both the gag and
pol genes is produced. This occurs despite a stop codon and a frame
shift at the end of the gag gene. The stop codon is weak in that
approximately one time in ten translation proceeds to the end of the
transcript. This ensures that gag proteins are more abundant than pol
proteins, as would be required for capsid assembly. The method by
which a frame shift can be read through successfully has been
described for Moloney murine leukaemia virus (Yoshinaka et al., 1985)
and may apply to HIV. A protease encoded by the 5' end of the pol
gene divides the gag polyprotein into functional units during assembly
of the virion. Env proteins are translated from a short, separate
mRNA. An infected cell also produces genomic RNA for incorporation
into the assembling virions during the latter stages of the
replicative cycle.
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REGULATION OF GENE EXPRESSION
The sor , tat , art/trs and 3'orf genes are thought to encode
regulatory proteins. Transfection of cells with full length DNA copies
of HIV with deletions of each of the proteins has been used to
investigate their roles in in vitro virus replication. Deletion
mutants lacking 3'orf grow in vitro (Fisher et al., 1986b), while
those lacking sor can replicate, but more slowly (Sodroski et al.,
1986b). More recently, sor has been shown to be essential for
infectivity. Strebel et al., (1987) showed that replication in
culture of sor deficient mutants was only possible because of direct
cell to cell spread, rather than through infection by extracellular
virus in the supernate. Released virions with sor deletions were
shown to be relatively non-infectious. Fisher et al., (1987) showed
that all stages in the replication of sor deficient mutants were
normal, and postulated that the effect of sor was
"post-translational". Although this might be a maturation or packaging
function, she also considered that sor might actually be present in
the virion, albeit in small amounts, and have a function in the early
stages of infection. With the notable economy in coding sequences of
HIV (and viruses in general), it is likely that 3'orf also plays an
essential role in natural infection. Furthermore, patients infected
with HIV develop antibodies to the 3'orf protein, indicating that it
is expressed in natural infection (Arya & Gallo, 1986).
Mutants deficient in tat and tat/trs do not replicate in vitro or
induce cytopathic effects (Dayton et al., 1986; Fisher et al.,
1986a; Sodroski et al., 1986a). Both gene products have been shown to
have trans-activating functions, although their sites of action are
not entirely clear. There is serological evidence for tat and
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art/trs gene translation (Feinberg et al., 1986; Knight at al. ,
1987). It is unfortunate that different methods of investigation of
the roles of tat have yielded conflicting results. Based on previous
work by Sodroski et al., (1985) on transactivation of HTLV-1 gene
expression by pX, Cullen (1986) attached the 5' LTR promoter sequence
to either chloramphenicol or interleukin-2 genes and found increased
levels of mRNA production in the presence of tat. This is evidence for
control at a transcriptional level, although it has been pointed out
that the increased level of transcripts may be due to a stabilising
effect of tat on these mRNAs).
On the other hand, deletion mutants of HIV lacking tat gene
expression were shown to have normal levels of viral mRNAs, but failed
to produce viral proteins (Rosen et al., 1986; Feinberg et al.,
1986). This is evidence for regulation by tat at a translational
level. The problem is not resolved at present. Disparate roles for
art/trs have also been described. Sodroski et al., (1986a) found
normal levels of mRNAs encoding gag and env proteins, but reduced
rates of synthesis (ie a similar effect to that found in tat
deletion mutants). On the other hand, Feinberg et al., (1986) found
depressed levels of gag/pol and env mRNAs and disproportionately high
levels of ■ multiply spliced 2000 base pair mRNAs encoding
non-structural proteins. Again, different investigators have found
regulation at different levels of gene expression. Knight et al.,
(1987) describe experiments that indicate a role for art/trs in
trans-activation of the env transcript. Unlike cellular mRNAs, the
promoter sequence of the env mRNA appears to have an intrinsic
translational block, possibly mediated by loop formation from
palindromic sequences, and that intervention from the 19 KDa protein
is required for translation.
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These experiments were generally performed in cells that supported a
lytic cycle of infection, without the establishment of latency. It is
therefore very difficult to speculate on what the role of the
regulatory proteins might be in a real infection. HIV is known to
infect a wide range of cell types, including T-lymphocytes,
macrophages and astrocytes in the brain. It is speculated that, during
the latent stage, the non-structural proteins mediate a
transcriptional or translational block that is released on
reactivation of the virus. HIV manages to continue to replicate in man
in the presence of specific humoral and cell-mediated immunity. Cells
bearing viral antigens would be expected to be rapidly destroyed by
the immune system. An attractive theory for HIV reactivation supposes
that the process is divided into two distinct phases. Firstly, the
relatively slow process of mRNA and genomic RNA synthesis is carried
out in the absence of translation of viral proteins. During the next
stage, viral proteins are rapidly synthesised from the accumulated
mRNAs, and the virions assembled before destruction of the cell.
To achieve this, HIV would require co-ordinated control at several
levels of viral gene expression, necessitating a simultaneous switch
to genomic and structural protein RNA synthesis followed by a
co-ordinated derepression of translation. This model us odrtsfcsefe?st;
with the known ability of HIV to continue replication in man despite
demonstrable specific immune responses to the virus (see below). It
may also explain why only a small proportion of circulating T-cells in
infected patients appear to contain viral proteins.
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HIV STRUCTURAL PROTEINS
The sequence and arrangement of genes encoding the structural proteins
resembles that of other retroviruses, and there are functional
homologies between the proteins they encode. Figure 2 shows the
translation and subsequent cleavage of HIV encoded proteins. The gag
and pol proteins are relatively well conserved from an evolutionary
point of view, but the env proteins are diverse. In particular, the
env proteins of lentiviruses appear to have specific features to evade
host immune responses (see below).
REVERSE TRANSCRIPTASE
The pol gene products include a 33 KDa endonuclease, a protease for
viral protein cleavage and a 65 KDa glycosylated protein, subsequently
cleaved to a 51 KDa form. Both forms have been shown to have reverse
transcriptase activity, and both are found in the purified virion
along with endonuclease. The functional significance of the two forms
is unknown. Reverse transcriptase is the target for current anti-HIV
drugs, of which 3'-azido-31-thymidine (AZT) is the best known example,
and which operates by mimicking thymidine and disrupting reverse
transcription. Cellular thymidine kinase converts AZT to the
monophosphate form, and thymydylate kinase and TDP kinase convert it
to the triphosphate form. This is incorporated into DNA by
HIV-specified RT but not by cellular DNA polymerase, and herein lies
the basis of the drugs specificity. It does not have the dual
recognition safety of ACG (that requires both virally encoded TK and
DNA polymerase for activity), and is significantly cytotoxic. Larder
et al., (1987) investigated the substrate binding areas of the enzyme
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by means of site-specific mutagenesis in attempts to design new drugs
with greater specificity for HIV. Preliminary clinical trials of the
efficacy of AZT indicate that only temporary remission of disease is
achievable (Yarchoan et al., 1986), and there may be worsening of the
disease on cessation of treatment. AZT is inactive against the virus
in its the latent form. A more effective drug would be one that
inhibited reactivation of virus, rather than one that only operated
during the initial stages of infection.
CAPSID PROTEINS
The capsid comprises predominantly p24, pl7 and pl3, the three
cleavage products of the precursor gag gene product. The arrangement
of the capsid proteins is unknown, and is likely to be complex as
variable amounts of uncleaved precursor proteins are also found in the
capsid. pl3 has been shown to have RNA binding activity. None of the
gag proteins are glycosylated. On natural infection, high levels of
non-neutralising antibody to p24 are induced, with more variable
reactivity with pl7 and-pl3. The epitopes of p24 and pl7 have been
investigated by monoclonal antibodies. Ferns et al., (1987) found
reactivity of monoclonals with p24 and pl7 to be mutually exclusive as
would be expected. pl7 monoclonals inhibited each other from binding
indicating that they recognised a single antigenic site on the
protein. p24 monoclonals did not normally cross-inhibit each other
suggesting reactivity with several different antigenic determinants on
the protein. However certain p24 monclonals were cross-inhibited by
those reactive with pl7, suggesting an antigenic area comprising both
proteins. The data are, however, preliminary and would require
corroboration. In particular, some monoclonals apparently failed to
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inhibit their own binding in this experimental set-up. An apparent
variability in the capsid proteins between isolates was indicated by
the finding that recent African isolates of HIV were not recognised by
several of the p24 monoclonals. Variation in the p24 protein was
described by Higgins et al. , (1986). who showed that isolates from
patients in the San Franscisco area showed differing reactivities with
monoclonals, allowing them to be subtyped into those resembling the
original HTLV-III isolate of Gallo, and those resembling the
Californian AIDS-related virus (ARV) strain.
ENVELOPE PROTEINS
The env gene encodes a 160 KDa membrane precursor protein. Cleavage
by cellular proteases produces a C-terminal 41 KDa portion containing
the transmembrane anchor region, and an external 120 KDa portion.
Disulphide linkages established before cleavage hold the two fragments
together, although shedding of gpl20 can be demonstrated. gp41
contains approximately 350 amino acids, of which 150 are within the
envelope. The reason for the large internal domain is not known. A
sequence of 23 hydrophobic amino acids is thought to span the
envelope. The external portion of the protein contains 4 sites for
N-linked glycosylation.
gpl20 is 480 amino acids long and contains several cysteine residues
that determine the conformation of the protein, and mediate attachment
to gp41. The protein has a total of 27 potential N-linked
glycosylation sites. There is also evidence for 0-linked
glycosylation, so the fully processed protein would be considerably
modified antigenically. Chang et al., (1985) showed that env antibody
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reacted predominantly with the C-terminal portion of gpi20 and the
adjacent attached gp41 region, both regions with relatively little
glycosylation.
Comparison of isolates from different geographical areas shows greater
variability in the env region that any of the other structural protein
genes. Furthermore, within the gpl20 region, certain areas are more
variable than others. Certain regions encoding hydrophilic loops are
found to be highly variable. Many of the potential glycosylation sites
are found in such areas. Comparison of African and French isolates
showed that half of the sites of N-linked glycosylation were not
conserved (Alizon et al., 1986), and this would be expected to affect
profoundly the antigenicity of the proteins. The three hypervariable
regions identified were bounded by conserved cysteines suggesting a
common folding pattern. The requirement for a functional T4 receptor
(see below) may account for the relative sequence conservation of 3
other regions of the protein.
VIRUS ATTACHMENT
Unlike HSV, the nature of both the viral and cellular receptors has
been established. There is overwhelming evidence that a T4 phenotype
is necessary for infection by HIV. Firstly, monoclonal antibodies
reactive with the T4 epitope have been shown to block the attachment
of HIV (Dalgleish et al., 1984; Klatzmann et al., 1984). Secondly,
MacDougal et al., (1986) described the formation of gpl20-T4
complexes in vitro . Thirdly, several T- and B-cell and fibroblast
human cell lines were rendered susceptible to HIV infection by prior
transfection of the cells with the complete DNA sequence for the T4
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receptor (Maddon et al., 1986). It was thought that the ability of
HIV to infect cells other than T-helper cells contradicted the role of
T4 in adsorption. However, not only macrophages, but also microglial
cells of the brain and endothelial cells of the intestine have
subsequently been shown to show the T4 phenotype.
It was surmised that gpl20 was responsible for attachment of HIV to
its target, on analogy with other retroviruses, and by the observation
that gpl20, on its own, could cause syncytium formation in cells of
the T4 phenotype (Lifson et al., 1986). HIV was shown to bind to
mouse cells transfected with the T4 gene but there was failure to
internalise the virus. This suggests a secondary interaction, possibly
between gp41 and another cellular protein (Maddon et al., 1986).
According to one hypothesis, the regions within the gpl20 protein that
interact with T4 are likely to be highly conserved due to functional
constraints. However, if there is immunological pressure for HIV to
mutate in order to evade neutralisation, then only variation in the T4
binding site could be expected to be effective. This second hypothesis
would predict neutralisation sites to be located in the variable
regions. Sequence data indicates that the residues between 37-130,
211-289 and 488-530 are relatively invariant between French and
African isolates (Alizon et al., 1986). Ho et al., (1987) raised
antisera to synthetic oligopeptides corresponding to various regions
of gpl20. Ten of the 22 antisera reacted with native gpl20, and of
these, only four were neutralising. They corrresponded to residues
280-293, 458-484, 616-632 and 728-751. Overall, it seems that the
neutralisation sites are not located in the conserved areas, and the
data supports the second hypothesis. This data is preliminary and
further work is required.
- 80 -
In summary, HIV causes a diverse and prolonged disease in humans. The
regulation of HIV replication suggests methods by which the virus
could maintain a state of latency. The heavy glycosylation and
variability of the viral envelope may indicate that immunological
pressures have shaped the evolution of HIV. The role that the T4
receptor plays in virus attachment accounts for the observed tropisms
of HIV for various organs in the body.
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CHAPTER 4
PATHOGENESIS OF HIV INFECTION
The processes by which HIV causes disease in humans have not been
determined, despite the great advances made in understanding the
virology of infection. This section will give an account of the
principal laboratory markers of HIV infection, particularly those of
immunosuppression. The cell-mediated and humoral immune responses to
infection will be discussed. Finally, the numerous theories concerning
the pathogenesis will be reviewed.
MARKERS OF INFECTION
The AIDS syndrome was described and investigated thoroughly before the
discovery of HIV. Such studies could not investigate asymptomatic
carriers and there is still a relative lack of information about this
group of patients. In AIDS patients, it is difficult to distinguish
the primary effects of infection with HIV from abnormalities arising
from secondary infection, cancers, or simply prolonged illness. There
was a tendency to attribute the entire range of AIDS symptomatology to
immunosuppression. The discovery of HIV led to the identification by
serology of a large number of infected but asymptomatic carriers. This
has led to an intensive area of research to investigate the markers,
pathogenesis and causes of progression to AIDS. This is a particularly
interesting area, since the time course of progression is so variable
between patients; furthermore, it is not known whether progression to
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AIDS is inevitable or if some patients can keep the disease in check
indefinitely. In terms of drug treatment, it would appear easier
to prevent progression than to prevent primary infection.
EXPOSURE & SEROCONVERSION (GROUP I)
It is difficult to study the events around seroconversion because of
the non-specificity of the clinical signs and the lack of a readily
available animal model. Most information has come from retrospective
serological testing, case studies and the experimental inoculation of
chimpanzees. The specific markers of initial infection are viraemia,
followed by the appearance of HIV-specific antibody.
There is some evidence that exposure does not necessarily lead to
infection. This was noted in a study by Burger et al., (1984) who
described the absence of seroconversion in the wife of a haemophiliac
infected with HIV. IgM was detected in the serum of the wife during
exposure, but it disappeared on cessation of sexual contact. This
observation is similar to that reported by Fultz et al., (1986) who
also detected a transient IgM response in a chimpanzee sharing a cage
with another experimentally infected with HIV. It is not known whether
infection is more readily transmitted by infected cells or by free
virus. Obviously, free virus is infectious since factor VIII regularly
infects haemophiliacs. Foreign cells would also be destroyed rapidly
by the recipient, so there would always be an extracellular phase
during the infectious process. Plasma from patients with HTLV-I and
-II is not infectious; it has been shown that infection requires the
inoculation of cells from an infected patient (Okochi et al., 1984).
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The interval between exposure and seroconversion is not known with
certainty, but appears to be prolonged in certain documented cases.
Much of the evidence is anecdotal, and has recently been reviewed by
Pinching (1987). There is a general consensus that clinical illness
associated with primary HIV infection precedes the appearance of
HIV-specific IgG. Cooper et al. , (1985) describe infection in twelve
male homosexuals. The times between exposure and illness and
seroconversion could not be accurately established in this study, but
were generally considered to be relatively short. In one patient, it
was estimated that 6 days elapsed between exposure and illness. The
time to seroconversion was in the range 19 to 56 days in three others.
Features of the clinical illness described included fever, myalgia,
malaise, lymphadenopathy and sore throat. A maculopapular rash
affecting the trunk was found in half of the patients. Studies of
T-cells showed transient elevation of T8 (cytotoxic/suppressor) cell
numbers with relatively unchanged numbers of T4 (helper) cells. These
T-cell findings are typical of many acute viral illnesses and do not
reflect an abnormal immunological response.
In a Veil documented needlestick incident (Editorial, 1985), blood
from a patient infected with HIV was inoculated accidently into the
hand of a nurse. The nurse developed an infectious-mononucleosis -like
illness by the thirteenth day; by 47 days she seroconverted for
antibody. Tucker et al., (1985) describe the illness associated with
primary HIV infection in a haemophiliac transfused with contaminated
factor VIII during a synovectomy operation. Transfusion was given over
several weeks so the time of exposure could not be exactly determined.
Features of the acute illness could be related to the time of
seroconversion. Rash and splenomegaly preceded the seroconversion by
about a week, while lymphadenopathy was first recorded one week after
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the development of antibody. This is unlike the illness described by
other investigators. Furthermore, a transient fall in T4 numbers was
also detected, while T8 numbers were erratic. The authors found a
transient depression in the T4/T8 ratio. However intercurrent
bacterial infection during the operation and the known abnormalities
in haemophiliac immune function may have accounted for these results.
Gaines et al. , (1987) describe symptomatic infection in a cohort of
20 male homosexuals in a prospective study and give accurate
information on the time to seroconversion. The time from exposure to
illness was determined in each patient and found to lie in the range
of 11 to 28 days, while HIV-specific antibody was detected 2 to 7
weeks after the initial illness. Prominent symptoms reported included
fever, sore throat, lymphadenopathy and rash. One patient had a
transient meningoencephalitis. Laboratory evidence of
thrombocytopoenia was found in twelve patients, while 15 showed
varying degrees of leucopoenia. T4 and T8 numbers were not recorded.
Denning et al., (1987) and Carne et al., (1985) describe acute
myelopathy and encephalopathy in association with primary infection.
Accepting the reservations about the applicability of animal models,
Alter et al., (1984) report an interval of about six weeks between
inoculation and seroconversion in captive chimpanzees.
Variation in the specificities for individual HIV proteins has been
reported during seroconversion. Using the immunoblotting technique,
antibody to p24, a core protein, is normally the first specificity to
be detected after seroconversion (Lange et al., 1986a; Groopman et
al., 1986; Schuepbach et al., 1985). The consensus between these
papers is that p24 reactivity is shortly followed by antibody to pr55,
the uncleaved gag precursor protein. Antibody to gp41 appears at a
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much later stage, while anti-gpl20 may not be detected at all in many
patients. All patients eventually develop antibody to pol gene
products, RT and endonuclease. Investigators using the RIP technique
have reported different findings; the first signs of seroconversion
are marked by the appearance of antibody to gpl60, followed by gpl20
and p24 (Gaines et al., 1987). Results from their RIP assay showed
that two patients developed antibody to gpl60, at a time when
they were negative for antibody in the conventional IB assay. p24
antibody reactivity first appeared several days later in these two
patients in the latter assay. Two groups have shown that the RIP
method is more sensitive for antibody to env proteins than the IB
assay (Ulstrup et al., 1986; Barin et al., 1985) in convalescent
sera, and this was advanced as the explanation for the discrepancy in
the results of the seroconversion studies.
Allain et al., (1986) used a new ELISA technique to study antibody
responses to a recombinant env gene product (an unglycosylated gp41
protein, including a small part of gpl20) and a similarly prepared
synthetic p24 antigen. The method of preparation ensured that there
was no contamination with other HIV proteins. Sera from 40
haemophiliacs taken around the time of seroconversion were tested
retrospectively for antibody to the. "env" and "core" proteins. The
timing of samples made the analysis of the results difficult, but
anti-"env" antibody was detected before anti-"core" in 21 patients and
these results resemble those of the RIP assay.
Using an ELISA for HIV antigen, Allain et al., (1986) reported the
detection of free virus in the sera' of 14 haemophiliacs before
seroconversion. The antigenaemia was also shown to co-exist with
anti-"env" antibody but became undetectable on development of antibody
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to p24. The hypothesis advanced to explain these findings was that
there was relative abundance of capsid proteins over envelope proteins
and the former were produced in such large amounts on primary
infection that it could overwhelm the initially restricted amounts of
antibody to p24. During resolution of the viraemia and the detection
of anti-"core", it would be predicted that immune complexes would be
found. The clinical evidence of rash and myalgia, two immune complex
phenomena, during primary illness would support this hypothesis.
The duration of the antigenaemia could not be accurately established
due to the spacing of samples. A statistical estimate could be made on
the basis that the prevalence of antigenaemia was 50% in a group where
the frequency of sampling was on average 3.5 months, while in the
group who were less frequently tested (5 months), the prevalence was
reduced to 25%. There is, therefore, an association between sample
spacing and detection of antigenaemia. Statistical analysis of this
data was not attempted. Goudsmit et al., (1986) used a similar
antigen assay in a study of the seroconversions of male homosexuals.
They reported a 31% incidence in antigenaemia where the average
spacing of samples was 3 months. Data from the two groups will be
discussed more fully later, since they are directly comparable to work
carried out in this thesis. Other investigators have confirmed the
existence of an antigenaemia before seroconversion; Wall et al.,
(1987) report simultaneous antigenaemia and primary illness in two
patients, followed by seroconversions 6-8 weeks later. There is
currently little evidence for prolonged antigenaemia in the absence of
seroconversion.
- 87 -
Parry & Mortimer (1986) described the development of an assay to
detect HIV-specific IgM, and its application to the study of
seroconversions. In contrast to many viral infections, IgM is not a
prominent feature of the early immune response, and may not be
detected at all in some patients. Where it is detected, it is
generally present at low concentrations. Bedarida et al. , (1986)
found IgM in sera of patients preceding seroconversion using an IB
assay with labelled anti-human IgM. IgM was detected in three of the
five experimentally inoculated chimpanzees by direct binding ELISA
(Fultz et al., 1986). No IgM was detected in the remaining two,
despite daily testing. In the others, IgM was detectable 1-2 weeks
before the appearance of HIV-specific IgG. The problems of measuring
IgM in the presence of IgG, and the possible effects IgM would have on
RIP and competition ELISAs are discussed more fully later.
ASYMPTOMATIC INFECTION (GROUP II)
As mentioned previously, patients classified as group II may show
minor degrees of immunosuppression or constitutional disease. This is
frequently reflected in a fall in absolute numbers of T4 cells, or,
more commonly, a rise in T8 cell numbers (Horsburgh -et al., 1986;
Melbye et al., 1986). A sudden fall in T4 numbers has been shown to
be a poor prognostic sign (Biggar et al., 1985), correlating with
progression to ARC or AIDS. Weber et al., (1986) reported, however,
that the variation of T4 numbers in promiscuous male homosexuals
tended to vary greatly for other reasons and they could not find a
correlation between T4 numbers and progression. Asymptomatic patients
show a reduced proliferative response to mitogens, such as
phytohaemagglutinin (PHA), and specific antigen in an in vitro assay
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of helper T cell function. Hypergammaglobulinemia, a feature reported
in AIDS patients, is also found to a lesser extent in asymptomatic
patients (Nicholson et al., 1985; Jaffe et al., 1985)
Antibody to HIV is present in patients during the asymtomatic period.
Antibody has been detected to all of the structural and non-structural
proteins of HIV. The presence of antibody is a reliable indicator of
past exposure, and is the method of choice in screening blood for
infectivity. Much data has been presented on the relative
sensitivities of currently used tests for HIV antibody. In general
terms, there is no significant difference between the results of the
different tests, whether they be direct-binding, competitive or
capture ELISA's, indirect immunofluorescence or haemagglutination
assays. The discrepancies arise from testing sera collected around
seroconversion, where some of the less sensitive tests fail to detect
the very low levels of antibody, often with restricted target
specificity, found in sera from patients at this time. This is
discussed later.
Antibody levels to HIV have been reported to be reduced in patients
with prodromal AIDS (Biggar et al. , 1985). AithougJv there is reported to
be no change in titre to gp41 (Weber et al., 1987), there is
accumulating evidence that there is a characteristic reduction in
antibody to gag proteins in patients progressing to AIDS. Schuepbach
et al., (1985) first noted a reduction in p24 reactivity in an IB
assay in patients who progressed to AIDS, but also reported greater
reactivity with gp41 in such patients compared with patients in the
early stages of the disease. Essentially similar findings were
reported by Lange et al., (1986b) in a larger study of male
homosexuals. Whether the decline in p24 antibody levels was the result
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of immunosorption of antibody by an increased rate of virus
replication and release, or whether it was due to clonal exhaustion of
the B cells producing HIV antibody was not resolved. Lange et al.,
(1986c) described the testing for p24 antibody of sequential samples
from a cohort of children infected with a single plasma donor. They
found an association between p24 antibody and lack of disease
progression (but not the converse); similar findings with adult
patients were made in two independent cohorts of infected patients
from London (Weber et al., 1987).
Groopman et al., (1986) contested these data and showed that by
extending the incubation times in the IB assay, p24 reactivity could
be detected in all patients in their cohort, whether symptomatic or
not. They did not, however, titrate sera for p24 antibody; if they
had, it is likely that they would have found higher titres in the
asymptomatic group and would have arrived at essentially the same
conclusion as the other investigators. They also advanced the
hypothesis that lack of reactivity with gp41 observed in some patients
in their study group indicated the existence of variant forms of gp41
encoded by the virus infecting those patients IB assay. This is
unlikely.
Lange et al., (1986a) used IB, RIP assays for HIV antibody and an
ELISA for HIV serum antigen detection in a follow-up study of a cohort
of male homosexuals. They found a strong correlation between
disappearance of p24 antibody and subsequent antigenaemia. This is
analogous, but opposite, to the course of events during
seroconversion. The detection of antigen late in infection was
surprising in view of the similarities to HIV
seroconversion with that of HBV. In the latter case, infection is
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accompanied by an antigenaemia which resolves on development of
anti-surface antigen (anti-HBs). Reappearance of surface antigen does
not occur in patients with anti-HBs. Goudsmit et al., (1987a) also
detected HIV antigenaemia in their cohort, in association with disease
progression, although significantly, there were patients who were
persistently antigenaemic, negative for p24 antibody but who remained
well. Antigen has also been detected in the cerebrospinal fluid of
patients with HIV infection (Goudsmit et al., 1986). The risk of
progression differs in different groups of patients. In particular,
children have been reported to have a high rate of antigenaemia, low
p24 reactivity, while remaining symptom-free (Lange et al., 1986c). A
similar picture may be seen in chimpanzees, where there is prolonged
antigenaemia, low levels of p24 antibody (Goudsmit et al., 1987b),
and no progression to overt AIDS.
The relationship between infectivity and antigen level has not been
established, although there is much evidence that antigen-negative
blood may be infectious. By analogy with HBV, it is possible that the
antigenaemia, where there is apparently excessive production of core
proteins over those of the envelope, may indicate defective virus
production, and not increased infectivity. Virus may be isolated from
patients at all stages of infection, including from those who are
antigen negative and with high anti-p24 levels. Most investigators
report that it is more difficult to isolate from patients in the
terminal stages of AIDS, where there may be high serum antigen levels.
This is most likely to be a function of the poor proliferative
response of T cells during the isolation procedure.
Neutralising antibody may be detected in the convalescent stage of HIV
infection, but only from a proportion of patients and at generally low
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levels (Folkes et al., 1985; Weiss et al., 1985; Robert-Guroff et
al., 1985). Weber et al., (1987) investigated the neutralising
ability of sera from patients infected with HIV and related the data
to the rate of progression to AIDS. There was a slight trend towards
increasing neuralisation titre with time in the patients, but no
independent correlation with disease progression. The low
neutralisation titres to HIV generally observed, compared with those
found in HTLV-I infection, probably accounts for the increased
transmissability of HIV in cell-free inoculation. HTLV-I typically
induces neutralisation titres 300 fold higher than HIV; this may
explain why HTLV-I infection can only be acquired by cell inoculation.
PERSISTENT GENERALISED LYMPHADENOPATHY (GROUP III)
This is a poorly defined group and probably encompasses several
distinct pathologies. Janossy et al., (1985) present evidence that
there are two distinct histological changes found in lymph nodes, each
with a distinct prognosis. Details of the histology are complex, but
are reviewed by Racz et al., (1986). In summary, there may be an
explosive follicular hypertrophy in patients who Janossy regarded as
having a good prognosis, while degenerative changes' were seen in those
with prodromal AIDS (Fernandez et al., 1983). Further studies are
necessary to confirm this correlation, and to investigate the
relationship with the the two distinct changes in T cell subset
numbers (ie. rise in T8 numbers or fall in T4) observed in patients in
groups II and III.
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ARC and AIDS (GROUP IV)
The laboratory markers of advanced disease vary between patients, and
there is always the possibility that secondary infections and cancers
might obscure the underlying pathological changes. The most striking
feature of AIDS is the depletion in T4 cell numbers; T8 numbers may be
elevated or relatively normal. There is some evidence that T4 cells of
different function might be differentially affected. The numbers of T4
cells involved in the lymphoproliferative response to antigenic
stimuli may be relatively unaffected, with a relatively greater
reduction of T4 cells effecting the DTH response (Nicholson et al.,
1984) .
T4 cells show impairment of function in addition to reduced numbers.
There is a reduced proliferative response to pokeweed mitogen and
failure to provide help for immunoglobulin production in an in vitro
assay of T cell function (Lane et al., 1983). Reduced
lymphoproliferative responses have also been reported for CMV and HSV
antigens (Hersch et al., 1985). The proliferative response to HIV
antigen was investigated by Wahren et al., (1987) in asymptomatic and
unwell patients (PGL, ARC and AIDS). Patients with advanced disease
showed poor responses to HIV compared with aymptomatic patients. There
was a selective reduction in the proliferation to whole HIV virions;
interestingly the response to individual virion components (p24, gp41
and gpl20) was greater than that to the whole virus; overall, p24
elicited the strongest proliferative response. HIV proteins did not
inhibit the proliferative response to HSV or CMV, ruling out a
p
non-specific immunosu^ressive effect of the virus. Interleukin-2
increased the response to antigens and mitogens, and the reduced
sensitivity of helper cells for interleukin-2 has been advanced as an
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explanation for their functional abnormalities (Gluckmann et al.,
1985 ) .
DTH responses are reported to be reduced in AIDS patients on skin
challenge; such patients also show a failure to produce granulomas.
Monocytes reduced in number and there is a defect in the maturation
process to macrophages (Hersch et al., 1985). Macrophage function was
found to be defective in AIDS patients; the recent discovery of HIV
infection in cells of the monocyte line may account for this, although
the effect described may be due to a failure of T cell-macrophage
cooperation. ^-interferon can restore the ability of macrophages from
AIDS patients to phagocytose Candida (Murray et al., 1984; Estevier
et al., 1986).
Several studies have investigated cytotoxic T-cell responses to HIV
antigens. Plata et al., (1987) found a high proportion of alveloar
macrophages from AIDS patients to be infected with HIV. They were
killed by autologous cytotoxic T cells in three of four patients
tested; killing was shown to be class I restricted. Cross-reactivity
between the effector and target cells was demonstrable between
patients of- the same HLA type. This indicates that HIV strain
variation was not a significant factor in the effectiveness of the
cytotoxic response. The authors suggest that a component of the lung
pathology observed in AIDS (interstitial pneumonitis) may be due to
infiltration of cytotoxic T cells. Walker et al., (1987) used a
vaccinia recombinant with inserted env or gag/pol genes to infect
B cells. T cells from the patients were then incubated with the
infected cells in a chromium release assay. Specific cell lysis of
cells expressing gag/pol proteins was found in three of the eight
patients, while all patients killed env-expressing cells. Neither
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paper gives data on the relation between CTL activity and progression.
Only this would show whether there was a defect in HIV-specific
cytotoxicity concomitant with other defects in immunity. CTL
reactivity with other antigens was shown to reduced in AIDS patients
(Sharma & Gupta, 1985).
B cells are present in normal numbers in AIDS patients although they
show abnormal function. There is a polyclonal hypergammaglobulmaemia,
with IgG levels typically being raised 50% above their normal value.
Titres of antibody to previously encountered antigen are similarly
raised. More striking is the failure of AIDS patients to develop an
antibody response to neoantigens, or to show a rise in titre to recall
antigens (Lane et al., 1983). Immune complexes are frequently
detected; this may indicate immune dysfunction (Euler et al., 1985),
but it may also reflect the HIV antigenaemia that often accompanies
advanced disease. Morrow et al., (1986) analysed polyethylene glycol
precipitates of sera from AIDS patients and detected HIV core proteins
in the immune complexes by immunoblotting. Lange et al., (1987)
detected HIV antigen in the immune complexes of in a wide range of
HIV-infected patients. They used a modified ELISA after disassociation
of the complexes, and were able to find antigen in patients who were
negative in the conventional ELISA test for antigen.
In summary, the main feature of AIDS is a reduction and loss of
function of T4 cells. At present it is not known whether the B cell
and macrophage defects are secondary to this, or reflect a different
pathological mechanism. The current evidence shows, increasingly, that
HIV infects a wide range of cells in the body, and macrophages are
considered by some to be the main target of HIV, and the pathogenesis
of HIV infection may involve more than simple T4 cell destruction.
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THEORIES OF PATHOGENESIS
Many theories have been advanced to explain various aspects of the
pathogenesis of HIV infection. The simple theory originally held was
that HIV was an infection of T4 helper cells, and that the disease was
caused by a progressive destruction of these cells with a concomitant
loss of immune function. Several lines of evidence challenge this
version of events.
Firstly, sequence data showed HIV to be related more closely to visna
and other lentiviruses than to HTLV-I and -II. Lentiviruses are known
to cause a range of diseases independently of immunosuppression, and
to be able to infect a wide range of different cell types, in
particular monocytes. HIV has been shown to infect a high percentage
of lung macrophages (Plata et al., 1987) and cells from the brain
(Gartner at al., 1986). There is also evidence that macrophages
mediate the copious diarrhoea via inflammatory responses in the bowel,
and cause the weight loss observed in patients with HIV by release of
cachexin (Torti et al., 1985).
Secondly, HIV appears to be resistant to neutralisation as compared
with HTLV-I and -II, with .demonstrable consequences in transmission
and spread in the body. HIV causes disseminated disease in the face of
an immune response whereas HTLV-I remains confined to the T cells that
were originally infected. Thirdly, widespread infection of T4 helper
cells in HIV-infected patients, even those with advanced disease,
could not be readily demonstrated when hybridisation probes were
developed and used to test for virus-specific sequences. Harper et
al., (1986) found only 1 T4 cell in 20 000-100 000 to contain specific
sequences of either RNA or DNA. Fourthly, while it is appreciated that
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HIV induces syncytium formation in T ceils in vitro as part of the
infectious process, such syncytia have been rarely observed in
lymphocytes from infected patients; the only evidence for a cytopathic
effect in vivo is the description of giant cells in the brain of
infected individuals (Vaseux et al., 1986).
This last section of the introduction will review current theories of
HIV infection. Many are contradictory, while others could be
considered to describe different aspects of the disease.
RESISTANCE TO THE IMMUNE SYSTEM
It is necessary to explain how HIV infection progresses in the face of
an immune response. The neutralisation titres of patients with HIV are
generally around 1/10 while those induced by HTLV-I infection are
1/3000-4000 (Weiss et al., 1985). There is circumstantial evidence
that the high degree of glycosylation of gpl20 of HIV is responsible;
HIV has 19 potential sites for N-linked glycosylation, while HTLV-1
has only two. The extra glycosylation may modulate the immunogenicity
of the protein by shielding the amino acid chain from recognition. The
existence of a strongly immunogenic carbohydrate epitope on gC-1 of
HSV (see chapter 1) indicates that this may not be the entire
explanation.
Equine- infectious anaemia virus (EIAV) has been shown to undergo rapid
point mutation in the envelope region of the genome in order to evade
neutralisation (Montelaro et al., 1984). Infection is characterised
by episodic reactivations of virus. Each replicative cycle produces
virus that is resistant to neutralisation by antibody collected during
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previous episodes (Salinovitch et al. , 1986). This is clear evidence
for rapid evolution providing a method by which virus may evade the
immune system. Visna virus also shows rapid evolution of the env
protein on experimental infection of sheep, but the inoculum strain
persists alongside the new variants (Lutley et al., 1983). This is
evidence that immunologically driven variation is not a feature of
infection with this virus.
The env region of HIV does show relatively high rates of variability
in sequential isolates from the same patient (Hahn et al., 1986), but
less than between isolates taken from different patients, which is, in
turn, less than that between isolates from different geographical
areas (Alizon et al., 1986; Starcich et al., 1986; Hahn et al.,
1986). The details of gpl20 variability have been discussed in chapter
3. The sequence data comparing sequential isolates from the same
patient require caution in their interpretation. Bolton et al.,
(1987) showed that the isolation procedure may in some circumstances
peripheral blood lymphocytes (PBLs) imultaneously in the same
patient. More specifically, they snuvwu ^„at PBLs in a sample from an
infected patient contained two antigenically distinct strains. While
both could be demonstrated on primary isolation, transfer to a
permanent cell line led to the disappearance of one of the strains.
Hahn et al., (1986) used such a cell line in their isolation
procedure, and therefore may have selected a variant form for the
eventual sequencing study. The possibility remains, that, like visna,
the original strain may have persisted in the patient alongside the
variant they investigated.
Another explanation for the poor neutralising response to gpl20 is
that it resembles the MHC class 2 antigen and is therefore tolerated
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by the immune system. On the basis that both gpl20 and the MHC 2
antigen interact with the T4 receptor and that both are glycosylated,
it is possible they might have a similar conformation, and cross-react
serologically. Circumstantial evidence to support this theory again
comes from the observation that HTLV-I, to which there is a strong
neutralising response on infection, does not bind to a cell via a
specific receptor. Sattenhau et al., (1986) have presented evidence
that there is limited sequence homology between the gpl20 and MHC
class II protein. Against this hypothesis is, firstly, the observation
of high neutralising titres to viruses such as polio, EBV and many
others that bind to specific cellular receptors, and, secondly, the
generally low neutralising titres in laboratory animals experimentally
immunised with HIV. Since the MHC antigens differ between species,
there ought to be no immunological tolerance to the binding site of
HIV. One way to prove or disprove the hypothesis would be to simply
measure the reactivity of anti-gpl20 antisera raised in animals with
human MHC class 2 antigens.
Another theory for the poor immunogenicity of HIV envelope proteins
comes from the observation of shedding of gpl20 after release from the
cell (Gelderblom et al., 1985). The authors ascribed this to a
failure of the gp41 and gpl20 to form disulphide bridges as the
precursor gpl60 is cleaved on budding. Another possible explanation
comes from the observation of a nonsense stop codon in some clones of
HIV-2 and SIV env genes, present in the transmembrane anchor region
of the protein (Franchini et al., 1987; Chakrabarti et al., 1987).
If this were expressed, then the protein would be secreted rather than
incorporated into the viral envelope. The stop codon is not found in
HIV-1 env sequences, but this may be because the isolates have
changed during the isolation procedure; some clones of HIV-2 also do
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not have this codon.
gpl20, shed in large amounts, could enhance the infectivity of the
virus in a number of ways. It could temporarily absorb neutralising
antibodies and allow the virus to survive the extracellular phase for
long enough to infect other cells. Secreted gpl20 might be able to
mediate immunosuppression by binding to T helper cells and thus
prevent a normal immune response. T4 bearing cells with complexed
gpl20 on the surface would be the target for cytotoxic T cells, ADCC
by K cells or complement lysis (the latter two mediated by
non-neutralising antibody). The wide distribution of the T4 marker on
other cell types might explain the extensive inflammatory pathology
seen in patients. gpl20 mediated destruction of T4 positive cells
resembles graft versus host disease that can be induced experimentally
in mice. Shearer & Moser, (1986) describe the immunological
abnormalities produced when mouse T cells are transferred to another
mouse that is genetically identical apart from the MHC class 2 locus,
and discuss the similarities with the immune dysfunction in AIDS
patients.
An immune response may require the interaction of an antigen
presenting cell (of macrophage origin) with an HIV-specific helper T
cell. If a large proportion of the macrophages were infected by HIV,
then such interactions may lead to a rapid depletion of HIV-specific
cells and a selective defect in immune response to HIV. Klatzmann &
Gluckmann (1986) advance this hypothesis as a possible explanation for
the loss of p24 antibody reactivity with time in patients infected
with HIV (see above). They explain the persistence of antibody to gp41
and gpl20 by postulating that variation in the env gene may cause
the original specific T cells to fail to recognise the modified form
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during antigen presentation. There are several problems with this
theory. Firstly, exposure to other viruses in HIV-infected patients
should lead to selective loss of immunity to them by the same
mechanism; this is not observed (HSV, EBV, CMV). Secondly, p24
antibody returns on AZT treatment, at the same time as the
antigenaemia disappears. This suggests that p24 antibody disappears in
advanced disease due to immunosorption by antigen rather than by a
specific defect in immunity.
Another method of evading the immune response involves the phenomenom
of latency discussed in chapter 3. This is the evidence for specific
adaptations in HIV and other lentiviruses to enable them to cause
silent infections of cells. At a later stage, the virus can replicate
very quickly after removal of the block on translation of accumulated
mRNAs; thus virus assembly and release may take place before
destruction of the cell. Regulation of gene expression undoubtedly
mediates latency of HIV, and cells infected in this way would not be
susceptible to immunological challenge. In the case of visna virus,
the targets of infection are known to be monocytes (Peluso et al.,
1985). Such cells are latently infected and their mobility in the
circulation and the tissues allows rapid and wide dissemination of
infection. Reactivation may then occur in several sites including the
CNS where immunological responses are generally poor. Since the
discovery of monocyte infection by HIV in humans, an analogy may be
drawn with visna to provide an explanation for immunological evasion
in the human disease (Haase, 1986). In particular, the theory explains
the finding of large numbers of infected macrophages in the lungs of
patients with AIDS (Plata et al., 1987), and the subsequent
inflammatory response by cytotoxic T cells. Spread of latently
infected macrophages also accounts for the observed dissemination of
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infection in the brain and the subsequent encephalopathy, and to the
gut and subsequent enteropathy.
Endogenous retroviruses may contribute to the immunological evasion of
HIV. One theory postulates that the env sequence resembles that of
endogenous retroviruses, and that expression of the latter during
ontogeny makes the immune system tolerant for this particular protein.
Evidence for expression of endogenous retroviral products is discussed
in Simpson, (1986), who proposes that many of the minor non H-2
histocompatability antigens in mice are retroviral products. However,
none of the hybridisation experiments have found reactivity of env
gene probes of HIV with human chromosomal material, indicating an
absence of sequence homology between HIV and endogenous retroviruses.
A related theory proposes that HIV may recombine with sequences of
such viruses integrated into the host cell DNA. HIV recombinants would
therefore bear a proportion of tolerated antigens. Such viruses would,
however, be immunogenic on transmision to another human. This theory
predicts, therefore, that infection would be followed by rapid
recombination events, and isolates taken subsequently will differ from
the inoculum strain. Isolates from different patients would be
predicted to differ more than sequential isolates from the same
patients, since different individuals, unless related, inherit
different endogenous retroviruses. To an extent, available sequence
data does support this proposal (Hahn et al., 1986), although there
are alternative explanations for the findings (see above).
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THEORIES OF IMMUNOSUPPRESSION
Although destruction of T4 cells plays a part in the immunosuppressive
effect of HIV, particularly in the late stages of infection, several
investigators have proposed alternative mechanisms to account for the
reduced T cell help and other immune dysfunctions.
Infection of macrophages by VV has been shown to induce the production
of a factor resembling interferon (Kennedy et al., 1985). The
relationship between it and ordinary interferon is not known, but it
is thought to resemble the abnormal interferon induced in SLE in
humans. It is suggestive that many of the symptoms of SLE resemble
those of HIV infection. The factor produced during VV infection of
sheep leads to abnormal macrophage function, and Denman, (1986)
proposes that this contributes to the immunopathology, particularly
the inflammatory changes in the lungs and brains in the absence of
active viral infection in the majority of cells. The pathological
changes consequent to abnormal interferon production resemble those
seen in autoimmune disease; in particular there is a striking
similarity to the arthropathy associated with SLE and other autoimmune
disorders.
Ruddle (1986) proposed that lymphotoxin production mediates the lysis
of infected T4 helper cells on viral replication. In particular, she
proposes that the tat gene product has a direct effect on expression
of the lymphotoxin gene. Lymphotoxin has been shown to be expressed
during normal helper cell proliferative responses, although in high
concentrations it is cytopathic. A recent paper (Strieker et al.,
1987) reports the discovery of antibody reactivity in AIDS patients to
a 18 KDa protein expressed on the surface of PHA stimulated T cells,
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but not on resting cells. The identity of this differentiation antigen
is not known. Sera from patients who were uninfected or who were in
the asymptomatic stage of HIV infection were reported not to react to
this protein, while reactivity was found in all patients with ARC and
AIDS. This antibody reactivity may be a useful marker for progression,
but the authors also contend that this autoreactive antibody may
contribute to helper cell destruction and mediate the
immunosuppression observed in AIDS patients. Interestingly,
lymphotoxin has the same MW as this protein, and they may be one and
the same, particularly as they are both only expressed on
differentiation. More recent work that looked for the presence of
lymphotoxin in the supernate of HIV infected cells produced negative
results (Ratner et al., 1987). This, and the growing evidence of
macrophage, rather then T-lymphocyte, infection in the pathogenesis of
HIV makes the involvement of lymphotoxin unlikely.
Ziegler and Stites (1986) propose that immunosuppression arises from
the possible cross-reactivity of gpl20 and the MHC class 2 antigens.
They discount the possibility that this would merely lead to tolerance
of the T4 binding area of gpl20, and they propose that HIV infection
would lead to an autoimmune response to the class 2 antigens. In time,
an anti-idiotypic response might then develop to the auto-antibodies;
it would therefore be reactive with the T4 receptor. In view of the
wide distribution of the T4 phenotype on many cells other than T
helper cells, the improbabilty of the immune system mounting an immune
response to the widely distibuted MHC antigen, and the general lack of
evidence for naturally occurring anti-idiotypic responses, taken
together make this theory extremely unlikely. The theory would also
predict grave consequences for vaccination in humans with subunit
vaccines comprised of gpl20, since this too might lead to an
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autoimmune response. Zagury, in correspondence with the journal,
Nature, described the administration of a vaccine containing gpl20 to
himself and twelve African patients. Despite subsequent
seroconversion, no ill effects have so far been reported. This is
evidence against the above theory.
A glycoprotein of feline leukaemia virus (pl5E) has been shown to have
an immunosuppressive effect, preventing responses to a wide range of
antigens and mitogens (Pahwa et al., 1985). Sandstrom et al., (1986)
proposed that gp41 of HIV also had a non-specific immunsuppressive
effect on the basis of the observation of reduced proliferative
responses to mitogens in the presence of inactivated HIV virions.
Wahren et al., (1987) tested the immunosuppressive effect of
individual viral components, gpl20, gp41 and p24 and whole virion on
the proliferative response to CMV or PHA. There was no difference in
the response to the stimuli whether the viral proteins were present or
not and they concluded that a direct immunosuppressive effect by HIV
was unlikely.
SUMMARY
It seems likely that there is a primary involvement of macrophages in
the pathogenesis of HIV infection, and that many of the features of
HIV infection may be accounted for by macrophage dissemination in the
infected patient and inflammatory changes at the sites of
reactivation. HIV differs from other lentiviruses in the degree of
immunosuppression caused. No theory at present explains the wide range




The author had previously tested a wide range of sera for antibodies
to HSV by immunoblotting (IB) and immunofluorescent (IF) techniques
before embarking on the PhD thesis. Convalescent sera from patients
with prior exposure to HSV showed marked reactivity in the IF assay,
and reacted with several bands in the IB assay. However, sera from
patients with primary infections with both HSV-1 and -2 showed only
faint membrane fluorescence by IF and restricted reactivity with 4
bands of similar molecular weight in the IB assay. The identity of
these bands (35-42 KDa) was not known; it seemed unlikely that they
were glycoproteins in view of their small size (the smallest HSV
glycoprotein is gD, MW 65 KDa). Reactivity of sera with only one or
two of the 4 bands was rarely observed, suggesting that they were
related antigenically. Substituting anti-human IgG with anti-human IgM
in the IB assay showed that the target of IgM in these sera was the
same as IgG.
Attempts were made to identify the target of this early antibody. The
sera from patients with primary infection that showed restricted
reactivity were tested by a live-cell IF assay. The purpose of this
assay was to measure antibody reactivity with antigen expressed on the
surface of the HSV infected cell; live cells were used to ensure the
integrity of the cell membrane and prevent reactivity with HSV
proteins present in the nucleus or cytoplasm. An assumption about this
experiment was that only glycoproteins would be expressed on the cell
surface. This was tested by comparing the reactivity of several
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glycoprotein and non-glycoprotein monoclonals by the conventional IF
assay using acetone fixed cells, and by a live cell assay. The results
showed that the glycoprotein monoclonals reacted in both assays, while
the p40 monoclonal and another against the major capsid protein (both
non-glycoproteins) reacted only in the fixed cell assay. This showed
that p40 was not on the surface of infected cells. In fact, p40 and
the major capsid protein were only found in the nucleus in the fixed
cell assay.
The reactivity of sera from patients with primary infection showing
restricted reactivity in the IB assay and in the fixed and live cell
IF assays was compared. In each case, reactivity with both live and
fixed cells was found, and constituted preliminary evidence that the
acute sera contained a hitherto undetected additional specificity for
a glycoprotein not detected in the IB assay. At around this time,
Ashley & Corey (1984) published results using a
radioimmunoprecipitation (RIP) assay that showed that sera from
patients with primary HSV-2 reacted predominantly with gB, a finding




The aim of the first part of the work described here was to compare
the sensitivity of different tests for antibody of differing
specificity, and by testing the same sera by a number of tests, to
establish which method detected antibody first during seroconversion.
This work, while of interest in the study of humoral immune responses
to HSV infection, was also of major use when setting up similar assays
to detect antibody to HIV. In the latter case, the widespread use of
screening for antibody to HIV as an indicator of past exposure to the
virus and infectivity of the patient made the development of a test of
high specificity and sensitivity a priority. High levels of antibody
are elicited by infection with HIV and since they are maintained
during all stages of the disease, it is relatively easy in the
majority of patients to determine past exposure and hence infectivity.
However, very sensitive tests are required for general screening in
order to detect the very low levels of antibody during seroconversion.
By analogy with other viruses, notably HBV, it was hypothesised that
Ire,
patients would^most infectious during primary infection, at a time
when antibody levels might be very -low. This consideration was of
particular interest to the Blood Transfusion Service (BTS), since they
were considering which test to adopt in screening of donors. That HIV
can be transmitted by blood and blood products was readily appreciated
at the time, on the basis of case reports of patients transfused with
infected blood, and, tragically, by the early discovery of AIDS and
ARC in a high proportion of American and, later, European
haemophiliacs using factor VIII concentrate. One of the aims of the
thesis was to compare the sensitivity of different commercially
available tests for antibody, and to develop other tests, notably IB,
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using experience gained from work with HSV.
This work was aided considerably by the availability of a wide range
of stored sera from differing patient groups. Of particular value in
the seroconversion studies were sera from a cohort of haemophiliac
patients under the care of Dr Ludlam. That they were infected with HIV
was established in 1984 using the forerunner of the Wellcozyme enzyme
immunoassay developed by Dr R. Tedder at the Middlesex Hospital,
London. Discovery of past infection in these patients was a surprise
since many had been maintained solely on locally produced factor VIII.
Using patient records, it was possible to establish which batch of
factor VIII led to infection of the haemophiliacs, and to calculate
the time of exposure and relate this to the time of seroconversion. In
total, 18 patients were shown to have been infected by the implicated
batch (Ludlam et al., 1985), and the stored serum samples were ideal
for studying early antibody responses to infection, particularly in
view of the fact that the time and dose of exposure was also known.
It was possible to study follow-up samples from the same cohort, and
to compare serological reactivity during the asymptomatic and
symtomatic stages of infection. The patients were relatively
intensively followed up, and regular serum samples were taken and
stored. This contrasts with other patient groups, particularly
intravenous drug abusers, from whom it was rarely possible to obtain
more than one sample. Another advantage of the haemophiliac cohort was
that all of the patients were probably infected with the same strain
of virus; differences in clinical outcome therefore must reflect
differences in individual susceptibility to HIV infection. This laid
the basis of research relating HLA haplotype to disease progression
carried out by Dr M. Steel at the Western General Hospital. By the
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same token, the follow-up serological studies were undertaken in the
absence of reinfection by other strains of HIV, thus considerably





CELLS. Vero cells (Flow) were grown in Eagle's minimum essential
medium (EMEM; Gibco) supplemented with 5% new born calf serum (NBCS;
Gibco); 2mM L-glutamine; 10% tryptose phosphate broth; 300 IU/ml
benzyl penicillin (Glaxo); 0.3 mg/ml streptomycin sulphate
and 120 mg/ml sodium bicarbonate (growth medium; GM).
VIRUS. Strain 1657 (Peutherer, 1970) was the reference HSV-1 strain
used in most experiments. It was typed by immunofluorescence and
microneutralisation. The type was subsequently confirmed by
restriction enzyme analysis. MS (Plummer, 1964) was the reference type
2 strain used in most experimemts. For comparison of different HSV-1
strains, 6 genital isolates (2490, 2746, 5028, 6517, 88 & 14739) and
two sequential isolates of HSV-1 from a member of staff with recurrent
labial HSV-1 infection (6785 & 14778) were available. All of these had
been typed as above.
CONTROL SERA. Rabbit pre-bleed, anti-HSV-1 and anti-HSV-2 sera were
available (Peutherer, 1970). Large volumes of HSV-1 antibody positive
serum (JFP) from a member of staff with culture proven recurrent HSV-1
infection were available. Human anti-HSV-2 serum was not available in
such large amounts, and sera from more than one patient with culture
proven genital infection were used on different occasions (S27629 was
normally used). Negative sera included S122 and S123, which were taken
from 2 children aged 5 and 8 with no evidence of past exposure to HSV.
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MONOCLONAL ANTIBODIES. Table 1 (Columns 1 to 4) lists the numbers and
specificities of several monoclonal antibodies (supplied as ascites
fluid) from Dr A. Cross, MRC Virology Unit, Institute of Virology,
Glasgow, and from Dr A.C. Mmson, University of Cambridge.
HUMAN IMMUNODEFICIENCY VIRUS
CELLS. Lymphoblastoid cells (CCRF-CEM; Flow) were grown in RPMI
(Northumbria) supplemented with 10% foetal calf serum (Gibco); 20mM
L-glutamine, 300 IU/ml benzyl-penicillin (Gibco); 0.3 mg/ml
streptomycin sulphate and 120 mg/ml sodium bicarbonate.
VIRUS. CEM cells persistently infected with strain HIV-RF (CEM-RF),
isolated from a patient with AIDS in the Caribbean (Popovic et al.,
1984), was used as antigen in an indirect immunofluorescence assay for
antibody to HIV.
ANTIGEN. Gradient purified HIV-1 (strain Illb) was purchased from
Dupont and used as antigen in an IB assay for HIV-specific antibody.
CONTROL SERA. Serum from an HIV-infected intravenous drug abuser
(J2) was available in large amounts and used in most experiments as a
positive control. Negative serum (JFP) was available in large amounts
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METHODS
HERPES SIMPLEX VIRUS
VIRUS CULTURE. Stock vero cells were split 1:3 twice weekly in GM.
When not in use, vero cells were harvested, resuspended in GM
containing 10% dimethylsulphoxide, and frozen slowly, eventually being
transferred to liquid nitrogen for permanent storage. For routine
passaging of HSV-1 and -2, confluent monolayers of vero cells were
infected with virus at a multiplicity of infection (moi) of 0.1 in a
small volume for one hour at 37C. The inoculum was then removed and
replaced with GM and incubated at 37C until a complete cytopathic
effect (cpe) was observed (generally 2-3 days). Cells were then
harvested into supernatant GM with glass beads, and the volume reduced
to 10ml by low speed centrifugation (1000 x g, 5 min.). Cells were
lysed in an MSE ultrasonicator at full power for 20 seconds and the
mfectivity determined by plaque titration.
PLAQUE TITRATION. Serial tenfold dilutions of virus ultrasonicate were
made in GM. 50 ul of virus dilution, 50 ul of vero cell suspension (at
0.75 x 10 cells/ml) and 50 ul GM were pipetted into wells of a
microtitre plate (Sterilin, tissue culture grade; generally 8 or 12
duplicates at each virus dilution). The plate was then covered and
incubated for 3 days at 37C in a humidified incubator containing 5%
carbon dioxide. Plaques were counted at each dilution and the virus
concentration, expressed in plaque forming units (pfu)/ml calculated.
Titrated virus was stored in aliquots at -70C for up to 3 months.
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FIXED CELL IMMUNOFLUORESCENCE. Vero cells were infected at a moi of 10
with HSV-1, -2 or mock infected, harvested at 18 hours with glass
beads and washed twice with phosphate buffered saline (PBS) using low
speed centrifugation as above. The cell concentration was adjusted to
0.5 x 106cells/ml in PBS and 50 jal drops applied to PTFE-coated
slides. After drying, the slides were fixed in acetone for 5 min. at
room temperature. Slides prepared in this way were either used
immediately or stored for up to 3 months at -20C. Sera to be tested
were diluted either 1/50 (human and rabbit), or 1/200 (mouse
monoclonal) in PBS supplemented with 5% NBCS (PBSS) and 20 }il applied
to slides bearing fixed HSV-1, -2 or control antigens. The slides were
placed in a moist box and incubated at 37C for 45 min. Slides were
washed in PBS and fluorescein isothiocyanate (FITC) conjugated
anti-human IgG (Scottish Antibody Production Unit; SAPU) at 1/50,
anti-rabbit IgG (SAPU) at 1/50 or anti-mouse IgG (ICN Biomedicals) at
1/100 in PBSS added to each well. The second incubation was also 45
min. at 37C in a moist box. After washing, slides were mounted and
observed with incident ultraviolet light using a Leitz Lux SM
microscope.
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR HSV ANTIBODY. Confluent
monolayers of vero cells were infected at an moi of 10 with HSV-1, -2
at 2U hours i. Cells were harvested with glass beads, and washed
twice with PBS. Cells were resuspended at a cell concentration of 107
cells/ml in 0.1M glycine, pH 10.0, 0.1M NaCl (coating buffer) and
ultrasonicated for 2 min. at full strength in an MSE ultrasonicator.
The cell lysate was centrifuged at 10 000 x g for 30 min. at 4C to
remove cellular debris. The protein concentration of the supernate was
determined by absorbance measurements at 260 and 280 nm in an
ultraviolet spectrometer. ELISA plates (Nunc immunoplate 1) were
- 114 -
normally coated at a protein concentration of 10 jig/ml diluted in
coating buffer, and left overnight at 4C. The plates were either used
immediately or stored for up to a month at -70C. Normally, alternate
columns of wells of the ELISA plates were coated with HSV (either
HSV-1 or -2) and control antigen. Test serum was diluted in PBS
containing 0.05% tween-20 (PBST), 1% bovine serum albumin (PBSAT), and
5% normal rabbit serum (PBSATR), and 200 added to each well. The
first incubation was for 60 min. at 37C followed by washing 5 times in
PBST using a hand washer (wash volume 5 x 300 jil). The second
incubation used 150 jil/well of either horseradish peroxidase (HRP)
conjugated anti- human IgG (SAPU) or anti-mouse IgG (ICN biomedicals)
diluted 1/500 and 1/2000 respectively in PBSATR, with an incubation
time of 60 min. at 37C. After washing, 150 jal of substrate (1.125 g
Na^HPO^ ; 0.28 g citric acid, pH 6.0; 10 mg o-phenylene diamine (OPD);
10 ul Ht<\ ; 50 ml distilled water, dH^O) was added to each well and
incubated at room temperature for- 30 min. 50 jil of 4M H^SO^ was added
to each well to stop the reaction. The plates were read immediately at
490 nm in an automatic plate reader (Dynatech MR 580).
MONOCLONAL ANTIBODY BINDING INHIBITION ASSAY (MABIA). Antigen coated
ELISA plates prepared as previously were used as the solid phase in
this assay. 100 yl of a 1/100 dilution of human or rabbit serum in
PBSTA was added to a well, followed by 100 yil of monoclonal antibody
diluted appropiately in PBSTA. The plate was incubated for 1 hour at
37C, washed as above and 150 jil/well of HRP anti-mouse IgG at 1/2000
in PBSAT supplemented with 10% normal human serum (HSV antibody
negative) added and incubated as above. Substrate development and
reading the plate were as above.
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POLYACRYLAMIDE GEL ELECTROPHORESIS. Confluent monolayers of vero cells
were infected at a moi of 10 with HSV -1, -2 or mock infected. Cells
were harvested at 24 hours, washed twice in PBS and resuspended in
sample buffer (1% sodium dodecyl sulphate, SDS, BDH; 0.0625M Tris-HCl,
pH 6.8; 1% 2-mercaptoethanol; 10% glycerol; bromophenol blue marker
dye) at a cell concentation of 5 x 10€cells/ml and heated to 100C for
3 min. Solubilised HSV-1, -2 or mock infected cell extracts were
electrophoresed on 10% polyacylamide gels using the discontinuous
buffer system of Laemmli, (1970). Samples were electrophoresed at 60V
using a high pH electrode buffer (0.025M Tris; 0.192M glycine; pH 8.3;
0.1M SDS) through the stacking gel (0.125M Tris-HCL, pH 6.8; 4.44%
acrylamide, BDH; 0.12% NN-methylene-bis-acrylamide, bis; 0.1% SDS
polymerised by ammonium persulphate in the presence of NNN'N
tetramethylethylene diamine). After stacking, proteins passed into the
separating gel (0.375M Tris-HCl, pH 8.8; 10% acrylamide; 0.27% bis;
0.1% SDS; polymerised as above) and electrophoresed at 150V until the
dye front reached 10 cm from the top of the separating gel. Gels were
stained conventionally (Coomassie blue) or blotted onto nitrocellulose
as described below. Purified proteins (trypsin inhibitor, 20 100 Da;
lactate dehydrogenase, 36 500 Da; glutamate dehydrogenase, 55.400 Da;
phosphorylase B, 97 400 Da; Boehringer) were used for molecular weight
determination.
PROTEIN BLOTTING. The method was based on that described by Towbin et
al., (1979). Resolved proteins were blotted electrophoretically on to
nitrocellulose (Schleicher & Schuell) at 15V overnight at 4C in
transfer buffer (0.025M Tris; 0.192 glycine; pH 8.3; 20% methanol).
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IMMUNOSTAINING. The nitrocellulose sheet, after transfer of proteins,
was blocked in 3% gelatin in trxs buffered saline (TBS; 20mM Tris-HCl,
pH 7.5; 0.5M NaCl) for 30 min. at room temperature. After washing in
TBS, sheets were either used directly or sealed in plastic bags and
stored at -70C indefinitely. For analysis of the target specificities
of various human and rabbit antisera, and that of monoclonal
antibodies, a dilution of serum (generally 1/20; 1/100 for
monoclonals) in TBS supplemented with 1% gelatin (TBSG) was made and
incubated with strips of nitrocellulose bearing the viral antigens.
This first incubation was for 2 hours at room temperature with
constant agitation on an MSE orbital shaker. Washing comprised an
initial rinse in dHa0, followed by two ten minute washes in TBS plus
0.05% tween-20 (TBST). The second incubation used HRP conjugated
anti-human IgG (SAPU; 1/500); anti-rabbit IgG (Sigma; 1/200) or
anti-mouse IgG (ICN; 1/500) diluted in TBSG for 2 hours at room
temperature with agitation as above. After washing as above, the
nitrocellulose strips were incubated in substrate (100 ml TBS, 60 jil
Ha02; 20 ml methanol, 60 mg 4-chloro-l-napthol; mixed immediately
before use) for 15 minutes at room temperature. The strips were washed
in water, dried and stored in the dark. Despite this latter
precaution, there was inevitably fading of bands, and yellowing of the
nitrocellulose over years of storage.
NON-DENATURING IB. Confluent monolayers of vero cells were infected at
an moi of 10 with HSV-1, -2 or mock infected. Cells were harvested at
24 hours with glass beads, washed twice in PBS and finally resuspended
in lysis buffer (PBS; 0.2 mM phenylmethyl sulphonyl fluoride, PMSF;
0.1 mg/ml DNAse II type IV, Sigma; 0.1 mg/ml phosphodiesterase I type
IV, Sigma) supplemented with detergents as described in the results.
Cells were incubated in lysis buffer for 15 min. on ice, and then
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centrifuged at 100 000 x g for one hour to remove insoluble material.
Supernate was either used immediately, or stored at -20C. The cell
lysate was diluted in sample buffer and electrophoresed using the gel
system as described above but with SDS in the sample buffer, electrode
buffer and gel solutions replaced with other detergents as described
in the results. Electrophoresis was performed at 4C instead of room
temperature to avoid degradation of proteins. In some experiments, the
acrylamide concentration was reduced to 7% (bis reduced to 0.18%) in
the separating gel. Blotting, blocking and immunostaining were as
described above. Purified proteins (cx-lactalbumin, 14 200 Da; carbonic
anhydrase, 29 000 Da; ovalbumin, 45 000 Da; BSA, 66 000 Da & 132 000
Da; urease, 240 000 Da; Sigma) were electrophoresed to investigate the
relation between rate of migration and protein size.
RADIOLABELLING. Confluent monolayers of vero cells were infected at a
moi of 10 with HSV-1, -2 or mock infected. After absorption for one
hour, the inoculum was replaced with a small volume of methionine-free
EMEM (supplemented with 0.5% NBCS; 20 mM glutamine; 300 IU/ml
benzyl-penicillin; 0.3 mg/ml streptomycin sulphate and 120 mg/ml
sodium bicarbonate), and the cells incubated for 4 hours at 37C. [3S S]
methionine (Amersham; 800 mCi/mmol) was added to each bottle to
produce a final radioactive concentration of 50 jiCi/ml and incubated
for a further 14 hours. Cells were harvested with glass beads, washed
twice in PBS and resuspended at a cell concentration of 10"7 cells/ml in
lysis buffer supplemented with 1% sodium deoxycholate (DOC), 1% triton
X-100 (TX100). After incubation on ice for 15 min., cell lysates were
centrifuged at 100 000 x g for 60 min. to remove insoluble material,
and stored in aliquots at -20C until required.
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RADIOIMMUNOPRECIPITATION ASSAY (RIPA). 10 jul of human or rabbit serum
or mouse monoclonal antibody, 25 jil of a 50/50 suspension of
sepharose-staphylococcal protein A (Pharmacia) in PBS and 200 jil of
PBST were added to a 0.5 ml conical bottomed plastic tube. The tube
was incubated at room temperature for 60 min. with agitation to keep
the sepharose in' suspension. Unbound serum components were removed by
two cycles of washing with PBST followed by low speed centrifugation
(500 x g, 1 min.). 50 jil of radiolabelled antigen prepared as above,
and 200 jil of PBS containing 1% DOC, 1% TX100 were added to the tube
and incubated for a further 60 min. After washing, 100 jil SDS sample
buffer was added to the sepaharose and the tube boiled for 3 min. 5 jil
(1/20 of the precipitated sample) was removed and dried onto
glassfibre discs for liquid scintillation counting. The remainder of
the immune precipitate was analysed by SDS-PAGE as described above.
Bands were visualised by autoradiography for 2 weeks at -70C with
Kodak X-Omat P film.
HUMAN IMMUNODEFICIENCY VIRUS
VIRUS CULTURE. Stock CEM cells were passaged twice weekly splitting
cells 1 to 3 or 4 depending on cell density. CEM persistently infected
with HIV-RF were maintained similarly. Cells were grown in a
humidified incubator, in 5% carbon dioxide. Cells were stored in
liquid nitrogen as above when not in use.
IMMUNOFLUORESCENCE. CEM and CEM-RF cells were washed twice in PBS and
resuspended at a concentration of approximately 10s cells/ml. The cell
supension was applied to slides and fixed as for HSV described above.
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Subsequent testing of human sera was similar to the method used in the
fixed cell IF assay for HSV antibody.
ELISAs FOR ANTIBODY TO HIV. Enzyme immunoassays (EIAs) for
HIV-specific antibody from Wellcome, Pasteur, Abbott (env/core
confirmatory assay) and Dupont were used according to the
manufacturers instructions. Quantification of antibody levels in the
latter two assays was performed as described in the results.
IMMUNOBLOTTING. 50 jig of purified HIV-IIIb (Dupont) viral lysate was
mixed with 1.5 ml sample buffer, and electrophoresed using the
SDS-PAGE system used for HSV. Modifications included increasing the
acrylamide concentration to 12% (bis to 0.32%); blocking in PBS plus
2% BSA; human serum diluted 1/50 in PBS plus 0.2% tween-20; anti-human
IgG conjugate diluted 1/200 in PBS plus 0.2% tween-20 and finally the
substrate changed to 0.05% diaminobenzidine, 0.05% H^O^, in PBS, pH
7.6. For some experiments, a commercially available IB antibody
detection system (Biorad) was used.
SERUM ANTIGEN DETECTION. Two capture ELISA kits (Abbott and Dupont)




ELISA FOR HSV ANTIBODY
The concentration of antigen required to coat ELISA plates was not
known. Non-specific binding of antibody to cellular proteins was more
likely with high coating concentrations, so titrations of coating
HSV-1, -2 and control antigens were performed. Figure 3 shows the
variation with HSV-1 or 2 antigen dilution (on an inverted scale) with
binding of several monoclonals. Non-specific reactivity of monoclonals
with control antigen was very low (OD less than 0.03). The graph
demonstrates maximum binding of each monoclonal antibody at antigen
concentrations of 11 jig/ml and above; a concentration of 10^ig/ml was
therefore used in all subsequent experiments. The uniformity of the
antigen dilution effect with each monoclonal was thought to result
from the limited protein binding capacity of the ELISA plate.
Figure 4 shows titrations of human. HSV-1 amd HSV-2 antisera against
type-homologous antigens in the ELISA. A straight line relationship
can be seen between antibody concentration (on a linear scale) and OD in
the range 0-0.7, with HSV-2 antisera showing a intercept with the
y-axis at zero. HSV-1 sera however showed an intercept at around 0.04,
signifying the binding of conjugate to HSV-1 in the absence of test
serum (at an infinite dilution). This occurred despite addition of
normal rabbit serum to the conjugate to block HSV-1 Fc binding
activity. An allowance for this binding was made in subsequent
experiments. The linear dilution response of sera allowed quantitation
of antibody levels in test sera by a simple ratio of the OD with that
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FIGURE4:TitrationofHSU-1(JFP)ndHS\/-2(S276 9)humanantiseraagai st type-homologousanti eniELISAf rantibodytH U.N t0Dy axis;linears rumdilut onscaleoaxis.
of a positive control, taking into account any difference in assay
dilution between the test and control sera. Antibody levels varied
widely so, in practice, test sera were tested at two dilutions,
generally 1/1000 and 1/10 000 to ensure that at least one OD fell in
the linear range of the graph. Testing at two dilutions confirmed that
almost all sera with appropiate OD values showed linear dilution
responses, confirming the validity of the test. For routine screening
of sera, multiple replicates of JFP with HSV-1 and S27629 with HSV-2
were used as positive controls in each assay run. Antibody levels in
test sera were expressed in units, with the positive controls
arbitrarily assigned 1 unit (U; 1000 mU).
MABIA
To maximise the sensitivity of this assay for blocking activity in
test sera, each monoclonal was first titrated against HSV antigen. Low
dilutions of monoclonal saturated the available binding sites (plateau
region); as the dilution was increased a point was reached where there
was a rapid drop in OD (linear region), where the amount of monoclonal
took over as the limiting factor. Figure 5 shows titrations of the
monoclonals used in the blocking assay. An inverted-dilution scale was
used in order to to encompass the wide range in titres observed;
replotting the data as in figure 4 confirmed that there was a linear
increase in OD with concentration of each monoclonal, but only over a
small range in those with low saturation OD readings. Using figure 5,
the concentration of monoclonal producing an OD midway between zero
and the saturation level was calculated and used subsequently in the
blocking assay.
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One problem encountered with the MABIA in its initial stages of
development was the inappropriate reactivity of anti-mouse IgG with
human IgG. The first experiments involved incubating a positive and a
negative human serum with monoclonal no.l (gD-specific), washing, and
then measuring the amount of monoclonal binding by tracing with the
anti-mouse label. The ODs achieved by the negative and positive sera
were similar. To investigate this, a second experiment was performed
in which the monoclonal was omitted. In this case, the OD with the
negative serum was roughly zero, while the OD with the positive serum
was about 0.6. This was caused by cross-reaction of conjugate with
human serum and completely overshadowed the inhibitory effect of the
positive serum in the first experiment. Inhibition in the first
experiment had actually occurred; the OD with the negative serum being
caused by the monoclonal binding. Although one could have attempted to
remove cross-species reactivity by prior immunosorption on a human IgG
coated column, it was simpler to simply block the conjugate during the
second incubation by diluting it in PBSAT containing 1% negative human
serum. This proved to be completely effective providing that care was
taken in ensuring that the human serum was HSV-antibody negative and
free from interfering substances such as rheumatoid factor. In
practice, an HSV negative serum from a 5 year old boy (S122) happened
to be readily available in large amounts and was used for blocking in
all subsequent MABIAs.
To test the specificity of the assay system, HSV-1 antiserum (JFP) was
tested at various dilutions against suitable dilutions of two
monoclonals, nos. 1 and 9. Monoclonal 1 reacts with native gD-1 and-2
(type-1 & 2) and might reasonably be supposed to be inhibitable. No. 9
reacts with both native and denatured gG-2, and in view of the
complete lack of antigenic cross-reactivity of gG-2 antibody with
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HSV-1 proteins, might reasonably be presumed to be uninhibitable by an
HSV-1 antiserum. Figure 6 shows the results of titrating JFP serum on
a linear scale in a blocking assay with the two monoclonals. The graph
shows concentration dependent blocking of no.l by JFP, but no
significant blocking of no.9 at any serum dilution.
Subsequently, sera were tested for blocking activity at a dilution of
1/100. The calculation to measure inhibition should take into account
the reactivity of monoclonal and/or serum with control antigen.
Therefore all experiments were performed with both HSV and control
proteins, and the latter subtracted from the former to give a net OD.
The next factor to be taken into consideration was variablility
between batches in the net OD achieved by the monoclonals. Minor
differences in incubation temperature or duration, or substrate
activity affected this, and so each batch contained several replicates
of monoclonal alone. The last consideration was the contribution made
by test serum on the OD achieved on incubation with the monoclonal
(additive effect), distinct from the inhibition (subtractive effect).
The additive effect arose from slight residual cross-reaction of the
anti-mouse conjugate with human afttibody, despite blocking. Since this
would vary with the titre of HSV-specific antibody, it had to be
measured for each test serum.
The calculation used to measure inhibition was as follows:
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Table 2 shows the results of another experiment investigating the
specificity of the MABIA. The calculation of the residual binding
value is shown for each serum and monoclonal combination. There was
little or no inhibition by either pre-bleed rabbit sera of any of the
monoclonals. The rabbit anti-HSV-1 serum and JFP showed almost
complete blocking of no.l, partial blocking of no.2 and no blocking of
no.9. Although the rabbit antiserum blocked no.5 partially, JFP (and
several other human sera, not shown) did not. The rabbit and human
(SB13166) anti-HSV-2 sera showed inhibition of nos. 1 and 9, but not
of no.5. The human serum did not block the type-specific monoclonal,
no.2; however, the type 2-specific rabbit antiserum produced an
inhibition value with this monoclonal below those of the negative
sera, indicating a possible weak inhibitory effect.
To investigate the relation between cross-reactivity of monoclonals
and cross-inhibition, as observed above, an experiment with four gD
monoclonals reported to be type-specific was performed (Table 3). Two
HSV-1 and 2 HSV-2 specific monoclonals were tested with
type-homologous and type-heterologous antigen to measure
cross-reactivity; cross inhibition was measured by blocking the
monoclonals with prebleed, anti-HSV-1 and anti-HSV-2 rabbit sera.
Monoclonal 2001 did not react- detectably with HSV-2, yet was
measurably blocked by the type 2 serum (pre-bleed 76%; anti-HSV-1 19%;
anti-HSV-2 47%). 2245 did cross-react, but with approximately l/5th of
the OD. It was cross-inhibited almost completely by the type 2
antiserum. pllO cross-reacted extensively with HSV-1 (1/4 of the OD)
and was almost completely cross-inhibited by the type 1 serum. pl05
reacted poorly in the ELISA, and the inhibition figures are based on
very low OD readings and are less accurate than those of the other
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cross-inhibition. This small study shows that sera cross-inhibit to
greater extent than the monoclonals cross-react. It is evidence that
inhibition is not necessarily epitope specific; rather it may occur by
binding to neighbouring epitopes that do not share the
type-specificity of the target epitope of the monoclonal (steric
hindrance).
To increase the sensitivity of the MABIA for gG-2 and other antibody
specificities, blocking of no.9 and no. 13 (gD-2) by rabbit HSV-2
antiserum was investigated at several coating antigen dilutions. By
reducing the target for monoclonals, greater inhibition of binding
might be observed in sera with low levels of blocking antibody.
However, the blocking was similar at antigen concentrations in the
range 10 ug/ml to 0.12 ug/ml (data not shown). Similarly, within this
range of antigen concentration, HSV-1 antiserum (JFP) showed no change
in the inhibition of binding of monoclonals 1, 2, 3 and 10.
Numerous preliminary experiments were performed to find a suitable
panel of monoclonals with which to screen test sera for blocking
activity. Table 1 summarises the findings that led to selection of
monoclonals 1, 2, 3, 10, 9 and 13 for subsequent screening. Monoclonal
4 was unreactive in the ELISA; no.5 was slightly reactive, but was of
low titre, and not inhibited by any human serum. No.6 and 7 were both
unreactive. No 8 (gG-1) was weakly reactive in the ELISA with a
maximum OD of .220 at dilutions of 1/20000 and less. With such low
ODs, it was difficult to obtain accurate and reproducible measurements
of inhibition of the control sera. Within these limits, it appeared
that the monoclonal was no more than 50% blocked by HSV-1 positive
sera, and was unaffected by negative and type 2 sera. No.12 was the
only monoclonal so far tested that appeared to be blocked by both
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negative and positive sera with no correlation between antibody titre
and extent of inhibition. The reason for this non-specificity is not
known, but could be explained by postulating that the monoclonal is
directed to an epitope within the Fc binding region of gE. Incubation
with either positive or negative sera would lead to binding to the
site, non-specifically blocking the monoclonal.
Table 4 summarises the protocol adopted for the screening of test
sera. Since multiple replicates of positive and negative controls were
included in each batch, it was possible to calculate the
reproducibility of the assay, and the range of error in calculating
the results. These are also shown in this table. Monoclonal no.11
(p40) was found to be uninhibitable by the control sera. It was
included in the screening of test sera to act as a control. In any
inhibition assay, there is the possibility of non-immunological
blocking by interfering substances in certain sera, particularly those
with bacterial contamination. All sera tested in the MABIA were also
tested against no.11, but none caused a reduction in the binding of
no.11 (data not shown). This confirms the immunological specificity of
the inhibition values obtained with the other monoclonals on
screening.
IMMUNOFLUORESCENCE ASSAY
Attempts were made to reduce non-specifity caused by Fc binding by gE
in this assay. Gallo, (1986) describes the use of low concentration of
acetic acid as a pretreatment for slides to be used in a fixed cell IF
assay for antibody to HSV. To test this, a comparison of slides
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5). The results show that membrane fluorescence of HSV-1 and 2
infected cells with negative serum was abolished by the acid
treatment, while not reducing the binding of positive serum. Diluting
test serum and fluorescein conjugate in PBS + 2% NBCS also reduced
non-specific binding (data not shown).
IMMUNOBLOTTING
Preliminary work established the amount of antigen necessary for the
assay; the blotting conditions to ensure complete transfer of resolved
proteins to nitrocellulose; the composition of buffers to avoid
background staining and the optimum concentration of conjugate.
Results from this work led to the adoption of the method described in
the methods section. Control sera were tested against both HSV and
control antigen in the IB assay (figure 7; table 6). No sera reacted
significantly with control antigen, and the results have not been
illustrated. Pre-bleed rabbit sera did not react with any HSV proteins
in the assay-(lanes 1, 10); negative human sera were also unreactive
(lanes 3-5, 12-14). Rabbit anti-HSV-1 and anti-HSV-2 sera and JFP were
reactive in the assay, producing several bands, reflecting broad
polypeptide specificity (lanes 2, 6 & 11).
Proteins were identified by the reaction of monoclonal antibodies of
known specificity in the assay. However, several were unreactive due
to denaturation of the target epitopes by the antigen solubilisation
proceedure. Nos. 14, 2, 5 and 9 did produce bands, and these are shown
in figure 7. The target of no.14 is gD and this appears as a band of
approximate MW 57 KDa (lane 7). gD of HSV-2 produced a band of similar
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FIGURE 7. Reactivity of control sera in the IB
assay.
HSV-1. Lanes 1 & 2: pre-bleed and HSV-1 immunised
rabbit antisera; lane 3, 4, 5: three negative
human sera; lane 6: human anti-HSV-1 positive
serum (JFP); lanes 7, 8, 9: monoclonals no. 14
(gD), no. 2 (gC-1) and no. 5 (p40); lane 10:
negative mouse serum.
HSV-2. Lanes 11 & 12: pre-bleed and HSV-2
immunised rabbit antisera; lanes 13, 14, 15: three
negative human sera; lane 16: human anti-HSV-1
postive serum: lanes 17 & 18: monoclonal
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102, 100 and 90 KDa (lane 8) with HSV-1, and none with HSV-2. The
reaction of nos. 5 (p40) and 9 (gG-2) are shown in lanes 9, 16 & 17.
Two procedures were performed to investigate variability in
antigenicity between different isolates of HSV. The first method
involved producing antigen from six isolates from patients with
primary genital HSV-1 infection The antigen was electrophoresed,
blotted and reacted with sera taken from each of the six patients. The
aim was to investigate whether patients reacted more strongly with
their own isolate than with those of other patients. The results
(figure 8) show that there was considerable variation between the
bands produced by each of the sera, and some difference between the
intensities of the bands between isolates. There was little consistent
evidence for a stronger reaction with their own (homologous) isolate
than with those of other patients (heterologous). A similar experiment
compared the reactivity of JFP with two homologous isolates and 1657,
the standard HSV-1 strain. Again there was little difference in
reactivity of JFP with the three viruses. On the basis of the results,
it was felt reasonable to use 1657 as the standard strain of HSV-1 for
all subsequent experiments.
The other proceedure to examine variation in antigenicity of the virus
used for IB assays involved passaging 1657 and MS at high and low
moi's. Passaging at high moi leads to an increasing proportion of
defective viruses and may lead to altered protein synthesis and a
different pattern of bands. Very early samples of 1657 and MS were
obtained from Dr I.W. Smith and passaged 4 times at an moi of 10
(high) or at 0.001 (low). The former cultures showed complete cpe at
24 hours; those of the latter typically showed individual plaques at 3
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passaging, antigen was produced from each of the four cultures and
used in an IB assay. No difference in the number, apparent MW or
antigenicity of the bands was detected between the high and low moi
cultures (data not shown).
RADIOIMMUNOPRECIPITATION ASSAY
Control sera were tested by RIPA, and compared with the results of IB
(table 6). The table gives both the counts of the immune precipitate
and the bands detected subsequently by SDS-PAGE. Antibody negative
sera produced low counts and no bands on analysis of the precipitate.
Positive sera produced elevated counts and several bands by
autoradiography. Several protein identifications were made by
monoclonals (figure 9; lanes 7-10 & 13). gD-1 (lane 7) and gD-2 (not
shown) both appear as broad bands of approximate MW of 66 KDa on
reaction with no.l. The bands are distorted by large amounts of
co-migrating IgG. There is also a weaker band of MW 121 KDa in lane 7,
probably the result of slight co-precipitation of other HSV proteins.
Richman et al., (1986), showed that gG-1 appeared in their RIP assay
as a band of similar apparent MW, and appearance as gD-1. Bands of
this size produced by test sera cannot be positively identified as
either so will be referred to as gD/gG.
gC-1 (no.2, lane 8) appears as a prominent band MW 121, with weaker
bands at 75K and 45K. gB-1 (no.3; lane 9) has two prominent bands of
size 118K and 112K, with two lower molecular weight bands of 56K and
50K. These probably represent cleavage products. gB-2 (lane 13) has a
major band of 110K and similar lower MW bands. No.4 (gE-1) was
unreactive in the assay. No.5 (p40) produced weak bands of MW 47.5, 45
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FIGURE 9. Reactivity of control sera in the RIP
assay.
Molecular weight markers (coomassie blue stain).
Lane 1: carbonic anhydrase (29 KDa); ovalbumin (45
KDa); bovine serum albumin (66 KDa). Lane 2:
lactate dehydrogenase (36.5 KDa); glutamate
dehydrogenase (55.4 KDa); phosphorylase (97.4
KDa); "X-macroglobulin (170 KDa).
HSV-1. Lanes 3 & 4: pre-bleed and HSV-1 immunised
rabbit antisera; lanes 5 & 6: negative and
positive human sera (S122 & JFP); lanes 7, 8, 9,
10: monoclonal antibodies no. 1 (gD); no. 2
(gC-1); no. 3 (gB) and no. 5 (p40).
HSV-2. Lanes 11 & 12: pre-bleed and HSV-2
immunised rabbit antisera; lane 13 monoclonal
antibody no. 3 (gB).
and 42.5 KDa with HSV-1 antigen (lane 10), and no bands with HSV-2.
No.6 produced faint bands of 158 KDa with both HSV-1 and 2 antigen
(not shown).
NON-DENATURING IMMUNOBLOTTING
Several detergents were investigated as alternatives to SDS for
immunoblotting. One paper describes the use of triton X-100 for
electrophoresis (Dewald et al., 1975), and this was the system tried.
The discontinuous buffer system described by Davis (1964), and
subsequently adopted by Laemmli (1970) for disassociated proteins, was
used with the addition of 1% Triton X-100 to all buffers, including
that used for solubilisation of the antigen. On electrophoresing the
sample, it was observed that migration was very slow; after 6 hours at
180 V, the dye front had moved only 3 cm. The gel was divided; half
was stained for protein, and the other half was blotted onto
nitrocellulose and reacted with an HSV-1 antiserum. Both procedures
showed that'there had been no protein separation; instead there was
clumping at the top of the gel with only very faint bands in the
separating gel. Similar results were obtained when the triton
concentration in the electrode, stacking and separating gels was
reduced to 0.1% or omitted entirely; the only difference was that the
marker dye migrated at its normal rate. These findings suggested that
the micelles formed by triton were too large for satisfactory
electrophoresis. Only water soluble, hydrophilic proteins that do not
interact with the detergent would be separated in this gel system.
The quoted weight of triton micelles is 120 000 Da (Helenius, 1976),
and a detergent with smaller micelles was sought. Sodium deoxycholate
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was chosen (micelles 12 000 Da) and the experimemt as described above
was repeated substituting this detergent. Although sodium deoxycholate
appeared soluble at pH 6.8 (pH of stacking gel), the detergent
precipitated during electrophoresis, both in the stacking gel and in
the lower electrode buffer (cathode) reservoir. Protein staining was
impossible since the entire gel became opaque in the staining
solutions; blotting revealed again that the HSV antigens were clumped
at the top of the separating gel.
3-[(3-cholamidopropylJdimethyl-ammonio]-1-propane sulphonate (CHAPS)
is a cholic acid derivative of small micellar size and this was the
next candidate. Serum, sheep red blood cells, and HSV-infected cells
were solubilised in a 1% solution of the detergent and electrophoresed
in the presence of the detergent. Haemoglobin remained red and the
protein separation could be observed during electrophoresis. There was
effective stacking of the haemoglobin and presumably of the other
proteins, and a normal rate of migration of the marker dye. A protein
stain of the gel showed effective separation of all of the serum
components, and several of the proteins in sheep red blood cells.
However, in the HSV-infected cell lysate, there was again clumping of
material at the top of the gel; although much protein had entered the
separating gel, it was smeared with only faint bands. An immunostain
of the gel confirmed that the antigenic material was largely clumped
at the top with some smearing down the gel. A subsequent experiment
with molecular weight markers showed clear resolution of the proteins,
although there was no relation between distance migrated and molecular
weight. These latter experiments showed that the only proteins
resolvable in this system were water soluble, and the detergent was
having little effect on the separation of membrane proteins.
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The same experiments were repeated with sodium taurodeoxycholate
(TDCA; cells solublised in 1% TDCA; 1% in separating and stacking
gels; 0.3% in electrode buffers). This is also a cholic acid
derivative of small micellar size, but differs from CHAPS in being
negatively charged in the pH range for electrophoresis (CHAPS is
zwitterionic, with no net charge). It was thought that a negative
charge might improve resolution of detergent solubilised proteins (cf
SDS). It also remains in solution at low pH (at least pH 4) so it
should not precipitate during electrophoresis. Experiments with this
detergent bore out these expectations. Firstly, there was normal
stacking of haemoglobin and other soluble proteins, and there was no
precipitation of detergent. A protein stain of the HSV-infected cell
lysate revealed an absence of clumping at the top of the separating
gel, and good resolution of numerous proteins (Figure 10; lane 1). An
immunostain of the cell lysate confirmed that all of the HSV proteins
had entered the gel to form a major band at Rf 0.15 (lane 4), and
several minor bands above and below. A subsequent experiment with
molecular weight markers showed no relation between migration and
molecular weight (data not shown). It was deduced that the detergent
solubilised and assisted in the separation of membrane proteins, but
did not interact with water soluble proteins. In this latter respect,
it differs from SDS.
Immunoblotting with TDCA was used as decribed above to test the
control sera. Figure 10, lanes 5-8 shows the development of reactivity
with the protein of Rf value 0.15 in the two HSV immunised rabbits.
Negative human sera were unreactive in the assay. Monoclonals were
used to identify proteins. No.3 (gB; lanes 2 & 3) reacts with the
prominent band (0.15 HSV-1, 0.13 HSV-2). No.l reacts very weakly with
the band at Rf value 0.65 (data not shown).
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FIGURE 10. Reactivity of control sera in the TDCA
IB assay. Lane 1: HSV-1 infected cell lysate,
coomassie blue stain; lanes 2 & 3: reactivity of
monoclonal antibody no. 3 with strips prepared
from HSV-1 and -2 antigen; lane 4: human positive
serum (JFP) with HSV-1 antigen; lanes 5 & 6:
pre-bleed and HSV-1 immunised rabbit antisera with
HSV-1 antigen; lanes 7 & 8: pre-bleed and HSV-2
immunised rabbit antisera with HSV-2 antigen.
Monoclonals nos.2 (gC-1), 4 (gE), 5 (p40), 6 (MCP) and 9 (gG-2) failed
to react with strips prepared in this assay. To investigate the
reasons for this, HSV-1 infected cells were solubilised in TDCA,
centrifuged, and then resolubilised in SDS and electrophoresed
conventionally. After blotting, strips were reacted with JFP serum,
and the three monoclonals previously shown to be reactive with
denatured proteins, nos. 2, 5 and 9. Only two bands appeared on
reaction with JFP; one had an apparent MW of 100 KDa, and the other
was of MW 65 KDa. It is likely that these two proteins correspond to
gB-1 and gD-1, the only proteins detectable in the original TDCA IB
method. Furthermore, none of the three monoclonals (2, 5 & 9) reacted
with the resolubilised material. It would appear that only gB and gD
are efficiently solubilised in TDCA; the other proteins must have been
lost during the high speeed centrifugation of the cell lysate. While
this might be expected for the two capsid proteins, p40 and MCP, it
was surprising that the other glycoproteins were also apparently
insoluble.
There was the unlikely possibility that monoclonals nos. 2 and 9 (gC-1
and gG-2) failed to react in the TDCA IB assay because the target
epitopes were concealed when the protein was in its native
configuration. To prove that this was not the case, strips prepared by
TDCA IB were pretreated by boiling in conventional SDS-containing
sample buffer, and then tested with the monoclonals. Reactivity was
not restored, confirming the absence of the proteins after TDCA
solubilisation.
To solubilise a greater proportion of HSV proteins, the TDCA IB assay
was modified by the inclusion of 3M urea in all buffers, along with
the TDCA. However, this caused smearing of proteins, and could not be
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used. Another approach was to modify the sample buffer and run
proteins on conventional SDS-containing gels. This was the approach
used by Cohen et al., (1987), in studies of gD. The first
modification was to use ordinary sample buffer, with mercaptoethanol,
but not to boil the cell lysate. Heating to 56C for 5 minutes gave
identical results to boiling. Keeping the cell lysate at room
temperature after addition of sample buffer led to clumping of a large
proportion of antigen at the top of the gel, but with similar
resolution of other proteins. Another method tried was to substitute
li
TDCA with 0.1% SDS in the conventional solubisation proceedure,
A
incubating on ice for 15 minutes with protease inhibitors and
centifuging at 100 000 x g to remove insoluble material.
Electrophoresis was performed at 4C with all electrophoresis buffers
supplemented with 0.1% SDS. However, there was extensive smearing of
proteins, clumping at the top of the separating gel, and little




The conventional IB proceedure was used with HIV, except that the
polyacrylamide concentration was increased to 12% (bis to 0.32%).
Since purified virus was used, there was no background reactivity and
it was possible to increase the sensitivity of the assay without
non-specific bands appearing. HRP conjugated anti-human IgG was used
at twice the concentration used for HSV. Diaminobenzidme was found to
be a more sensitive substrate than 4-chloro-l-naphthol and was used
for all experiments. Experiments with other substrates were also
performed, with mixed results. Taketa et al., (1986) report the use
of nitro blue tetrazolium in the presence of NADH and phenol. The
method was tried, but although it was more sensitive than 4-chloro-l
naphthol, it was inferior to diaminobenzidine. Supplementing
diaminobenzidine with imidazole has been reported to enhance
detection, but, when tried with HIV, merely increased background
staining of the strips, with no intensification of the specific bands.
The normal brown bands produced by diaminobenzidine can be changed to
purple by the addition of 0.1% nickel chloride to the substrate; this
significantly darkens the bands and can give a useful increase in
sensitivity.
The purified virus was supplied by Dupont in a buffer containing
triton. This, and its high price restricted developments of
alternative solubilisation procedures. However, an investigation into
the effect of heating the antigen prior to conventional SDS-PAGE was
carried out. Antigen was added to sample buffer with 2 %
2-mercaptoethanol and to sample buffer without reducing agent. Heat
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treatment included none (room temperature); 5 mm at 37C; 30 min at
37C; 5 and 30 min at 56C, and finally 5 min at 100C (normal method).
The samples were electrophoresed conventionally, blotted, and then
probed with J2 (figure 11; see Results section for identification of
bands). The blot showed poor resolution of proteins without reducing
agent, and there were no extra high MW bands, indicating an absence of
disulphide linked protein complexes. Comparison of the heat treatments
showed a difference in the antigenicity of samples. Samples, both
reduced and non-reduced, that were prepared at 37C, or unheated,
showed equal resolution as the boiled samples, and showed an extra
band corresponding possibly to gpl20 or gpl60.
ELISA FOR ANTIBODY TO HIV
A commercially available EIA for HIV antibody was used to quantitate
levels of antibody. Figure 12 shows titration of J2 in the ELISA. The
solid circlesshow replicate titrations of the positive serum plotted
on an inverse scale. The readings were averaged and replotted on a
linear scale to determine the relation between concentration and OD
(hollow circles). It can be seen that there was a linear relationship
in the range 0-0.8 OD units. If this were the case with other sera, it
would be possible to quantitate antibody levels by simple comparison
of the OD of the test serum with that of the positive control, taking
into account the difference in dilution of test and control sera (ie.
the same method as used to quantitiate HSV antibody levels). In
practice, some sera did not show a linear dilution response; this is
presumably due to there being predominant reactivity with a minor
antigen on the ELISA plate. Sera not showing a linear dilution
response would give different antibody levels when tested at different
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FIGURE 11. Effect of solubilisation conditions on
the antigenicity of HIV proteins in the IB assay.
Lanes 1 to 6: non-reduced; lanes 7-12: reduced in
2% 2-mercaptoethanol. Lanes 1 & 12: Room
temperature; lanes 2 & 11: 37C, 5 min.; lanes 3 &
10: 37C, 30 min.; lanes 4 & 9: 56C, 5 min.; lanes


































FIGURE12:TitrationofJinELISAf rantibodyHIV.yxis:OD at290nrn;solidcircles:repl catedilutionsi ver logdilutionscale;holl wcircles:averag dvalueso lineardilutionsc le.
dilutions. If this was the case, then the OD from the dilution that
predicted the highest antibody level was used (generally at higher
dilution). Test sera were generally tested at 1/1100 and 1/11000 in
the ELISA, although some sera taken close to seroconversion had low
levels of antibody and were tested at lower dilutions.
QUANTIFICATION OF "env" AND "core" ANTIBODY
In theory, it would have been possible to modify the Abbott
confirmatory EIA for "env" and "core" antibody by dispensing with the
anti-HIV label used for competition, and using the recombinant antigen
coated beads in a direct binding assay. This would have allowed easier
quantitation of antibody levels, but would have brought in the
possibility of reduced assay specificity and would have prevented
direct comparison of the results with those of other investigators.
Figure 13 shows that there was not a straight line relation between
log inverse serum dilution of J2 and OD in the conventional assay.
Replotting serum dilution on linear and other scales also failed to
show a simple relationship. To quantitate antibody levels in a test
serum, the ODs at two serum dilutions were plotted on figure 13 and
the distance horizontally between it and the standard curve measured.
This distance, which could be either positive or negative, is
proportional to the log of the difference in antibody level between
the test serum and the positive control. The anti-log gives the ratio
of antibody levels between the test serum and the positive control.
Since J2 was arbitrarily assigned 1 unit in both the anti-"env" and
anti-"core" assays, the ratio calculated for a test serum corresponded
to its antibody level in units. Several sera were tested at multiple
dilutions, and the antibody level calculated from each. Provided the
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FIGURE13.TitrationofJ2innti-"env"ndanti-"core"competitionassay.•anti-"env";oanti-"core".
OD fell within the range 0.15 to 0.7, the antibody levels calculated
from the OD at each dilution were similar. For use in screening, sera
were tested at 1/1000 and 1/10000 for "env" antibody, and at 1/2.5,




NEGATIVE SERA. Since one cannot rely on a patient's medical history
for evidence of past HSV infection (because primary infection is often
undiagnosed and recrudescences not universal), it was decided to use
sera from children aged 3 to 15 that appeared to be antibody negative
by conventional methodologies (complement fixation). The young age
would make it less likely that there had been infection with HSV so
long ago that antibody levels subsequently waned to a level below the
sensitivity of the screening test. The results obtained from the use
of these sera were supplemented with those from the pre-bleed rabbit
sera when necessary.
HSV-1 POSITIVE SERA. A similar problem from unreported past exposure
with HSV-2 precluded the extensive use of adult sera that were HSV-1
antibody positive. There would no guarantee, for example, that HSV-2
antibodies did not contribute to the reactivity of adult sera with
HSV-1 antigen. The most satisfactory solution was again to use child
sera since they are very unlikely to have been exposed to HSV-2. Any
antibody detected was assumed to"be HSV-1 specific. Sera from children
in the age range 3 to 15 with complement fixing activity were used in
several experiments. Other HSV-1 antibody positive sera were available
from laboratory workers, and from HSV-1 immunised rabbits. For
completeness, sera from adults with recurrent genital HSV-1 infection
were also tested, although of course there is no definite information
about past HSV-2 infection.
- 140 -
HSV-2 POSITIVE SERA. Although sera from adult patients with
recrudescent HSV-2 infection were readily available, there was no
information about prior infection with HSV-1. Sera from patients with
primary HSV-2 infection were available, but since the patients were
generally not followed up for more than 2 weeks, they were not typical
of convalescent sera in that they would probably contain IgM and have
a very limited range of IgG antibody specificities. Also, since they
were taken from adults, they may have had low level HSV-1 antibody.
The only sera guaranteed to be HSV-2 specific were immunised rabbit
sera. Sera from patients with recrudescent HSV-2 infection were used,
but the possible contribution of HSV-1 antibody to the results should
be borne in mind.
REACTIVITY OF NEGATIVE SERA. These sera were tested against HSV-1 and
HSV-2 antigen in the IB assay. The vast majority of sera were
completely unreactive with any proteins in the assay. However, a small
proportion did show weak reactivity. The following bands appeared in
the IB assay witk HSV-1 antigen: two bands of 40 and 90 KDa (sera
nos. 4, 17, 18), 110 KDa (serum no. 20) and 65 KDa (no. 22). Two sera
(nos. 9 & 11) reacted weakly with HSV-2 antigen in the IB assay,
producing bands at 90 and 110 KDa respectively. The identity of any of
these bands could not determined.
The same sera were tested by other methods (table 7). The ELISA
results show that the vast majority of sera are unreactive with HSV-1
antigen (antibody levels of 5 mU and below were considered to be
negative). The only three sera to react significantly with HSV-1
antigen were sera 22 (63 mU), 20 (29 mU) and 17 (30 mU). The MABIA
showed no inhibition of any of the monoclonals by all but 3 of the
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also reactive by ELISA and IB, as can be seen in the table. Serum 18,
IB positive, ELISA negative showed borderline inhibition of nos. 1, 2
and 3 although the significance of this is uncertain. The
immunofluorescence antibody assay with HSV-1 and mock infected cells,
using the modification to prevent Fc binding, was used to test these
doubtful sera. The results were read double blind by the author and
another laboratory worker experienced in HSV IFAs; the latter read the
slides with no knowledge of the other results of the sera. The assay
confirms the presence of antibody reactivity with sera 22, 20 and 17,
and agree precisely with the ELISA results. Fluorescence was confined
to the cytoplasmic membrane, suggesting reactivity with HSV envelope
proteins.
Further testing was performed for antibody to other herpesviruses that
may possibly cross-react in the assays. The results showed no
interference of the other herpesvirus antibodies with any of the
tests; the majority of sera were unreactive despite variable levels of
antibody to each of the other viruses. However, it is possible that
the high titres of antibody to CMV (1/64) in serum 20 and to VZV
(1/32) in serum 18 may have been the cause of the apparent reactivity
of these sera with HSV. The numbers of sera involved are too small to
be definite one way or the other.
The negative sera, apart from the three sera of uncertain status, were
plotted on a scatter diagram to show the average, range and standard
deviation of inhibition of the various monoclonals used in the MABIA.
The diagram (fig. 14) shows the relatively tight clustering of
inhibition figures around the 90-100% range. The average figures of
the negative sera varied between the different monoclonals, with no.3
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FIGURE 14: Scatter diagram representing the results of testing
HSU antibody negative sera, HSU-1 antibody positive
sera, and sera from patients with HSU—2 infection.
Mean and 1 standard deviation from mean of negative
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FIGURE 14 (cont'd): See preceding page for legend.
others which were clustered from 90 to 95%. No.3 shows significantly
greater variability than the others, possibly a reflection of the
errors associated with the low OD values that this monoclonal
achieved. In fact, the standard deviation of the values of these
negative sera is only slightly larger than batch to batch variation
revealed by the multiple testing of the replicate positive controls
(table 4).
TARGETS OF ANTIBODY IN CONVALESCENT SERA.
HSV-1 SERA. Figure 15 and table 8 show the results of testing the
child and adult sera by IB, ELISA and MABIA. The IB assay shows very
broad reactivities with several HSV-1 specified proteins (there was no
significant reactivity of these sera, or any others in this study with
mock antigen in the IB assay; data not shown). There was variation in
the strength of reaction (intensity of bands) and breadth of antibody
(number of bands visible) between the sera. One problem with analysing
these IB results is the number of bands and the smearing in some
places on the strip. It was not really possible to distinguish
reactivity with the major glycoproteins gB, gC-1 and gE by this
method, although p40 and gD/gG are more clearly resolved. All sera are
positive for antibody to p40, while 18/21 are positive for gD/gG.
There is prominent reactivity with a protein of MW 108K-104K in 15
sera, weaker reactivity in two others and absent reactivity in the
remaining four. The antibody levels, as determined by ELISA are in the





FIGURE 15. Reactivity of HSV-1 antibody positive
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The MABIA gave numerical data on antibody levels to individual
proteins (table 8; figure 14). The HSV-1 positive sera without
exception showed significant levels of blocking activity to
monoclonals nos. 1 (gD), 3 (gB) and 10 (gB), and the vast majority
showed blocking activity with no. 2 (gC-1). While the blocking
activity of nos. 1, 3 and 10 was concentrated in the range 0-10%, the
blocking of no.2 was around 40% and never less than 33%. The former
monoclonals were therefore completely blockable; the partial blocking
observed with no.2 presumably involves an epitope not exposed during
the normal course of infection. A possible clue to this observation
comes from the behaviour of the monoclonals in the IB assay. Only no. 2
reacted with the denatured form of the target, and is therefore
directed towards a linear epitope. It is possible that it is only
partially exposed on the surface of the glycoprotein. The
conformational epitopes of the other monoclonals are presumably part
of the major antigenic areas of the proteins.
The sera from the children, assumed^not contain HSV-2 antibody, were
also tested against the HSV-2 monoclonals in the MABIA. The results
with no.9 confirm the results with the control sera, in that there was
no detectable blocking activity, with the average and range of the
inhibition values very similar to that of the negative controls. This
emphasised the specificity of the assay. The results with no.13 show
another feature of the assay; with this monoclonal, there was a range
of blocking activity from 1 to 65%, concentrating around 12%. This is
despite the apparent type-specificity of the monoclonal. Experiments
with the control sera also showed more extensive cross-inhibition than
cross-reactivity of the monoclonals.
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There was no obvious difference between males and females in antibody
levels, IB patterns or inhibition of monoclonals. There appeared to be
no difference betweeen the adult and the child sera.
HSV-2 SERA. Figure 16 and table 9 show the results of testing the sera
from patients with HSV-2 infection. The analysis is complicated by the
possible presence of HSV-1 antibody in a large proportion of the sera,
particularly when comparing the results of the inhibition experiments
with those of the ELISA and IB assays. The IB assay again showed a
broad reactivity with numerous HSV-2 specified proteins. There were
differences between sera in the patterns of reactivity, in that some
sera had antibody to one or two proteins, while others reacted with a
wide range, particularly in the range 110 to 70K. All sera appeared
reactive with p40 in this assay. There appeared to be reactivity with
gG-2 in the IB assay, on comparison of the bands produced with many of
the sera and those with monoclonal no.9. Antibody to gD was not
readily detectable, in contrast to the IB results with HSV-1 sera.
The ELISA antibody levels were in the range 40 to 1480 mU, and
correlated poorly with the observed intensity of the bands in the IB
assay. The MABIA with cross-reacting and HSV-2-specific monoclonals
revealed a wide range of inhibition values, greater than that produced
by the HSV-1 sera, and not correlating with the IB or ELISA results.
Analysis of the MABIA results on the scatter diagram (figure 14)
showed several interesting features. Inhibition of no.9 was varied,
but with an average figure lower than that of the negative or HSV-1
sera. The partial inhibition achieved by the HSV-2 sera is even less
complete than the inhibition of no.2 with HSV-1 sera. As mentioned
previously, no.9 was also reactive in the IB assay, showing the target









FIGURE 16. Reactivity of sera from patients with
culture proven genital HSV-2 infection in the IB
























































































































































































































































































































Reactivityofserafr mpatientsw thcul ureproveng alHSV-2infec ioni ELISAforHSVantibody,andbyMABIAgainsttype-commonanHSV-2specific monoclonalantibodies.
gG-2. Inhibition of no.13 was almost total with most sera, with an
average less than that of the HSV-1 sera, as might be expected.
Inhibition of the cross-reacting monoclonals, nos. 1, 3 and 10 was
similar to that of HSV-1, but there a second, smaller clustering of
sera showing partial inhibition. This was most pronounced with no.10,
but can also be discerned with the other two. Checking with the table
showed that the three clusters comprised roughly the same sera. These
results could be interpreted as making a partial distinction between
sera with HSV-1 and HSV-2 antibodies (complete inhibition of nos. 1, 3
and 10), and those with HSV-2 infection only (intermediate inhibition
values).It would require a type-specific assay to show unequivocally
whether this was indeed the case.
SEROCONVERSION STUDIES
STUDY GROUP. Patients presenting to the GUM clinic with symptoms and
signs of genital HSV infection were investigated by viral isolation
and serology. Blood samples were collected routinely at the first
visit and at a subsequent visit approximately two weeks later and
tested by complement fixation for HSV-specific antibody. Patients with
a positive isolation and a standing titre were considered to have had
a recrudescence, while those showing a rise in titre were considered
to have had a primary infection if the first serum was negative. First
and second sera from patients with primary infection of both types
were used in the study. The low sensitivity of the CF test required a
further check with a more sensitive assay for antibodies in the first
sera. This was to ensure that there was no pre-existing low levels
antibody present, either from previous exposure or because the
patients had presented relatively late in the course of the primary
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illness. The test used was IB, and patients with first sera reactive
by IB, however weakly, were excluded from the study. As will be seen
later, this was not the most sensitive test to use. Several patients,
although negative by IB, were positive by other assays for
HSV-specific antibody.
FIRST SERA. Table 10 gives the full results of testing the first sera
from all 20 patients in the study. Sera were tested for antibody to
other herpesviruses, and the results recorded in columns 4-6. As with
the child sera, such antibody did not appear to interfere with testing
for HSV-specific antibody. Column 7 records the duration of symptoms
of genital HSV infection before attending the GUM clinic and
collection of the first serum sample. This appeared to affect the
likelihood of detecting antibody in the first serum. Column 8 gives
the IB result; as mentioned previously all first sera were unreactive
in this assay. Columns 9 and 10 record the indirect ELISA and IF assay
results; the IF slides were read double blind as for the negative sera
above. Columns 11 gives the TDCA IB results, and 12 and 13 record the
counts and bands in the RIP assay. Finally, columns 14 to 19 record
the results of the MABIA with the full panel of monoclonals.
Sera were tested for HSV-specific IgM in an indirect ELISA. These
results were not satisfactory, since during development of the test it
was noted that negative sera reacted detectably with HSV antigen, both
HSV-1 and -2. Blocking with control antigen was effective at
eliminating much of the reactivity with the control wells, but there
remained apparently specific binding to the viral antigens, by both
negative control sera and the anti-human IgM conjugate. However, the
positive controls gave high OD readings distinct from the negative
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with HSV antigen. Of the patients with HSV-1 infection, nos. 6 and 7
showed some IgM reactivity distinctly different from that of the
negative controls. Patients 14, 19 and 20 showed greater than
background serological IgM reactivity with HSV-2 antigen.
IgG antibody was unequivocally present in some of the first sera,
albeit at a very low level. The detailed comparison gives data on the
sensitivity and specificity of each test for antibody to HSV. Sera
that were clearly positive for IgG are indicated, and were from
patients 1, 4, 5, 7, 8, 10, 12, 13, 15 & 19, based on the consensus of
results from columns 8 to 13. Inhibition of monoclonal antibody
binding in the MABIA is not evidence for specific IgG, since
apparent reactivity may be mediated by IgM.
Patient 1 showed reactivity in the ELISA, by IF, by TDCA IB and in the
RIP assay. Patient 4 was reactive by TDCA IB and RIP; the results of
the ELISA and IF assays are equivocal. Patients 5 was strongly
reactive in the RIP assay, by TDCA IB and by ELISA. Patient 7 was
reactive in the IF, ELISA and TDCA IB assays; there are unfortunately
no RIP results for this patient. Patient 8 is similar although
reactivity in the ELISA is borderline. Patient 10 is reactive by RIP
and TDCA IB, but equivocal by IF and negative by ELISA. Patient 12 and
13 are positive for IgG by RIP, TDCA IB, IF and ELISA. Patients 15 and
19 are positive by TDCA IB and IF although the ELISA results are
equivocal. There were some discrepancies in the results of these
patients; patient 10 would appear to have a false negative ELISA
result. Similarly, the counts in the immune precipitate of patient 12
are zero, despite showing gB and 130 K reactivity by autoradiography.
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Sera from patients 2, 3, 6, 9, 14, 16, 17 and 18 were clearly negative
in the assays for IgG, although patient 14 showed some reactivity in
the RIP assay. The counts recovered in the immune precipitate from
this latter serum were low, despite apparently showing reactivity with
130 KDa and gB proteins on SDS-PAGE.
This leaves two sera of uncertain status from patients 11, and 20.
Patient 11 is negative by ELISA, RIP, and IF, but reacts in TDCA IB
assay. Patient 20 is negative by TDCA IB, borderline by ELISA, but
reactive in the IF assay. There is little evidence to show that the
IF, RIP or TDCA IB assays are systematically more sensitive for IgG
antibody than each other. This can be seen the results of patients 11
and 20, where the tests coming up positive differ between the two
patients. The ELISA gives the most discrepant results, showing
equivocal and negative results in several sera clearly positive by the
other tests.
Of particular note is the detection of gB antibody reactivity by the
RIP and TDCA IB methods in sera that were negative by conventional IB.
The identity of the 130 KDa band produced with HSV-2 sera in the RIP
assay is uncertain. The differences between the results of the TDCA IB
and SDS IB assays indicate that it was the solubilisation of antigen
that was responsible for the reduced sensitivity of the conventional
IB assay; this was the only methodological difference between the two
t
assays.
The results of the MABIA are not directly comparable to those of the
other tests, since positive results may have arisen from reactivity
with HSV of other immunoglobulin classes, notably IgM. Sera from
patients 4, 5, 6, 7 and 8 with HSV-1 infection showed inhibition
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figures of monoclonal antibodies nos. 1 and 3 significantly below the
range of the negative sera. Comparing with the IgG results, patient 1
was HSV-IgG positive, but negative in the MABIA. Of the MABIA positive
sera, sera from patients 4, 5, 7 and 8 were also positive for HSV-1
specific IgG. Sera from patients 6 and 7 showed reactivity in the IgM
assay (with due respect to the preliminary nature of this data); this
may acccount for the reactivity of the IgG-negative serum from patient
6 in the MABIA.
Turning to HSV-2 infection, inhibition of no. 13 was the most
frequently observed (sera from patients 10, 11, 12 & 14). This
compares with the results of the assays for IgG that showed 10, 12,
13, 15 and 19 to be reactive, 11 and 20 to be borderline and 14, 16,
17 and 18 to be negative. IgM reactivity was found in sera from
patients 14, 19 and 20. Therefore, overall, there was poor correlation
between the MABIA results and those for specific immunoglobulins in
the sera from patients with HSV-2 infection.
SECOND SERA. Table 11 shows the results of applying the same battery
of tests to the second sera. The second column gives information on
the number of days elapsed between collection of the first and second
sera. The remaining columns give the serological results in the same
format as the previous table.
All sera showed reactivity in the IB assay, although in two patients,
19 and 20, the bands produced were very weak. Seventeen out of the
twenty sera reacted with p40; this was the predominant antigen in both
HSV-1 and -2 infection both in prevalence and in intensity of
staining. All sera were positive by ELISA with a range of antibody
levels to type-homologous virus from 20 to 860 mU. Similarly, all
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PATIENT
12 11 13 15
IB bands gD/gG p40 112K p40
112,85,70K gD/gG,?40 112K p40 112K p40
ELISA /mU 270 130 190 380 860
TDCAI£ bands gB gB gB gB gB,gD
cpm 3159 3104 2791 3644 7939
RIP
bands gB gB gB gB gs,gc
MABIA
Inhibitionof
44 50 52 45 28
76 91 93 80 47
48 45 59 50
0
10 58 80 58 33
0
TF 11 12 13 14
TT
19 14 15 10 10 18
~8BK p40 112K p40 112K p40 112K p40
TTo" 140 190 260





42 57 55 52
47 73 69 42




gB gB gB gB 0.63 gB
2386 2181 1789 3832 769
MCP,gB 130,95,38K MCP,gB 130,95,32K MCP,gB 130,95K MC?,gB 130,95K MCP,gB 130,95K
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second sera were reactive with gB in the TDCA IB assay, although two
sera showed further specificities for other bands; in the case of
patient 5, the band had been identified as gD by monoclonal no.l.
Reactivity with gB was exceptionally weak in some sera, as indicated,
and this correlates with the ELISA antibody level. Finally, the RIP
results show elevated counts with the sera tested, and universal
reactivity with gB on SDS-PAGE analysis. Sera from patients with type
2 infection also reacted with MCP, a 130 K protein, a 95 K protein and
some lower MW species. Patient 5 also showed reactivity with gC, but
not to gD as found in the TDCA IB assay.
Figures 17, 18 and 19 show examples of the reactivity of the first and
second sera in the SDS-IB, RIP and TDCA IB assays. They are from
patients 2, 5, 9 and 7, and show the absence of reactivity of the
first sera in the IB assay, despite gB antibodies in the other two
assays. Figure 17 shows the prominent reactivity of the second sera
with p40 in the IB assay, while figure 18 and 19 show the reactivity
with gB in the same sera.
Figure 20 is a diagram to show the inhibition results more clearly.
The negative sera mean and 1 standard deviation ranges are shown above
a set of arrows that represent the change in inhibition' figure that
occurs between the first and second sera. The arrows are in the same
order as the table, with the HSV-1 sera above those from HSV-2, and
the females above the male patients. With monoclonals nos. 1, 3 and
10, there are very large decreases in inhibition figures, signifying
increases in antibody levels to the target proteins. As is found in
the experiments with the convalescent sera, sera from patients with
type 1 infection inhibit monoclonal no.l more effectively than those
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FIGURE 17. Reactivity of first and second sera
from patients with primary HSV infection in the IB
assay with type-homologous antigen. Lanes 1 & 2,
first and second sera from patient 2; lanes 3 & 4,
patient 5; lanes 5 & 6, patient 9; lanes 7 & 8,
patient 7.
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FIGURE 18. Reactivity of first and second sera
from patients with primary HSV infection in the






FIGURE 19. Reactivity of
first and second sera from
patients with primary HSV
infection in the TDCA IB
assay with type-homologous
antigen. Lanes as in
figure 17.
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Monoclonalno.13
FIGURE20(cont'd):Seeprec dingageforleg n .
and 10 between HSV-1 and -2 antisera. Although several HSV-2 sera
failed to develop reactivity with the target of monoclonal no.l, the
results with no.13 confirm the presence of gD antibody in the
majority; testing sera from patients with HSV-1 infection showed, in
turn, less inhibition of this monoclonal than sera from patients with
HSV-2.
Patients who did not develop antibody capable of inhibiting a
given monclonal antibody normally show very short arrows that point in
both directions within the negative range of the monoclonal. This
appears to be the case with HSV-2 sera with monoclonal no.2. However,
sera from some patients with HSV-1 infection show definite decreases
in the inhibition figure, signifying the appearance of gC-1 specific
antibody. The reverse applies to monoclonal no.9 (gG-2), where there
is no clear trend with the HSV-1 sera, and the arrows lie largely
within the negative range. By contrast, there is a leftward trend with
the arrows from the HSV-2 sera, with several second sera clearly being
positive for antibody to gG-2.
Overall, there was good correlation between the tests osto which second
sera were strongly reactive, and which ones were weak. Typically, sera
that produced high numerical results and low inhibition figures also
appeared to be more broadly reactive in the immunoblotting and RIP
methods. However, there were marked differences in the sensitivity of
the tests for antibody of differing target specificities. The
insensitivity of coventional IB for glycoprotein antibody is
demonstrated, firstly, by its failure to detect such antibody in any
of the first sera, and by the prominence of the reaction with p40, a
tegument protein in most of the second sera. The TDCA IB and RIP
methods showed sensitivity for glycoprotein antibody, but did not
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detect antibody to p40 or, in the case of HSV-1 sera, to any capsid
proteins. However, both methods failed to detect gG antibody in any of
the HSV-2 sera, despite the evidence for such antibody by conventional
IB and, to a limited extent, by the MABIA. Taken together, the tests
demonstrate antibody reactivity with a range of glycoproteins, and to
at least one capsid protein, in the second sera, and clear evidence
for gB, and possibly gD, antibody at low levels in some of the first
sera.
Unfortunately, there are no RIP results for most of the male sera.
However, the ELISA antibody levels show an average male level of 127
mU and and average female level of 300 mU. The variability in antibody
levels results in their ranges overlapping, so the figures are not
significant statistically, although they do point towards a
sex-related difference in antibody response.
HUMAN IMMUNODEFICIENCY VIRUS
STUDY GROUPS
The immunoblotting method for the detection of HIV antibody was used
to confirm the presence of antibody in sera referred to the reference
laboratory. Sera were sent from various hospitals and the Blood
Transfusion Service that had been found to be positive by conventional
screening assays. The IB method was also used to investigate sera that
showed borderline or discrepant reactivities in the screening tests.
The results both clarified the diagnosis of patients, and was useful
in the investigation of the different types and causes of non-specific
reactions, and comparison of the sensitivity and specificity of the
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different commercially available tests. Two years ago, sera were
screened by the Abbott direct binding assay, and confirmed with the
Wellcome test. However the Abbott test produced so many false positive
reactions with stored or heat inactivated sera that its use was
discontinued. Only the results comparing the IB assay with the
Wellcome and Pasteur assays are presented. One problem with this work
stems from the impossibility of knowing for certain whether the
patient had been exposed to HIV in the past. In particular, many sera
were from blood donors, in whom risk factors could not be assessed.
The majority of the positive sera confirmed by IB were from IVDAs,
although several positive male homosexual and haemophiliac sera were
also referred.
Figure 21 shows the result of testing a number of HIV-antibody
positive sera by the IB assay. The sera show a typical range of
reactivities with several HIV-encoded proteins. The identification of
proteins was made on the basis of molecular weight, and comparison
with the results of other investigators. Table 12 shows the
identification of bands, their apparent MW, and, in the case of
prominent bands, the prevalence of reactivity to them in a panel of 66
HIV antibody-positive sera. Samples were considered to be positive if
they reacted with at least two bands in the IB assay, provided the
bands indicated reaction with proteins from different genes.
Sera referred to our laboratory could be divided into two groups for
the purposes of this investigation. The unreactive group comprised
sera that produced no bands by IB, while the reactive group was made
up of sera that broad reactivity in the IB assay, reactive with at
least three bands. Sera showing restricted reactivity with only one or
two bands were investigated separately in the next section.
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FIGURE 21. Reactivity of 22 HIV antibody positive
sera in the IB assay with purified HIV as antigen.
Accepted nomenclature of bands on right; coded
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The results of testing sera unreactive in the IB assay by the Wellcome
EIA (competition assay) and in the Pasteur assay (direct binding) are
shown in figure 22. Several sera were only tested by the Wellcome
assay. These results are presented in a separate graph to the left of
the figure; however, the axes are aligned so the results may still be
compared. The results from the Wellcome assay are expressed as the
ratio of the ODs of the cut-off value (calculated from control sera
provided in the kit) to the test result. Therefore, a ratio of 1.0 or
greater indicates a positive test result; all sera with ratios below
1.0 are to be considered negative. The average reading of these
unreactive sera was 0.653 with a standard deviation of 0.227. However,
the distribution is skewed, with a greater than normal numbers of sera
with high ratios. The ratios in the Pasteur assay were calculated by
dividing the test value with the cut-off value (determined from
control sera). Ratios of unreactive sera in this test tended to
cluster around zero (average 0.69, range T 1.50). While the Pasteur
assay gave no positive reactions, 8 sera were above the cut-off in the
Wellcome assay, and a total of 21 sera were above 1 standard deviation
from the negative mean. The ratios of these sera in the Pasteur assay
suggested that these sera were actually negative. However, these sera
were repeatably more reactive than average in the Wellcome test, and
the evidence from the BTS suggests that donors with sera that produce
high ratios continue to do so at subsequent donations, often over some
years.
Serum A and a follow-up serum, marked B, from the same individual were
referred by the North London BTS, as being positive in their screening
test for antibody to HIV. On testing, they showed repeatable
reactivity in the Wellcome test, but could not be confirmed as
positive by either Pasteur or IB, and were investigated more
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extensively by several other assays. Both sera reacted
non-specifically with uninfected T-lymphocytes to a far greater extent
than normal sera in the IF assay, with no evidence of increased
fluorescence with CEM cells infected with the RF strain of HIV. Serum
A was negative for antibody in the Dupont direct binding assay and
both sera were negative for "env" and "core" antibodies in the highly
specific Abbott confirmation assay. The extra tests confirmed that the
serum was negative for HIV antibody, although if the non-specificity
was caused by antibody to cellular components, as suggested by the IF
assay, then it is not clear how such antibodies could interfere with
the Wellcome assay.
Sera marked C and F were referred by Dr R. Tedder, Middlesex Hospital,
London. They were taken from low risk patients and were known to cause
non-specific reactivity in a wide range of tests. Serum C showed
slight or no reactivity in the Pasteur EIA, butArelatively reactive
in the WeUcome assay. Serum F showed some reactivity in both tests,
although was negative by IB. Samples marked D and E were referred from
Dundee BTS; they showed weak reactivity in the Wellcome assay, but
could not be confirmed by the other two tests. No sera have yet been
found that give a false postive result in the Pasteur assay, although
this may be a reflection of screening policy. In both this laboratory,
and in the BTS, sera are generally screened by Wellcome, and reactive
samples confirmed by Pasteur. If the Pasteur assay was used for
primary screening, then non-confirmable reactive samples may be found
in this assay.
The results from testing the reactive sera are shown in figure 23
(note the change in scale from figure 22). All but two sera were
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FIGURE23:ReactivityofBpositiveserainWellcomeandP steurEIAs.Re ul s expressedainFigur22(notchangefscale).St xtforxplanation ofresultsindicatedbyarrow.
correlation between the ratios produced by the two tests. The serum
marked with the solid arrow was from a patient who was the recent
sexual contact of an HIV carrier. The serum was antigen positive on
preliminary screening suggesting that the patient was very close to
seroconversion for antibody. The reactivity of the serum in the IB
assay was weak, with antibody restricted to p24, pr55, p51 and p65.
The serum was on the cut-off value of the Dupont direct binding assay.
Although this serum was positive, the ratio was indistinguishable from
many of the negative sera. In the seroconversion studies to be
described, borderline ratios with the Wellcome test are often
associated with seroconversion, where antibody levels may be very low.
The serum labelled with the hollow arrow was repeatably negative in
the Pasteur assay, but positive by Wellcome and reactive with several
bands in the IB assay. The reason for the discrepancy has not been
found, but may reflect a sensitivity difference between the tests.
The last group of sera that arose from routine screening of referred
sera comprised those that produced abnormally restricted patterns in
the IB assay, and were investigated further by a number of methods.
Due to differing availability of various tests for HIV antibody at
different times, and the small volume of some of the samples, the
analysis of some sera has not been comprehensive. Several sera have
shown reactivity with pl7 and no other HIV protein. One serum in an
evaluation panel from Colindale showed this pattern, but there was
insufficient to investigate it further. It had been reported as
being of borderline reactivity in the original Abbott EIA. However,
the same pattern was found in two unrelated blood donors from Fife,
who had been identified as borderline in a Dupont ELISA screen. The
samples from these two patients were negative by Pasteur (0.2, 0.0);
negative by Wellcome (0.5, 0.5); and negative for both anti-"core" and
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anti-"env" in the Abbott confirmation assay. Since they were blood
donors, it was difficult to determine risk factors, but they were aged
55 and 60 making HIV infection unlikely. Neither had travelled to
Africa. Samples from previous donations from both patients were
available as far back as 1983. These were tested by IB and also found
to have the same pattern. This discounts a seroconversion as a
cause for the restricted reactivity. Furthermore, the prevalence of
HIV infection in Fife in 1983 was so low as to discount HIV as a cause
of this antibody reactivity. Sera from both patients were negative for
HTLV-I antibody.
Seroconversion accounted for several very restricted patterns observed
in referred samples. Sera from a haemophiliac (p24 only, Wellcome 1.0,
anti-"env" positive, anti-"core" positive, p24 antigen positive), a
male homosexual (p24, pr55, Wellcome 1.0, Pasteur 1.6, anti-"env"
positive, anti-"core" positive), and two sera from a blood recipient
taken three days apart (both pl7, p24, Wellcome 0.5, 0.5, Pasteur 0.5,
0.5, both anti-"env" borderline, both anti-"core" negative, both
antigen positive) were picked up on routine screening. Follow-up sera
from all three patients taken after 1 week, 2 months and 1 week, were
clearly positive by all tests. Further sera from the haemophiliac
patient and the blood recipient were investigated in more detail (see
next section).
The most unusual serum came from a middle-aged man who had worked in
Kampala, Uganda. A blood donation from this patient was outside the
normal range on the Wellcome screen but below the cut-off value. The
serum reacted very weakly with p25 and pr55 in the IB assay, but was
negative by Pasteur and Dupont direct binding assays. It was
repeatably weakly positive for anti-"env" antibody in the Abbott
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confirmation assay, but very strongly reactive for anti-"core"
(stronger than any other serum so far tested, including those positive
for HIV antibody). The serum was negative for HTLV-I antibody, but
obviously requires testing for HIV-2 (not available at the time of
writing).
SEROCONVERSION STUDIES
Using the stored serum collection in the Hepatitis Reference
Laboratory, it proved possible to trace back known antibody positive
patients and to identify the time of seroconversion. In some patients,
notably haemophiliacs, several sera were collected at close intervals
around seroconversion, and therefore would be suitable source material
for critical comparison of the various tests. Sequences of sera from 8
patients were suitable for the comparison of the sensitivity and
specificity of the IB assay, the Wellcome EIA, the Dupont EIA, the
Abbott confirmatory EIA and the immunofluorescence assay described in
the methods. Table 13 presents the data obtained from these patients.
Column 4 records the number of days elapsed between collection of the
last antibody negative serum of and collection of subsequent sera. As
can be seen, this inevitably was very variable between patients,
making the analysis of the results more difficult.
Column 5 records the IB results. None of the negative sera produced
any bands, while the first positive sera commonly showed reactivity
confined entirely to p24 (band B) and pr55 in many patients.
Subsequent sera showed a broadening of antibody reactivity to proteins
encoded by the pol and env genes. The table does not record the
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show this, figure- 24 (a-e) shows several examples of seroconversions.
The seroconversion from patient 7 (figure 24e) is particularly useful
since the samples happen to very closely spaced. The restricted
reactivity of the first sera would cause problems with interpretation
if they were found on routine screening. However, with the knowledge
that follow-up sera from the patients were subsequently clearly
positive by several assay methods, reactivity with p24 alone in the IB
assay appeared to be significant. This is despite the fact that the
sera would be classified as negative by conventional criteria
(reactivity with at least two bands encoded by different genes).
The next column shows the cut-off to test ratios of the sera in the
Wellcome assay. The ratios of the negative sera were in the range 0.4
to 0.6. The first positive sera were clearly reactive in 4 of the 8
patients, borderline in one, and unreactive in the remaining three.
The ratios of the sera from patients 1 and 8 were marginally elevated
from those of the negative sera, but the second and third sera from
patient 2 were indistinguishable from the negative sera. The two sera
were tested by the Edinburgh BTS, who, with much larger batches and
numerous controls, routinely apply statistical methods to detect weak
reactions in the Wellcome assay that would not be found in a
diagnostic laboratory. Both sera were completely unreactive and
indistinguishable from a large panel of negative blood donors, while
the weak reactivity of second serum from patient 1 was detected by the
Edinburgh BTS.
The Abbott results are recorded in the next column. The result from
the first serum of patient 8 indicates the non-specificity of this
test. The serum produced a ratio of 1.8, but subsequent investigation
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FIGURE 24. Reactivity of sera from patients
seroconverting for antibody to HIV in the IB
assay. Time, in days, from date of collection of
last antibody negative serum indicated under
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FIGURE 24 (cont'd). See above for legend. Panel b:
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FIGURE 24 (cont'd). See above for legend. Panel e:
patient 7.
next section). Since this serum and 2 other negative sera were
reactive in the Abbott assay, there was little point in comparing its
sensitivity with the other tests. Sera taken several months after the
seroconversion did, however, show strong reactivity in the Abbott
test, clearly distinct from the range of reactivities found with
negative sera.
The IF assay results, read double blind, showed good agreement with
the IB results, with no false positive reactions. However, the second
and third sera from patients 2 were IF negative, despite clear
evidence for the presence of low levels of HIV antibody. The second
sera from patients 1 and 3 were graded as +/- and were distinguishable
from negative sera by this test. However the weak reaction would lead
to problems of interpretation if the test were used with unknown sera.
The results of Dupont assay were quantified as described in the
methods. There was good agreement with the IB assay, and the test
detected weak antibody reactivity in the second and third sera from
patient 2. However, if the criteria for positivity recommended by the
kit had been followed, any sera with less than 2 mU of antibody would
be classified as negative. The second sera from all the other patients
were, however, clearly positive. Steadily rising levels of antibody
was found in all of the patients after seroconversion.
The Abbott Confirmatory EIA was designed to be a highly specific and
sensitive test for HIV antibody. The detection of anti-"env" proved to
be as sensitive and specific as the IB assay. The cut-off value
calculated from the controls supplied with the kit would produce a
level of around 0.3 mU, so the levels detected in the second and third
sera of patient 2 were significant. The anti-"core" component of the
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assay failed to detect antibody in these two sera, although positive
results were obtained with the second sera from all other patients.
Finally p24 antigen was detected in the first (antibody negative) sera
of patients 4 and 7, in the second serum of the latter patient, and in
the second and third sera of patient 2. The association of
antigenaemia with seroconversion is investigated in the next section.
Although there was good agreement between the IB and anti-"env"
assays, it is noteworthy that the IB assay detected antibody
reactivity confined to p24, a core protein, in most of the first
antibody positive sera, while the same sera all had detectable
anti-"env", specifically gp41, antibody in the Abbott assay. As with
the various assays for HSV antibody there appeared to be a difference
between the tests in sensitivity for antibody of differing
specificities. This study demonstrates the lack of sensitivity of some
of the screening ELISA's for HIV antibody and gives information about
the significance of restricted patterns of reactivity in the IB assay.
THE HAEMOPHILIAC COHORT
The circumstances by which some haemophiliacs in Edinburgh became
infected by HIV differ markedly from the experience elsewhere, and
constitute a unique group with which to study the course of infection
with this virus. As described in the introduction, the source of
infection of eighteen haemophiliacs was a single batch of factor VIII
concentrate. The prevalence of HIV infection in Edinburgh in 1983 was
so low that it is probable that the batch was contaminated by a single
blood donation, and as such constitutes a single source of infection.
Apart from the opportunity to study viral evolution in this cohort, it
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constitutes a relatively homogenous group in which the duration and
dose of infectious material administered to each patient was known.
Furthermore, this batch was the only source of infection of all but
one of the cohort.
Although the 18 patients in the study were infected at approximately
the same time with the same material, they differ in their current
clinical condition. Since one of the aims of studying this cohort was
to relate serological results to progression to AIDS and related
illnesses, the patients were designated as either well (W) or unwell
(U) depending on clinical assessments made by Dr Ludlam and Dr
Cuthbert over the first three years following exposure. 10 patients
(Wl-10) have remained asymptomatic; table 14 gives details of the
remaining 8 patients who developed symptoms before March 1987 (Ul-8).
Two of the patients classified as well developed splenomegaly;
although this may be the result of HIV infection, it may occur in
haemophiliacs for other reasons. There was no other evidence of
disease progression in these two patients and so they have been
classified in the well-group. The unwell group (8 patients) comprises
those with AIDS, ARC and persistent generalised lymphadenopathy (PGL).
One patient (W2) emigrated after receiving the contaminated batch but
before seroconversion. It has not proved possible- to study his sera,
and he has been omitted from the study. Two patients (U1 and U8) were
lost to follow-up after the first year of infection, but samples were
available in 1987. Patient U2 received commercial factor VIII after
seroconversion, and possible re-infection with another strain of HIV
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SEROCONVERSION FOR ANTIBODY. Sera were tested by IB and and by the
anti-"env" component of the Abbott confirmatory assay for the earliest
signs of seroconversion. The two methods were in complete agreement
over the timing of the appearance of antibody in each patient and
allowed the last negative and first positive sera from each patient
to be identified. These sera were then tested further by other assays,
including the Dupont ELISA for p24 antigen. The full results are
presented in table 15.
The second and third columns record the time and dose of exposure to
the implicated batch. This data was obtained from Dr R. Cuthbert of
the Haematology Department, but has been repeated here since it
relates directly to detection of antibody and antigen. In 6 patients,
the last HIV antibody negative serum was collected before the first
exposure to the implicated batch. While these sera have been tested
for antigen and found to be negative, the data are not included in the
table since they are not directly relevant to the study described
here. The antigen results of the first sera from the remaining 11
patients are shown in column 4. A range of antigen levels from 15 to
3600 pg/ml was found in five of the 11 sera.
The time between exposure and collection of the first antibody
positive serum in each patient is shown in the next column. These sera
were tested in the Dupont EIA, for anti-"core" and for antigen. All
sera were reactive in the Dupont EIA, although the serum from patient
U1 would have been scored as negative if the kit recommendations had
been followed. Three sera were negative for anti-"core", as measured
by the Abbott confirmatory assay, although two were reactive with gag
proteins in the IB assay. In patients W5 and Wl, anti-"core" antibody
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respectively. However, all subsequent sera from patient W10 remained
negative for anti-"core" and unreactive with gag proteins in the IB
assay.
The results of the first positive sera in the IB assay are shown in
figure 25. All but one sera reacted with p24, and the precursor gag
protein, pr55. Reactivity with gp41 and pol gene product was less
frequent, and generally the intensity of the bands was weaker than
those of gag proteins. There was some correlation between breadth and
intensity of antibody reactivity in the IB assay with anti-"env"
antibody and Dupont antibody levels. Patient U1 showed extremely weak
reactivity in the anti-"env" assay (3 mU) and only one faint p24 band
in the IB assay. Furthermore, it would have been classified as
negative in the Dupont assay if the calculated cut-off value had been
used. The opposite extreme is represented by the first positive serum
from W9, who shows broad reactivity in the IB assay, and high levels
of antibody in each of the three ELISA's. All first positive sera were
tested for antigen. Two of the 17 sera were positive (Ul, U2).
Subseqent sera from both patients were antigen negative (13 and 15
days later). The first positive serum from patient U2 was
simultaneously anti-"core" and p24 antigen positive.
The relationship between time, duration and dose of exposure with time
to seroconversion and detection of antigenaemia is illustrated in
figure 26. In some patients, samples were available prior to the last
antibody negative sample, and were tested for antigen in order to fix
a definite time limit on the duration of the antigenaemia. Sera from
patient W8 were antigen and antibody negative; antigen postive
antibody negative; and antigen negative, antibody negative in
successive samples; similar patterns may be seen in patients Ul and
- 165 -
FIGURE 25. Reactivity of the first positive sera
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U2. The duration of antigenaemia appears to be short; in patient U2,
the duration had an upper limit of 37 days.
Despite the difficulties caused by the irregular spacing of samples
from different patients, it was possible to see variation in the time
to seroconversion after exposure. At least 157 days elapsed before the
appearance of antibody in patient U1, while antibody appeared in
patient U2 between 30 and 36 days. Comparison of the time to
seroconversion and dose administered reveals a weak association, in
that patients W4 and U1 (10 and 9 bottles respectively) seroconverted
at least 108 and 157 days after exposure. This data is currently being
analysed statistically by Dr R. Cuthbert.
FOLLOW-UP PERIOD
Sequential sera from the patients in the cohort were available in the
3 years following exposure. Table 16, 17 and 18 and figures 27, 28,
29, 30 and 31 show the results of testing sera from the patients in
mid-1985, mid-1986 and mid 1987 by a number of tests. While the first
positive, mid-1985, and mid-1986 sera from each patient were tested
with the same kit batch for anti-"env" and anti-"core" antibody
levels, the mid-1987 samples from each were tested using a different
batch and did not give comparable results. Seasonal differences in
incubation temperature may have accounted for some of the differences.
However, the main cause of the problem probably results fom minor
alterations in the antigen coating and conjugate between different































































































































































































































































































































































300 400 500 600












100 200 300 400 500 600 700 800 900
Days from first exposure
FIGURE 27: Reactivity of sera from the haemophiliac
patients in ELISA for anti-"env" antibody,
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FIGURE 29. Reactivity of sera taken in mid-1985
from patients in the haemophiliac cohort in the IB
assay.
FIGURE 30. Reactivity of sera taken in mid-1986
from patients in the haemophiliac cohort in the IB
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FIGURE 31. Reactivity of sera taken in mid-1987
from patients in the haemophiliac cohort in the IB
assay.
The results with the anti-"env" component of the test are shown in in
column 6 of tables 16 and 17 and graphically in figure 27. All
patients showed steady rises in anti-"env" antibody levels with time
after exposure. There were differences in the level of antibody
finally achieved, although this did not correl ate with clinical
progression; there was no statistical difference in the average level
of antibody between the well and unwell groups at any of the three
sampling times.
Antibody levels in the Dupont assay were recorded in column 5; tables
16, 17 and 18, and graphically in figure 28. All patients showed a
steady rise in levels of antibody over the first two years, The
majority of patients, both well and unwell, continued to show small
rises into the third year of the study. The relative uniformity of the
serological response between the well and unwell groups is striking,
in view of the differences in clinical condition between the patients
in the first two years of infection.
However, differences between patients emerged thereafter. Patients W4,
W5 and W9 showed marked increases in antibody level, achieving levels
many times higher than the average for the well group. In contrast,
patients U2, U3 and U8 showed prolonge'd falls in antibody level in the
third year, possibly reflecting clinical progression and dysfunction
of the immune system. The patient with AIDS (U2) showed the most
drastic and sustained fall of the three patients. This fall began at
about the time AIDS was diagnosed, and continued ' until death
r~
from secondary infections at 1100 days (the last sample was taken 7
days before). The falls observed in patients W3 and U7 are based on
the result of testing single sera and would need to be corroborated by
further sampling. However, it is notable that patient W3 developed
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constitutional symptoms of sufficient severity to warrant inclusion in
group IVa within the last three months, co-incident with the fall in
antibody level.
Sera were screened for antigen, and positive samples confirmed by
neutralisation. Two patients (W1 and W8) showed evidence of long-term
antigenaemia (column 3), and were tested in greater detail. Antigen
appeared in patient W1 at 329 days, and has remained until the present
day, at the same low levels. Antigen first appeared in patient W8 at
245 days (30 ng/ml). Levels rose throughout 1985 and 1986 to a level
of 200 ng/ml at 844 days. Two further patients (W10 and U7) had
detectable antigen, confirmed by neutralisation, in the mid-1987
samples only. Patient U3 showed low level antigenaemia in four sera
taken after seroconversion. Two were retested in an attempt to
demonstrate neutralisation but were found to be unreactive in the
presence of both positive and negative sera. However, the most recent
sample (tested by S. Rebus) was found to be antigen positive, and
confirmable (60 pg/ml). The mid-1987 sera from patients U4 and U8 were
initially weakly reactive in the assay, but were not confirmable. It
is is possible that these patients will become antigenaemic, by
analogy with U3.
Figures 29, 30 and 31 and column 4, tables 16, 17 and 18 show the
results of testing the sera with the IB assay. Comparison with the
first positive sera (figure 25) with those from mid 1985 shows that a
marked increased antibody reactivity to several HIV proteins developed
over the first year on infection. The only exception was patient W10,
who continued to show an unusually weak pattern of reactivity at all
times after infection. That this patient was truly infected and not
merely immunised is shown by the appearance of antigenaemia in 1987
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and steady increases in antibody level in the Dupont and anti-"env"
assays over the follow-up period.
However, reactivity with p24 and pl7 was variable between patients,
with many showing a loss of reactivity p24 and pl7 over the first
year. The anti-"core" assay (column 11, table 15; column 7, table 16)
measures antibody reactivity Lc recombinant p24 in a competition
ELISA, and provides numerical data on reactivity with core proteins.
It can therefore be used to corroborate the findings of the IB assay.
Patients W1, W8, U2, U3, U4, U6 and U7 all showed reduced reactivity
in the IB assay, and falling levels of anti-"core" antibody in the
specific ELISA over the first year of infection.
In contrast, the changes in antibody reactivity between sera taken in
1985 and those from 1986 and 1987 were relatively minor. Little change
in reactivity to proteins encoded by the env and pol genes was
noted in the majority of patients. However, patients U2, U3, U7 and U8
showed a general weakening of reactivity with these bands, and this
correlates with the fall in total antibody level found on testing in
the Dupont assay (see above). Reactivity to gag proteins also varied
little in the last two years of follow-up. Patient U8 showed a fall in
reactivity with p24 in the IB assay, and a fall in anti-"core" level,
between 1985 and 1987. Unfortunately, there are no samples available
for 1986, so it is not known when the loss of antibody occurred. This
patient developed antigenaemia over the same period.
The seven patients showing falls in antibody reactivity to
gag -encoded proteins in the first year were investigated more
thoroughly. The results of testing sera taken at more frequent
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quantification of the initial increase followed by loss of anti-"core"
antibody. There was good correlation between the observed intensity of
the p24 band in the IB assay with the anti-"core" level. An example of
the IB results is shown in figure 32. As can be seen, the p24 band
weakened, but did not disappear, between days 123 and 1048 days; this
is further evidence for the greater sensitivity of the IB assay for
p24 antibody over the specific ELISA for anti-"core" antibody. Low
level antigenaemia was detected and confirmed in the last sample
available from the patient before death. Patients U3, U7 and W1 also
show loss of anti-"core" antibody; the latter patient also became p24
antigen positive at the same time as p24 antibody was lost. The time
after seroconversion that the loss of reactivity occurred varied
between these four patients.
The three patients in table 19, part B also showed losses in
anti-"core" reactivity, but subsequent events distinguished them from
the patients those in part A. Sera from patient U4 showed a fall in
anti-"core" level between days 107 and 210; antibody became
undetectable by day 231. However, anti-"core" subsequently re-appeared
and was still rising by day 833. Figure 33 shows the result of testing
these sera in the IB assay, and confirms that a fall followed by a
rise in antibody to core proteins had occurred. The mid-1987 sample
(1214 days), however, showed a fall in the level of anti-"core" and
reduced reactivity with p24 (figure 31). The patient remained antigen
negative throughout the follow-up period.
A fall in anti-"core" followed by a rise was also seen in patient W8,
and confirmed by the IB assay. Serum p24 antigen was detectable from
day 245 onwards, the first appearance co-inciding with the initial
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FIGURE 32. Reactivity of sequential sera from
patient U2 in the IB assay. Days elapsed from
first exposure to implicated batch of factor VIII
indicated under the strips.
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FIGURE 33. Reactivity of sequential sera from
patient U4 in the IB assay. Days elapsed from
first exposure to implicated batch of factor VIII
indicated under the strips.
reappearance of anti-"core". Finally, patient U6 showed fluctuating
levels of anti-"core", relatively constant low level reactivity with
p24 in the IB assay, and remained antigen negative.
There was some overall correlation between anti-"core" levels and p24
reactivity with clinical progression in this cohort. Patients who
showed steadily rising levels of anti-"core" over the two year
follow-up could be grouped in the normal response group. Patients
showing this pattern were W3, W4, W5, W6, W7, W8, W9, and patient U5
(PGL). Patients showing falls in anti-"core", fall followed by rise,
fluctuating or absent anti-"core" levels could be put into the
abnormal response group. Patients in this group were W1, W8, W10, U2,
U3, U4, U6, U7 and U8. If PGL were not considered as evidence of
progression to AIDS, then the figures would read 8 well and no unwell
patients in the normal response group, and 3 well and 5 unwell (4 ARC,
1 AIDS) in the abnormal response group. It remains to be seen whether
the abnormal immunological responses to core proteins in the
latter three well patients is prodromal for progression.
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DISCUSSION
ANTIBODY TO HERPES SIMPLEX VIRUS
It is well established that infection with HSV in man elicits a
humoral immune response. Antibodies may be detected to a wide range of
HSV-encoded polypeptides, of which a proportion are neutralising. The
specificities of the IB, RIP and TDCA IB assay were determined by
preliminary experiments with a number of control sera. Subsequently,
the assays were used to investigate the antibody response to primary
infection with HSV; IB was also used to investigate the targets of
antibody in a number of human negative and HSV-1 antibody positive
sera, as well as those from patients with recrudescent HSV-2
infection.
IMMUNOBLOTTING ASSAY
One of the problems with the IB assay was that of identifying the bands
produced on reaction with antibody positive sera. There are two main
reasons f6r this. Firstly, many of the monoclonals used for
identification of proteins failed to react in the assay. This was
presumably due to denaturation of their target epitopes during the
antigen solubilisation procedure prior to electrophoresis. This
concords with the results of Braun et al., (1983), who reported
denaturation and loss of antigenicity of the targets of some, but not
all, monoclonal antibodies in their IB assay. In the present study,
only those reactive with gD, p40, gC-1 and gG-2 (nos. 14, 5, 2 and 9)
reacted with denatured epitopes. Comparison of the bands produced by
- 172 -
these monoclonals with those produced by control or test sera allowed
some identifications to be made. However, although similar bands to
those produced by no.14 were found on testing human sera in the IB
assay, caution was needed before identifying them as gD. Richman et
al., (1986) describe the comigration of gG-1 to the same area of the
gel and it is possible that the bands found on reaction with sera from
patients with HSV-1 infection reflected an antibody specificity to
this latter protein.
In theory, further identifications of proteins could be made by
comparing the IB results with those obtained from assaying monoclonal
antibodies in the RIP assay. Although the methodologies of the two
assays are different, both use SDS-PAGE to resolve individual
proteins, which would be expected to migrate to the same areas of the
gel. In practice, however, it was found that the appearance and
apparent mobility of proteins in the two assays differed. This can be
seen by comparing the bands produced by no.2 (gC-1) in both assays
(lane 8, figure 7 with lane 9, figure 9) and nos. 1 and 14 (gD; lane
7, figure 7 with lane 8, figure 9). The reason for the discrepancy in
the appearance of gC-1 in the two assays is.unclear. However, it is
possible that herpes proteins are subject to a degree of proteolytic
cleavage in the second incubation of the RIP assay, .despite the use of
inhibitors (see below); this may modify their appearance on SDS-PAGE.
Some investigators have used monospecific rabbit antisera to
individual HSV glycoproteins for identification of proteins, in
order to circumvent the problem of monoclonals failing to react in the
IB assay (Eberle et al.,, 1984; Bernstein et al., 1986).
Unfortunately, these were not available for the work described here.
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The second problem with identification of proteins was caused by the
large number of bands in the 80 to 130 KDa range produced by many
convalescent sera in the IB assay. Even if the MWs of the target
proteins are known, it was rarely possible to differentiate reactivity
with them from that to the numerous other bands in the same area. It
would be hazardous to distinguish reactivity to gB, gC-1, gG-2, gH-1
and MDBP on the basis of MW in these experiments, all of the proteins
being so similar in weight. Furthermore, even though the monoclonal
no.9 revealed the appearance of gG-2, and no.2 identified gC-1 in the
IB assay, it was impossible to clearly identify reactivity to them in
the control antisera (figure 7). Similarly, it was difficult to
identify the targets of many of the HSV-1 antibody positive sera and
those from patients with recrudescent HSV-2 infection (figures 15 and
16) .
In summary, the identification of the target proteins of sera in the
IB assay is complicated by the large number of comigrating bands. The
similarity in MW of several proteins leads to the possibility of
misidentification through comigration of bands. In this study, and in
those of other investigators (Eberle et al. , 1983; Lehtinen et al. ,
1985; Teglbjaerg et al., 1986), the use of IB to investigate the
target specificity of convalescent sera is limited by this
consideration. Investigation of sera taken from patients with primary
infection is more straightforward because of their restricted range of
reactivity.
Eberle et al., (1985) and Bernstein et al., (1984); Eberle et al.,
1984) described the reactivity in the IB assay of sera taken from
patients with primary HSV-2 and HSV-1 infections respectively. In the
former case, patients were shown to develop antibody to p40 and the
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MCP on seroconversion, and subsequently, to other proteins. In primary
HSV-2 infection, antibody specificities for p40, gG-2 and, to a lesser
extent, to gD and an 80K protein were detected in acute phase sera.
The highest titres of antibody were to p40. The identity of p40 was
shown by reactivity of a monoclonal antibody in the IB assay. A
restricted pattern of reactivity to p40 was found in guinea pigs 14
days after experimental inoculation with HSV-2.
p40 reactivity was found in all of the patients with primary HSV-1,
but only in 7 out of 11 of the patients with HSV-2 infection.
Reactivity of monoclonal no.5 in the IB assay confirmed the
identification (compare lane 9, figure 7 with lanes 2, 4, 6 & 8,
figure 17). In most cases, it was the most prominent band produced,
although additional specificities for other proteins were found in
almost all sera (table 11). In contrast to the findings of Eberle et
al., 1985, no reactivity with HCP was found in any of the patients
with primary HSV-1 infection. Reactivity with a 112 KDa protein, was,
however, frequently found. Reactivity with gG-2, 107 KDa and 103 KDa
was found in many of the HSV-2 sera.
RADIOIMMUNOPRECIPITATION ASSAY
More monoclonal antibodies were reactive in the RIP assay than in the
IB assay, and allowed the identifications of gB, gD, gC-1, and p40 to
be made. The migration of gD was clearly affected by large amounts of
comigrating immunoglobulin carried over from the immune precipitate,
leading to a diffuse band clearly different from that produced by
no.14 in the IB assay. gC-1 appeared to have a MW of 121 KDa, with
weaker bands at 75 and 45 KDa. Both gB-1 and gB-2 also showed lower
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molecular weight forms. The multiple forms of gC-1 and gB in the RIP
assay are probably the result of proteolyic cleavage during the second
incubation of the assay. Attempts were made to prevent this by the
addition of PMSF to the lysis buffer. This appeared to be insufficient
to prevent the action of the released cellular proteases. Proteolytic
cleavage of gB and gC is not found in the results of other
investigators using the RIP assay, and this may be due to
methodological differences between the various assays. For example,
Ashley & Corey, (1984) incubated serum and antigen together on ice; in
this case, the lower temperature probably prevented the proteolysis,
perhaps at the expense of reducing the antibody/antigen binding
reaction. p40 appears only faintly in the RIP assay, in contrast to
the IB assay. This may be a reflection of the low solubility of HSV
capsid and tegument proteins in non-denaturing detergents, and is
probably the reason for the failure of monoclonal no.6 (MCP) to react
in the RIP assay (see below).
Co-precipitation is one of the problems of the RIP assay. The separate
bands produced on SDS-PAGE analysis of an immune precipitate do not
necessarily indicate antibody reactivity to each protein. The
detergents used for RIP assays are commonly non-denaturing, and
non-dissociating. One • way to minimise this problem is to
ultracentrifuge the cell lysate before use in order to remove
insoluble material. Preliminary experiments carried out during the
development of the RIP assay illustrated that co-precipitation does
occur, and does affect the results.
Comparison of the proteins in a HSV infected cell lysate by SDS-PAGE
before and after ultracenrifugation showed the disappearance of a 155
KDa band, as well as many other in the 50-80 KDa range. EM analysis of
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the pellet produced during ultracentrifugation of the cell lysate
revealed relatively large amounts of intact and degraded
nucleocapsids. Surprisingly, many nucleocapsids were associated with
what appeared to be viral envelopes. Comparison of spun and unspun
HSV-1 antigen in the RIP assay showed the 155 KDa protein to be
present only in the immune precipitate of the unspun material.
Furthermore, the total counts of the immune precipitate were markedly
increased, as was the intensity of all of the bands, including those
later identified as glycoproteins, on SDS-PAGE analysis. This data
indicated that the nucleocapsid is poorly soluble in the commonly used
detergents for RIP assay. There is also some evidence for the
incomplete solubilisation of the viral envelope.
Steps were taken to remove insoluble material by ultracentifugation
from the cell lysate before use in the RIP assay, and the reaction of
the monoclonals in the RIP assay showed that there was independent
precipitation of gC-1, gB and p40. However, the immune precipitate of
no.l appeared to contain relatively large amounts of a 65 KDa protein
(gD) and a small amount of a 130 KDa protein of uncertain identity
(figure 9, lane 7). The MCP was not found on testing the HSV-1
antibody positive control sera with spun antigen in the final version
of the RIP assay (table 6; figure 9). However, RIP analysis of the
HSV-2 antibody positive control sera, as well as those from patients
with primary HSV-2 infection, revealed the presence of a a weak 155
KDa band corresponding to the MCP of HSV-2. It is not certain if this
is due to incomplete removal of insoluble material, or that the
proteins of HSV-2 nucleocapsids are more soluble than those of HSV-1.
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Zweerink and Corey, (1982 ) did not ultracentrifuge the cell lysate
before use in their RIP assay. Mann & Hilty (1982) spun the antigen at
only 10 000 x g prior to incubation with serum. This is inadequate to
pellet intact nucleocapsids remaining after solubilisation. The
results presented by both research groups indicate apparent reactivity
of all antibody sera tested with 148 and 152-159 KDa proteins
respectively. Prominent reactivity with MCP was not found by other
investigators (Gilman et al., 1980; 1981; Ashley & Corey, 1984;
Ashley et al., 1985), all of whom spun the antigen at 100 000 x g
before use. On this basis, the results of Zweerink & Corey (1982) and
Mann & Hilty (1982) must be disregarded.
The three negative human and both pre-bleed rabbit sera were
unreactive in the RIP assay. Non-specific reactivity in the RIP assay
has been reported. Zweerink & Corey (1982) found apparent reactivity
of negative sera with MCP and gpl30. As mentioned before, the cell
lysate was not ultracentrifuged and undoubtedly contained whole
virions, and it is possible that the known stickiness of HSV particles
contributed to this non-specific reaction. Baucke & Spear (1979)
report the Fc binding activity of gE. In theory, this might be
expected to cause non-specific reactions since binding of a
radiolabelled HSV protein to IgG in the control or test serum might
occur independently of immunological recognition. The result would
explain the apparent reactivity of negative sera with gE. However, in
the experiments described here, and in those of others investigators
using the RIP method, no such reaction occurs. The RIP assay of
Johnson & Feenstra (1987) appears to show non-specific reactivity with
gB; this may be a reflection of the high specific activities used in
the radiolabelling required to show the reactivity of g70.
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Human and rabbit control antisera produced numerous bands in the RIP
assay, of which gB-1, gC-1 and gD/gG-1 (HSV-1) and MCP, gB-2 and gD-2
(HSV-2) could be recognised. Gilman et al., (1980; 1981) also found
predominant reactivity in almost all convalescent sera with HSV-1
proteins (MW 133, 99 and 82 KDa) and HSV-2 proteins (131 and 101 KDa).
Reactivity with other proteins was weaker and more variable. Eberle &
Courtney, (1981) used a glucosamine label, and hence did not
investigate reactivity to non-glycoprotems. Convalescent sera
were found to react with gA (pgB), gB, gC and gD in this assay.
gB was the predominant target of antibody elicited by primary
infection in the RIP assay described here. Not only did all of the
second sera tested show reactivity with this protein, but also 6 of
the first sera. In 4 of the 5 patients with HSV-1 infection, antibody
reactivity to gB was the only target specificity detectable. The
second serum of patient 5 showed reactivity with gC-1. Of all of the
second sera, this showed the strongest reactivity in the ELISA. All of
the second sera from patients with HSV-2 infection showed additional
reactivity with MCP, and 130 and 95 KDa proteins; two of these showed
reactivity with lower MW proteins. The identity of the 130 and 95 KDa
proteins could not be ascertained. The 95 KDa protein was generally
very faint, and may have been a precursor or degradation product of
gB. The 130 KDa protein was, however, prominent, and the sharpness of
the band makes it unlikely to be a glycoprotein. Ribonucleotide
reductase and MDBP are present in relatively large amounts in the HSV
infected cell and are both candidates for this protein. Ashley & Corey
(1984) also detected reactivity to a 130 KDa protein, and identified
it as a form of gB (the other being of MW 110 KDa). The reactivity of
monoclonal no.3 in the RIP assay (figure 9, lane 13) shows that the
observed MW of gB-2 is lower than 130 KDa in the SDS-PAGE system used
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in the work described here.
There was no evidence of antibody reactivity with any of the other HSV
glycoproteins in the RIP assay. Ashley & Corey, (1984) and Ashley et
al., (1985) found initial reactivity of sera from patients with
primary HSV-1 and -2 infection to gB. In sera from patients with HSV-1
infection, reactivity with gC-1 and, to a lesser extent with HCP, was
also found, while those from patients with HSV-2 infection showed
strong reactivity with gB and an 88 KDa non-phosphorylated protein.
Some reactivity was also seen with MCP. On follow-up, patients with
HSV-1 infection developed antibodies to a 88 KDa protein, gE, gD and a
66 KDa protein. Sera from patients with HSV-2 infection showed
reactivity with gC-2/gE-2 (not differentiated), gD and the 66 KDa
protein.
NON-DENATURING IMMUNOBLOTTING
There is surprisingly little 'in the literature concerning the
separation of membrane proteins by non-denaturing PAGE. Most of the
methods published describe the separation of water soluble proteins on
native gels, in the absence of any detergent. Since the proteins of
HSV are either membrane inserted, or are part of a self-assembling
nucleocapsid, mild dissociating conditions are required to bring the
individual HSV polypeptides into solution. Developing a non-denaturing
IB system involves the selection of a detergent capable of
solubilising HSV proteins effectively yet retaining their
antigenicity, and permitting electrophoresis on a size basis.
Satisfying the first two considerations involves a compromise, since a
powerful dissociating detergent inevitably denatures proteins (cf
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SDS), while mild detergents may fail to solubilise a proportion of the
virion components. In particular, the nucleocapsid seems to relatively
insoluble in the Triton/deoxycholate detergent mixture used in the RIP
assay (see above).
Dewald at al., (1975) published a method using triton to solubilise
membrane proteins prior to PAGE in a detergent-containing gel. This
was the method originally tried in the work described here. However,
the failure of this method with HSV proteins led to considerations of
the properties of detergents and the selection of those showing
optimal properties. Helenius & Simons, (1985) and Helenius et al.,
1979 reviewed the properties of a wide range of detergents and these
descriptions were used to select TDCA as a candidate. The failure of
PAGE in the presence of triton could be explained by its large
micellar size; proteins solubilised in triton would have a minimum
size of 120 OOODa, and this probably explains the failure of the
proteins to migrate. Subsequently, only detergents of smaller micellar
size were considered. Experiments had shown that sodium deoxycholate
(micellar size 12 000 Da) precipitated below pH 7.0 and therefore
could not be used, while proteins solubilised and electrophoresed in
CHAPS failed to migrate, possibly due to the fact that this
zwitterionic detergent has no net charge. TDCA appeared to suffer from
none of the shortcomings so far mentioned. Firstly, it is of small
micellar size, similar to that of SDS and sodium deoxycholate,
secondly it has a low pKa, and in pratice remained soluble at pH4.
Finally, it had a net negative charge, which would be expected to
assist the separation of proteins.
When used to replace SDS in the IB assay, these expectations were
borne out to a certain extent. Membrane proteins solubilised in TDCA
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could be separated on a gel, as indicated by the lack of aggregation
of protein at the top of the separating gel on coomassie blue
staining. Furthermore, gB was found to have an Rf value of 0.15, on
reaction with the appropiate monoclonal antibody. Assaying the control
antisera in the TDCA IB assay also indicated the existence of other
faster migrating HSV-encoded proteins, of which one could be
identified as gD-1. Electrophoresis of water soluble marker proteins
by TDCA PAGE showed that there was no relation between molecular
weight and distance migrated, unlike the behaviour of proteins,
whether water soluble or not, on analysis by SDS PAGE. The observed
relationship between migration and MW observed with SDS solubilised
proteins may be accounted for by the equal binding of both hydrophilic
and hydrophobic proteins to SDS. Since SDS contributes the majority of
the negative charge of the solubilised protein, only the size of the
protein rather than its charge/mass ratio influences its rate of
migration on electrophoresis. The absence of any relationship between
MW and rate of migration in TDCA PAGE indicates that TDCA failed to
bind to water soluble proteins. Experiments that used TDCA PAGE to
separate different membrane proteins of known MW would establish
whether there was constant or variable binding of TDCA to water
insoluble proteins.
The failure of the other monoclonal antibodies to react in the TDCA IB
assay was investigated by SDS-PAGE analysis of the TDCA-solubilised
material, and by treatment of TDCA IB strips by boiling in
conventional SDS sample buffer, in the hope of revealing hidden
epitopes. The former investigation revealed that p40, gC-1 or gG-2
were not detectable in the TDCA cell lysate by conventional SDS IB
analysis using specific monoclonals reactive with denatured proteins.
The second experiment showed that immunogenicity of p40, gC-1 or gG-2
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was not restored by SDS treatment. Taken together, these results
indicate that TDCA fails to solublise not only a tegument protein, but
also two HSV glycoproteins. By implication, the absence of reactivity
of no.4 and no.6 (gE and MCP) and the weak reactivity of no.l (gD) in
the TDCA IB assay may also be accounted for by poor solubility. It
would appear that gB is more soluble than the other glycoproteins in
this detergent. This is a surprising finding which may have
consequences for other detergents and other assays.
Cohen et al., (1986) reported the application of a non-denaturing IB
assay to study the discontinuous (denaturation sensitive) and
continuous (resistant) epitopes of gD with a panel of monoclonal
antibodies. The method involved initial solubilisation of proteins in
SDS at room temperature, followed by electrophoresis on a detergent
free gel. The results showed that the native gel system retained the
antigenicity of denaturation sensitive epitopes. Unfortunately, it was
not made clear whether the method was capable of resolving other
proteins; monoclonal antibodies of other specificities were not used,
nor was a protein stain of the gel shown. However, Snowden et al.,
(1985) and Snowden & Halliburton (1985) reported a similar method in
the analysis of antibody to gB. They modified the conventional SDS
PAGE method by omitting the boiling step prior to electrophoresis, and
demonstrated that this retained the antigenicity of one or more
epitopes of gB of HSV that cross-reacted with those found on
equivalent proteins of other herpesviruses.
Modifications of the SDS-PAGE method were tried, and the results
confirmed that gB could be resolved by omitting the boiling step.
However, there was clumping of proteins at the top of the gel, and
generally very poor resolution of proteins, not only with detergent
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free gels, but also with gels supplemented with 0.1% SDS. These
experiments were carried out at 4C; the reason for the failure to
detect antibody to gD may be that there was more efficient
solubilisation at the room temperature used by Cohen et al., (1986)
for electrophoresis. Further work should investigate whether room
temperature SDS-PAGE efficiently sclubilises proteins other than gB
and gD, and retains their antigenicity.
In collaboration with Dr B. Cohen, Western General Hospital,
Edinburgh, attempts were made to resolve HSV-encoded proteins by
isoelectric focussing (IEF) in the presence of triton. As mentioned
above, PAGE in the presence of triton failed possibly because of the
detergent's large micellar size. However, IEF does not rely on a
seiving effect by the gel for the resolution of proteins, rather,
proteins migrate to their isoelectric point on a pH gradient
established by applying an electric field to a solution of ampholines.
Consequently, the gel may made from agarose which does not obstruct
the movement of micelles of any size. The method can be used with
native gels, or those containing non-ionic detergents. This ruled out
the possiblity of using detergents other than triton for the
solubilisation of HSV proteins.
Triton solubilised lysates of HSV-1, -2 and mock infected cells were
resolved by IEF, followed by blotting to nitrocellulose and probing
with control sera. The results were not presented formally in this
thesis due to technical problems with the method. A single
HSV-specific band was observed with both HSV-1 and -2 antigen on
reaction with positive serum (JFP). The absence of other bands may
have been the result of failure of the separation or immunoblotting
stages. However, in the light of the results with TDCA. it is possible
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that the poor solubility of several HSV proteins in triton accounted
for the failure of IEF IB to detect more than one HSV-specific band.
In summary, the TDCA IB method allowed the separation of a proportion
of HSV-encoded proteins. The reactivity of monoclonals nos. 1 and 3 in
the TDCA IB showed that the method retained the antigenicity of both
gB and gD otherwise lost in the conventional IB assay. The method was
used to test the first and second sera of the patients with primary
HSV infection. Reactivity with gB was found in all of the second sera.
Only one showed additional specificities for gD. The surprising
feature of the TDCA IB results was the detection of antibody
reactivity to gB in some of the first sera, when conventional IB found
them all to be antibody negative. A comparison of the sensitivities of
the tests is to be found in the next section.
COMPARISON OF THE TESTS FOR HSV ANTIBODY
The most striking feature of the results of testing sera from patients
with primary HSV infection was the detection of antibody reactivity in
many of the first sera, all of which had been screened by IB and found
to be negative. To a certain extent, the ELISA and IF results of the
same sera confirmed the presence of antibody in some of the apparently
positive first sera, although the results showed variability and some
contradictions between tests. Undoubtedly, the low levels of specific
antibody in the first sera contributed to the uncertainty.
The other main difference between the results of the IB assay with
those of the RIP and TDCA assays was the identity of the target of
antibody elicited by infection. It seems likely that the extensive
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denaturation of HSV antigen prior to electrophoresis contributes to
the insensitivity of the conventional IB assay for antibody of certain
specificities. It would appear that the epitopes of p40 are relatively
less sensitive to denturation than those of the HSV glycoproteins. The
similarity of the TDCA IB results with those of the RIP assay confirm
that it was the solubilisation of the antigen rather than any other
methodological difference between the RIP and SDS IB assays that led
to the discrepancy in the results.
The TDCA IB results are therefore useful in discounting a number of
alternative explanations based on other differences between the IB and
RIP tests. One possibility would have been that there was an IgG
subclass difference in target specificity. The IB assay used an
anti-human IgG second antibody to detect binding of test serum to the
HSV antigens. However, most RIP assays, including this one, use
staphylococcal protein A (SPA) in the immunoprecipitation. It is well
known that SPA fails to bind to IgG subclass 3, yet it has been
established that, in viral infection, specific antibodies of subclass
IgG3 and IgGl predominate. That the absence of IgG3 binding by SPA did
not affect the results was shown by the TDCA IB results, which agreed
with the RIP assay, yet used the same anti-human IgG conjugate as the
IB assay. Ashley et al., (1985) suggested that the ' discrepancy
between her results and those of Eberle et al., (1984) arose from
differences in the affinity of antibody to p40, which was supposed to
bind more efficiently to immobilised proteins (in the IB assay) than
to those in solution (RIP), the converse being true for antibodies to
gB. The TDCA IB assay showed that reactivity to p40 may not be
detected because of reduced solubilty in the detergents used in RIP
analysis. Furthermore, the reactivity of first sera and monoclonal
no.3 with gB in the TDCA IB assay showed the antigenicity of gB to be
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retained even when immobilised; loss only occurring after SDS
treatment.
While denaturation accounts for the insensitivity of the IB test for
glycoprotein-specific antibody elicited during primary infection, it
is difficult to account for the observed absence of antibody to other
glycoproteins on testing acute phase sera in the RIP and TDCA IB
assays. Before concluding that the early humoral immune response is
confined to one glycoprotein, certain experimental findings need to be
accounted for.
As mentioned above, the MCP showed poor solubility in the detergents
used in the RIP assay, and this accounted for its absent or weak
reactivity in the RIP and TDCA IB assays. A similar argument could be
made for p40, which showed weak reactivity with monoclonal no.5 (in
contrast to the strong reactivity of this monoclonal in the IB assay),
and possibly for some of the other capsid and tegument proteins.
Analysis of TDCA IB solubilised material indicated that, not only was
p40 undetectable, but also gC-1 and gG-2. The latter two proteins
would be expected to be fully soluble in most detergents. The absence
of these two proteins, and possibly of several of the other HSV
glycoproteins, is one reason for the inability of the TDCA IB assay to
detect antibody to proteins other than gB and gD in hyperimmune or
convalescent antisera.
Similar constraints may apply to the RIP assay, since similar
detergents are used, and the solublisation procedure is identical to
that of the TDCA IB assay. An argument against this is the observed
reactivity of monoclonal antibodies of numerous specificities in the
RIP assay, both reported here and extensively elsewhere. However, the
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extreme sensitivity of the RIP assay and the relative excess of
antibody may mask differences in the ability of the RIP to detect
antibody to different proteins. Insolubilty of glycoproteins may
result from intermolecular associations of homologous or heterologous
glycoproteins in the viral envelope, or perhaps between glycoproteins
and proteins of the tegument mediating attachment of the envelope.
Both gB (Snowden & Halliburton, 1985) and gD (Cohen et al., 1986)
have been observed to form dimers in the presence of SDS; this is
evidence to show that the non-covalent intermolecular associations may
survive the relatively powerful dissociating effect of this detergent.
Stannard et al., (1987) have observed a degree of organisation of
glycoproteins in the viral envelope, with different HSV glycoproteins
associated with distinct morphological elements on the virion surface.
It is not impossible that these structures, or parts of them, may
resist dissociation in non-ionic detergents, thereby preventing full
solubilisation. Different glycoproteins would be expected to show
greater or lesser solubility; some may be effectively dissociated and
remain in solution during the ultracentifugation step of the
solubilisation procedure, while others may be largely removed at this
stage. Evidence to support this comes from EM analysis of the pellet
obtained on centrifugation of HSV-1 infected cells in 1% triton and 1%
sodium deoxycholate. Abundant nucleocapsids were found, both
unenveloped and partially enveloped.
If it were established that there was differential solubility of HSV
glycoproteins (the data presented here is preliminary and the
discussion speculative), then the RIP results presented here, and
those of previous investigators, would need to be re-interpreted to
account for the possibly greater abundance of, and hence greater
sensitivity for antibody to, proteins such as gB, compared with the
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apparently less soluble gC-1 and gG-2 glycoproteins. The discussion
above illustates some of the problems in comparing antibody levels to
different proteins. The MABIA was developed as an alternative to these
gel-based methods to provide further information on the target
specificity of sera.
MONOCLONAL ANTIBODY BINDING INHIBITION ASSAY
Early experiments with the MABIA were designed to investigate the
nature of the inhibition shown by antibody positive sera on the
binding of HSV-specific monoclonals. The first experiment compared the
blocking activity of a HSV-1 antibody positive serum (JFP)) on two
monoclonal antibodies (one type-common, one HSV-2 specific) and showed
that there was specific inhibition of the former, but no blocking of
the type 2 monoclonal at any serum dilution. Further experiments with
a range of positive and negative human sera, and pre-bleed and
immunised rabbit antisera established that the test could demonstrate
the specific inhibition of a range of monoclonals. No monclonals,
other than no.12 (gE-1 specific), were affected by negative sera,
while there was virtually complete inhibition of binding of monclonal
no. 1 and partial inhibition of nos. 2, 5 and 9 by antibody positive
sera. As mentioned in the results, no.12 may be a special case, in
view of the known Fc binding activity of gE. The possible localisation
of the site of binding of no.12 within this area would allow
non-immunological blocking by IgG.
The target epitopes of the monoclonals were not characterised, but it
was possible, indirectly, to obtain information on whether inhibition
was epitope specific, or whether only reactivity within the same
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antigenic area was necessary to mediate inhibition. Two HSV-1 specific
and two HSV-2 specific monoclonals to gD were obtained and tested by
ELISA. The results indicated varying amounts of cross-reactivity of
the monclonals (table 3). The same monclonals were than tested in a
MABIA with pre-bleed, HSV-1 and HSV-2 antibody positive rabbit
antisera. The results of monoclonal no. 2001 show that, although it
did not cross-react with type-heterologous antigen, it was measurably
inhibited by the HSV-2 antiserum, albeit less efficiently than that of
HSV-1. The other monclonals showed varying degrees of
cross-reactivity, and still greater "cross-inhibition" by
type-heterologous antisera. From this data, it could reasonably be
inferred that precise blocking of the target epitope of the monoclonal
by the antiserum was not necessary to mediate inhibition of monoclonal
binding, although type homologous antisera did block more efficiently
than sera of the opposite type.
Experiments that directly measure the inhibition of one monclonal by
another have been reported and tend to confirm the above conclusion.
Marlin et al., (1985) investigated the cross-inhibition of 14
monoclonals to gC-1. By measuring the ability of each monclonal to
block the binding of each of the others, they could be assigned to two
groups, 1 and 2. Group 1 monoclonals effectively inhibited each other,
but had no effect on those of group 2. The converse was true for those
of group 2. Experiments with truncated proteins localised the
antigenic site of group 1 monoclonals to the N-terminus half of the
molecule, while those of group 2 reacted with all truncated forms
indicating reactivity with the C-terminus half. The later findings of
Sjoeblom et al., (1987) indicate that one of the two antigenic areas
of gC-1 may be composed of carbohydrate.
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Several monoclonal antibodies were screened for reactivity in the
ELISA and inhibitability by control antisera. The results revealed a
range of inhibition values, two p40-specific monoclonals being
resistant to inhibition by human sera. A possible explanation for this
latter observation would be that the mouse was immunised with a
preparation of HSV antigen bearing epitopes not normally exposed
during the course of infection in man. Evidence to support this
hypothesis comes from the partial inhibition of no.5 by the HSV-1
rabbit antiserum, but not by the human sera (table 2); the rabbit,
too, may have received unnatural immunogens.
Experiments with the negative sera, those positive for HSV-1 antibody,
and those from patients with HSV-2 infection provided much data on the
specificity of the test. The negative sera without exception showed no
significant inhibition of any of the monclonals used, with little
variation in inhibition values. Since it was established that the
patients with HSV-1 antibody had not been exposed to HSV-2, it was
possible to compare the inhibition values of no.9 (gG-2) from these
sera with the negative sera to further establish the specificity of
the test. The results showed that there was no inhibition of no.9 by
any of the sera positive for HSV-1 antibody, and the average and range
of the values was similar to that of the negatives.
Binding of monoclonals nos. 1, 3 and 13 was completely inhibited by
most HSV-1 and HSV-2 antisera, although a minority of sera of both
types showed only partial inhibition. However, monoclonals no.2 and 9
were less readily blocked. No sera showed inhibition values below 32%
with no.2, while a proportion of sera from patients with HSV-2
infection showed inhibition figures within the range of the negative
sera. The susceptibility of monoclonal no.10 to blocking by HSV-1 and
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-2 antibody sera was intermediate in extent between monoclonals nos.
1, 3 and 13 and no. 2 and 9.
The reason for the difference in inhibitability of the monclonals is
not entirely clear. It is notable, however, that the monclonals found
to react in the IB assay, and hence with linear epitopes, were poorly
inhibited by most antibody positive sera. In contrast, the monoclonals
unreactive in the IB assay were readily inhibited (nos. 1, 3 and 13).
There does seem to be an association between inhibitability and the
nature of the epitope. Conformational epitopes may be relatively
large, often involving the interaction of more than one polypeptide
chain. For example, Eisenberg et al., (1985b) showed that the
conformational epitopes designated I, III, IV and VI of gD-1 were
°l
found on distinct hydrophilic loops, yet monclonals to eachA them
showed a degree of cross-inhibition. This data, and the predic ted
tertiary structure of the protein indicated that the four epitopes
associated to form a relatively large antigenic area on the protein.
Generalising from this information, it can be seen that inhibition of
a monoclonal reactive with one of the conformational epitopes in a
large antigenic area, such as described for gD-1, could be mediated by
a wide range of human antibodies to gD. In this case, the size of the
antigenic area would appear to the important factor mediating
susceptibility of a monoclonal to blocking.
It is well established that epitopes retaining antigenicity in the IB
assay are linear, and therefore depend on the amino acid sequence of
the polypeptide rather than its conformation. Eisenberg et al.,
(1985b) showed that, for gD-1, linear epitopes could be precisely
localised and were not found in association with the hydrophilic
antibody binding site of the protein. Indeed, epitope V is found on
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the interior side of the membrane and may not be exposed to the immune
system during natural infection. Unlike the conformational epitopes,
the target for inhibition is relatively small since there are no
neighbouring epitopes. This may be the explanation for the relatively
ineffective blocking of monclonals nos. 2 and 9 in the MABIA. Human
sera would require relatively large amounts of extremely specific
antibody to effectively block monoclonals to linear epitopes, in
contrast to the relatively low specificity required to block those to
conformational epitopes.
There is little in the literature to compare with the results obtained
in the MABIA. Ross et al., 1985 describe a similar assay and
investigated the blocking ability of four gB and gC monoclonals by
several human sera. However, there were several problems with this
work. The assay was insensitive, in that no change in inhibition
values of any of the four monoclonals could be found in sera from
patients with primary infection. The monoclonals were not titrated
before use, and inhibition values were tested at a fixed monoclonal
antibody concentration of 1/100 (human serum at 1/25). This excessive
amount of monoclonal antibody was probably one reason for the
insensitivity of the assay. The inhibition values of the negative sera
were extremely variable, and overlapped considerably in range with
those of convalescent HSV-1 and HSV-2 antisera.
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DETECTION OF ANTIBODY BY MABIA DURING SEROCONVERSION
Figure 20 summarises the results of testing the first and second sera
from patients with primary infection with HSV-1 and -2. All of the
patients with HSV-1 infection showed the development of antibody to
gD, since all showed a significant fall in inhibition value with
monoclonal no. 1. Not all patients with HSV-2 infection showed
significant reactivity with no.l, but did so with monoclonal no.13.
There is clear evidence therefore that antibody to gD is elicited by
infection with both HSV-1 and -2.
All patients developed antibody to gB, as shown by the significant
inhibition of both monoclonals nos. 3 and 10 in all of the second sera
and in proportion of the first. The relatively ineffective blocking of
monoclonal no.2 by convalescent sera is reflected, perhaps, in the
failure of the MABIA to detect the development of gC-1 antibody in a
proportion of patients with HSV-1 infection. However, on comparison
with the results of patients with HSV-2 infection, there does seem to
be a trend towards lower inhibition values in the second sera. While
the arrows representing the results of patients with HSV-2 point in
both directions and are largely confined to the negative range, those
of patients with HSV-1 infection tend to point leftwards, and to show
inhibition values significantly lower than the negative range. The
precise converse holds true for patients with HSV-2 infection. There
in no evidence for gG-2 antibody in patients with HSV-1 infection,
while a convincing case could be made for the presence of antibody to
gG-2 for at least five of the patients with HSV-2 infection.
It is unfortunate that a wider range of monclonals was not available
to study the evolution of antibody during primary infection. In
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particular, it would have been desirable to have used monoclonals to
gC and gG that were more readily inhibited. In all probability, the
data obtained do not exhaust the possible repertoire of antibody
specificities to be found in primary infection.
There are two problems when comparing the data on antibody specificity
obtained by the MABIA with that from the IB and RIP assays. The first
one has been mentioned; the observed inhibitions may have been
mediated by IgM, while the other tests only detect IgG reactivity.
Secondly, the inhibition figures obtained by different monoclonals
cannot be used to compare the relative amounts of antibody to each
protein. Firstly, monoclonals differ in their ease of inhibition,
possibly as a result of the size of the antibody binding site
associated with the epitope. Secondly, the extent of inhibition
depends on the affinity constant of the monclonal relative to the
range of values found in the polyclonal antiserum used for
competition. A monoclonal with high affinity may bind to its target,
despite the relative excess of antibody of similar specificity but
lower affinity in the antiserum.
From a theoretical point of view, the MABIA can only detect the
presence of antibody; it cannot indicate its absence. It is only by
collecting statistical information on the reactivity of a large number
of antibody positive sera that reasonable inferences can be made about
the likelihood of an apparently negative serum in the MABIA actually
containing HSV-specific antibody or not. Fortunately for the work
described here, the results were largely positive. The author was
initially reluctant to develop the MABIA, since it may simply have
produced predominantly negative results that would defy
interpretation. This may also be the explanation for the apparent lack
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of reports in the literature concerning its use.
Although the MABIA results cannot be directly compared with those of
the other methods, the ready detection of antibody of several target
specificities does support the idea that not only the IB, but also the
RIP and TDCA IB assays show different sensitivities for antibody to
different proteins. Investigation of the solubilty of HSV proteins in
non-ionic detergents indicated that gB may be over-represented (see
above). This may well be the explanation for the apparent restricted
reactivity of acute phase sera in the RIP assay found here and by
other investigators. Although the antibody to gD, gC-1 and gG-2 found
in the MABIA may have entirely of the IgM class, this seems unlikely
in view of the ready detection of HSV-specific IgG to other proteins,
such as gB and p40, at the same time.
SUMMARY
The comparison of numerous methods to study the target specificity of
sera from patients exposed to HSV has revealed more about the
limitations of the conventional tests than about the humoral antibody
response to viral infection. The IB assay was shown to be of limited
sensitivity as a result of denaturation of antigens. The apparently
low solublity of proteins, including certain HSV-encoded
glycoproteins, in the detergents used in the TDCA IB assay accounted
for its failure to detect antibody to proteins other than to gB and
gD-1. The similarity of the detergents used in the TDCA IB assay with
those of the RIP assay led to the suspicion that the RIP may, too, be
insensitive for antibody of numerous specificities.
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The ready detection of antibody to gD, gC-1 and gG-2, as well as to gB
by the MABIA in sera from patients with primary infection contrasts
with the apparently restricted specificity for gB found in the same
sera in the RIP assay. The results from the MABIA do not contradict
the idea that antibody to all of the HSV proteins may be elicited on
primary infection. Although direct comparison of MABIA results with
those of the RIP assay may be faulted, it would appear that the
observed restricted nature of the early antibody response found by the
RIP assay in the work described here, and by other investigators, is
an artefact of the methods used. The differential sensitivity of the
RIP assay, in particular for gB, may not be noticed on assaying sera
with relatively high titres, such as those from immunised animals,
monoclonals and convalescent sera from humans. By contrast, testing
for the extremely low levels of antibody found in patients close to
seroconversion, subjects the RIP method to much closer scrutiny, from
which it may be shown to be deficient.
FUTURE WORK
It would be difficult to devise alternative solubilisation conditions
with the current range of available detergents to improve the
performance of the RIP and IB assays. There is a compromise between
effective solubilisation and preservation of antigenicity, as the
discrepancy in the results of the IB and RIP assays shows. It may be
possible to subject proteins dissociated in SDS or other powerful
detergents to a renaturation procedure, as has been achieved for some
insoluble enzymes. However, a procedure that has been shown to be
effective at restoring the activity of a single enzyme would be
unlikely to be able to restore the antigenicity of any more than a
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small proportion of the numerous epitopes on the wide range of
HSV-encoded proteins.
A possible method to quantify antibody response would involve the
titration of test sera against a panel of individually purified HSV
proteins in an indirect ELISA. One could ensure that equal amounts of
target protein were available for reaction with the test serum (unlike
the RIP assay) by adjustment of the protein content prior to coating
on the solid phase. However, the problems of dissociating proteins in
the original preparation would remain, and again there would be a
compromise between yield of protein and retention of antigenicity. The
method would also be elaborate and costly to use. It would also suffer
from the continual problem of ensuring that the preparations of the
individual proteins were pure. As an alternative, recombinant proteins
could be used as antigen, although this would inevitably lead to
problems in ensuring that the synthetic protein folded in the same
conformation as the wild-type, and that all of the epitopes were
present. Successful comparison of relative antibody levels to
individual proteins elicited by HSV infection is likely to remain an
elusive goal.
The MABIA has many features that would make it suitable for use in a
type-specific assay for HSV antibody. The problems with the current
attempts using purified type-specific antigens are as follows.
Firstly, they rely on the solubilisation and subsequent immunological
or non-immunological purification procedures to isolate the
type-specific protein. Production of pure indivdual proteins is very
difficult to accomplish, yet the specificity of the test is totally
dependent on this being achieved. The isolation of proteins relies on
the solubility of the proteins in detergents, and in practice is
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confined to glycoproteins. Thirdly, since the whole protein is used as
the antigen, no differentiation is made between antibody binding to
the different antigenic sites. Although type-specific antibody binding
sites are commonly found on HSV proteins, it is unusual to find
proteins with no cross-reacting areas. Although antibody to gC-1 was
at one time considered to be type-specific, it has since been shown
that there is a second partially cross-reacting area on the protein.
The exterior parts of gG-1 and gG-2 appear to be totally unrelated,
and these two proteins may be candidates as type-specific antigens.
However there is cross-reactivity of the internal part of the
proteins. Furthermore, homology between gG-1 and gD-1 has recently
been reported (see chapter 1). It is not clear whether these proteins
would be suitable for use.
None of these disadvantages are found with the MABIA. Firstly, its
specificity resides in the monoclonal, and no purification of antigen
is required before use. Secondly, the inhibition of binding of
monoclonals in confined to reactivity within the same antigenic area,
rather than to the whole protein. Thus, a type-specific assay based on
the carbohydrate area of gC-1 would . be a possibility. Another
advantage is that the assay may be used with insoluble proteins. This
would allow the use of some of the proteins of the tegument or capsid,
should any be shown to be type-specific.
Further work could be pursued to find and investigate more monoclonals
with a view of developing a MABIA for type-specific antibody. No. 9 is
unsuitable since it is only poorly inhibited, but another monoclonal
to gG-2, preferably against a conformational epitope, would be ideal.
For HSV-1 antibody detection, monoclonals against gG-1 or the
carbohydrate epitope of gC-1 could be used. There is a relative lack
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of monoclonals to gG-1, LP10 being of no use in the MABIA. No. 2
(gC-1) was only partially in hibitable and was not found to be
suitable, although other gC-1 monoclonals may be. In view of their
relatedness, monoclonal antibodies to other proteins of HSV would be
less likely to be successful in a type-specific MABIA. Although many
monoclonals appear to be type-specific, cross-inhibition might be




The limitations of the IB assay for antibody to HSV could also be
expected to operate on testing sera for antibody to HIV.
Unfortunately, the problems involved in HIV culture and the
preparation of antigen confined studies of antibody to HIV to
commercial sources of antigen. The results of a RIP assay using
metabolically radiolabelled HIV and mock infected cell lysates as
antigen were considered too preliminary for inclusion in the thesis,
although it is hoped that this method will subsequently be improved
and used to complete the seroconversion studies. Reference will be
made in this discussion to the results of other investigators who have
used the RIP assay more extensively.
TARGET OF ANTIBODY .IN CONVALESCENT SERA
Table 12 records the prevalences of reactivity to the various bands in
the IB assay of HIV-antibody positive sera. The sera were those
referred to the laboratory for the confirmation of the presence of
antibody, and were taken from patients in a wide variety of risk
groups. Of all of the bands, only reactivity to p24 was observed in
all of the sera tested, although there was also a high prevalence of
antibody to p65, p51, gp41 and p33. Antibody reactivity with pl7 was
more variable, being found in approximately half of the patients
tested. Antibody to gpl20 was less readily detected in this assay.
The identification of bands was relatively straightforward, largely as
a result of the relatively small numbers of HIV encoded proteins. The
55 KDa band was identified as pr55, the precursor polyprotein formed
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on translation from the gag gene and cleavage from that of the pol
gene. The cleavage of pr55 in vivo leads to the appearance of bands
of MW 25 (p24) and 19 (pl7) KDa in IB assay. There is a further
fragment of 12 KDa, but this was too small to be resolved by this gel
system. The proportion of protein in the uncleaved precursor form
relative to the lower MW forms varied on the source of virus.
Comparison of the bands on strips prepared from antigen obtained from
the National Institute of Health, USA in figure 21 with those in
subsequent figures, prepared from antigen purchased from Dupont shows
that pr55 is present in only small amounts in the former preparation.
I.t was a little surprising to find such relatively large amounts of a
precursor protein in purified virions, and suggests that cleavage of
the gag polyprotein may not be an essential stage in virus assembly.
An alternative explanation may be that the cleaved gag proteins of the
nucleocapsids remain aggregated even after boiling in SDS and
mercaptoethanol. This seem unlikely.
There is also evidence that bands of MW 45 KDa and 40 KDa are also
derived from the gag gene. This is on the basis that differences in
antibody reactivity to p24 and pr55 correllates with the appearance of
these two bands (see figures 24; 25; 29-33) on the strips. Again,
there was variation between different sources of antigen in the
detection of these bands. It is probable that these bands are
intermediate products in the cleavage of the gag polyprotein, pr45
perhaps representing the combination of p24 with pl7, while p40
represents the combination of p24 with pl2. Henderson et al., 1987
showed that virions of the closely related equine infectious anaemia
virus contained several intermediate proteins in cleavage pathway of
the gag polyprotein, and showed that alternative pathways were
operative.
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A monoclonal antibody to p24 of HIV, kindly provided by Dr B. Ferns,
Middlesex Hospital, showed weak reactivity with a 28 KDa proteins as
well as with the 25 KDa band (data not shown). Furthermore, a
hyperimmune serum obtained by immunising a mouse with purified HIV
also showed reactivity with this protein, as well as strong reactivity
to the other gag encoded proteins (data not shown). This band has
not been observed on reaction with human sera. Although the evidence
suggests this 28 KDa protein is derived from gag, it does not seem to
fit into any possible cleavage pathways. It therefore may be a
degradation product of one of the larger gag proteins.
p65 and p51 are derived from the pol gene and represent the RT
enzyme found in the nucleocapsid. The lower MW form is derived from
p65 by cleavage of a 12 KDa RNAse fragment. p33 represents the
endonuclease. Comparison of the IB results shows that there is
correlation between antibody reactivity to the three proteins. There
is no evidence for the 100 KDa percursor protein in the IB results.
Several authors have mis-identified p65 and p51. Lange et al.,
(1986a) imagined that p65 was a glycoprotein derived from the env
gene, although work published subsequently from this group no longer
contains this error.
Antibody to gp41 is readily detected in convalescent sera in the IB
assay; however, antibody to gpl20 and the precursor gpl60 is not
commonly detected. That this partially due to denaturation of the
antigen can be seen from the results of varying the temperature of the
sample buffer prior to electrophoresis (figure 11). gpl20/gpl60 of
unheated HIV, both reduced and non-reduced, shows slightly more
antigenicity on reaction with J2 than that heated to 56C or boiled.
The bands, however, remain extremely faint and one needs to consider
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whether this is the explanation for the failure of IB to detect
antibody to the protein.
Gelderblom et al. , (1985) provided evidence that gpl20 is shed from
the envelope of the virus on budding from an infected cell. The
functional significance of this has been discussed in chapter 4 of the
introduction. It is possible that extensive shedding of gpl20 occurs
during the purification of virus and that little remains in the
antigen used for the IB assay. No band corresponding to gpl20 can be
seen on a protein stain of the purified virus from Dupont after PAGE.
However, no bands corresponding to gp41 can be seen either, yet
immunological reactivity with this protein can be readily detected in
the IB assay.
At first sight, the results of the RIP assay would appear to support
the idea that gpl20 is absent in the IB assay. The RIP studies
published (Kitchen et al., 1985; Barin et al., 1985; Gaines et al.,
1987; Chiodi et al., 1987 and many others) all show prominent
reactivity of sera with gpl20 and the precursor gpl60. Since RIP
assays generally use cell lysates as a source of antigen, it might be
expected that relatively larger amounts of gpl20 might be available
for reaction, since much of the viral material is intracellular at the
time of harvesting. On the other hand, it is established that
solubilisation of antigen in the RIP assay is less denaturing, and the
prominent appearance of gpl20 may be the result of greater reactivity
of antisera with non-denatured antigen. The RIP results contribute
little to the settling of the problem.
Pan et al., (1987) used HIV infected cell lysates as antigen in an IB
assay for virus-specific antibody. Although this may lead to problems
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of non-specific antibody binding to cellular proteins, there was some
evidence of reactivity to several HIV proteins. In particular, and in
contrast to studies using purified virus as antigen, promin ent
reactivity was seen with a band identified as gpl60. Weaker and more
variable reactivity was seen with bands identified as gpl20 and gp41.
However, caution should be exercised in the interpretation of these
results. The use of MW markers for the calculation of MW of the
observed bands was not reported. No positive identifications of
proteins were made by monoclonal antibodies of known specificity.
Furthermore, test sera were not tested with uninfected cells as a
control, in order to exclude the possibility that some of the bands
produced were, in fact, cellular proteins. These are serious omissions
in view of the different appearance of the blots compared to those of
other investigators, particularly the apparent detection of
HIV-specific antibody to unusual proteins such as those of 48 and 28
KDa. No explanation was given for the abnormal dilution response of
positive sera on titration. While antibody to p24, gp41 and the 55 KDa
protein was detectable at dilutions of at least 1/10,000, no sera
showed reactivity with gpl20 at dilutions of less than 1/50.
Surprisingly, there is little published data that actually proves the
existence of antibody to gpl20. Evidence from RIP assays that purports
to show antibody to gpl20 may be criticised on the grounds that steps
were not taken to dissociate gpl20 from gp41 before incubation with
the antiserum. There are disulphide bridges between the two proteins
which would remain intact in the detergents used for the
immunoprecipitation, but which would be reduced on subsequent SDS-PAGE
analysis of the immune precipitate. Co-precipitation undoubtedly
occurs in all of the published RIP results, and the hypothesis that
antibody to gp41 is largely responsible for the immune precipitation
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of gpl20 remains to be disproven. It is notable that both of the
methods used for radiolabelling would lead to preferential
incorporation of isotope into gpl20 rather than gp41. Surface
labelling with iodine would obviously favour the externally positioned
gpl20 proteins, while metabolic labelling with cysteine would also be
more efficient for gpl20 (the number of cysteine residues in gpl20
greatly outnumbers those in gp41; Alizon et al., 1986). This might
explain the relatively greater intensity of the gpl20 band compared
to that of gp41 in published RIP assay results.
There is other circumstantial evidence that supports the idea that
there is little antibody to gpl20 produced on natural infection with
HIV. Firstly, it would seem difficult to account for the generally low
neutralising titres to HIV, if it is supposed that there are high
titres of antibody to gpl20. It has been suggested that such antibody
may be directed away from the sites responsible for interaction with
the T4 receptor. However, it is difficult to see how steric hindrance
of the T4 receptor resulting from the attachment of antibody to
neighbouring sites could be avoided, particularly in view of the
relative sizes of gpl20 and IgG. It is well known that antibody to
those glycoproteins of HSV shown to be inessential in vitro may be
neutralising; the mechanism presumably being steric hindrance of the
proteins that mediate attachment or fusion.
Gnann et al., (1987) produced synthetic polypeptides corresponding to
parts of the amino acid sequence of p24, gp41 and gpl20. All four of
the gpl20 polypeptides and all six of those corresponding to gp41 were
shown to elicit an antibody response in rabbits. However, while
antibody to 4 of the 6 polypeptides of gp41 was found in convalescent
sera from HIV infected patients, none of the human sera reacted with
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any of the four polypeptides corresponding to gpl20. These results
would indicate that there is less naturally occuring antibody to gpl20
than gp41. However, only linear epitopes would have been present in
the synthetic proteins, and it remains to be seen whether there is a
similar lack of antibody to conformational epitopes of gpl20.
Several studies have demonstrated the presence of antibody to
non-structural proteins of HIV (Arya & Gallo, 1986; Knight et al.,
1987). Recent work investigating the role of the sor gene has shown
that it is essential for the infectivity of the virus (Fisher et al.,
1987; Strebel et al., 1987). There is the possibility that sor is
present in the virion, although its detection in the IB assay with
purified virus has not been reported. There may be other explanations
for its non-detection; it may be present only in small amounts, or
alternatively, it may have predominantly conformational epitopes that
would be lost on sol.ubilisation in SDS. However, careful scrutiny of
the results of the IB assay does reveal the presence of a 23 KDa band
in the IB assay on reaction with some sera (eg. J2; patient 4 of the
seroconconversion study: panel c, figure 24). Significantly, the mouse
antiserum, while showing marked reactivity with gag proteins (see
above), does not react with the 23 KDa band, indicating that it is not
merely an degradation product of p24.
In summary, convalescent sera show a wide range of reactivities with
HIV encoded proteins. As with HSV, there are discrepancies between the
peitrliSKedL
results of the IB and^RIP assays. Little evidence presented
conclusively proves that there are significant levels of antibody to
gpl20.
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CONFIRMATION OF POSITIVE SERA BY IB
Reliable detection of antibody to HIV is important in determining past
exposure to the virus, and hence public health measures to prevent the
spread of HIV in the community. In particular, screening and
confirmation should be able to give a positive or negative result for
every serum tested; an equivocal result is unacceptable in view of the
health implications of HIV. Tests therefore need to combine high
sensitivity with specificity. Unfortunately, IB is impractical for
widespread use, in view of the complexity of the procedure, and the
experience required in interpretation. However, IB has a role in the
confirmation of positive results from simpler screening tests, such as
ELISAs, and in the investigations of samples showing equivocal results
on initial testing.
IB has been used for this purpose in the Edinburgh Reference
laboratory for the last two years. Over this time, several interesting
sera have been investigated by the IB assay, as well as the routine
confirmation of positive sera. Confirmation of positive sera has been
relatively straightforward with few discrepancies between the ELISA
results and those of the IB assay. In many cases (figure 22),
borderline reactivity of certain sera in the Wellcome assay could not
be confirmed in the IB assay or Pasteur EIA. All of these sera were
referred by the BTS, apart from one which was of unknown origin. In
view of the large number of donors screened by the BTS, such
reactivities in the Wellcome assay can be seen to be very rare.
Investigation of one of the sera revealed absent reactivity in several
other sensitive tests for HIV antibody. It has been suggested by
others that weak reactivity in the Wellcome assay could be mediated by
serum anti-HRP antibodies, or non-specific enzyme inhibitors. There is
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no evidence that suggests low levels of antibody to HIV. The Wellcome
assay produces considerably fewer false positive that indirect ELISAs
for HIV antibody. Early experience with the original Abbott assay, and
those from Dupont and Organon indicated frequent false positive
reactions. In many cases, increased serum stickiness from storage,
heat inactivation or malaria could be attributed as causes. This
latter cause is discussed in Biggar et al., (1985a).
Other sera investigated showed different patterns of reactivity in the
various tests for HIV antibody. Several sera showed weak reactivity in
the Wellcome test, and were shown to have weak reactivity in the IB
assay, typically producing a single p24 band. Subsequent sera from the
same patients indicated that the patients had recently seroconverted
for antibody, the results of these, and sera from several other
patients with acute infection are discussed below. Several sera showed
isolated reactivity with pl7, and were referred after detection of
weak reactivity in the Dupont or Abbott EIAs by the BTS. Unlike the
sera from patients with acute infection, no change over time was seen
in the reactivity with pl7 in the two patients who were investigated
further. No reactivity was seen in the competitive ELISAs for HIV
(Wellcome, Abbott confirmatory test). Where possible, an enquiry was
made into possible risk factors for HIV,infection. Neither of the two
donors investigated were in the at-risk age group, and neither had
travelled to Africa. In view of these results, HIV infection was
therefore ruled out as a cause of this reactivity in the IB and Dupont
assays.
There have been several reports of isolated reactivity in the IB assay
with pl7 and pr55 (Courouce et al., 1986), or with p24 and pr55
(Biberfeld et al., 1986; van der Poel et al., 1986, amongst others).
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Variation in the relative amounts of precursor gag proteins between
different sources of antigen may account for the failure to detect
antibody to pr55 in the results presented here. The sera described by
these investigators were described as being false-positive on the
basis of failure to develop further bands on follow-up (ruling out
seroconversion), absent risk factors, absent reactivity in alternative
assay systems, and, in one study, absent mfectivity (as shown by
absence of seroconversion on follow-up of recipients of blood taken
from donors showing reactivity to p25 and pr55). Lelie et al.,
(1987b) compared the reactivity of sera previously shown to be
false-positive (p24 and pr55 bands only) with acute phase sera from
patients with primary infection with restricted reactivity to p24
only. The investigators used an IB assay with unheated antigen, and
found some reactivity with a higher MW band, identified as gpl20, in
sera from patients seroconverting for antibody, but not in the false
positive sera. These results agree with the finding above of slightly
enhanced reactivity of J2 with gpl20 on comparison of different heat
treatment for HIV antigen.
None of the investigators have proposed reasons for the false positive
reactions in the IB assay. The possibility of cross-reactivity with
viral or non-viral antigen needs to be considered. It is interesting
to speculate on the presence of, so far, uncharacterised retroviruses
in the community, with sufficient homology to cause cross-reaction of
antibody elicited by infection. Such viruses may be non-pathogenic or
may be associated with some of the diseases of obscure aetiology.
There have been serious suggestions that rheumatoid arthritis and
multiple schlerosis (MS) may be of retroviral aetiology. The latter
suspicion is based of evidence of involvement of HTLV-I in tropical
spastic paraparesis, a disease that resembles MS. Cross-reactivity of
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HTLV-I, -II or HIV-2 in the IB assay are other possibilities to
account for the false positive IB results, although the evidence to
show cross-reactivity of HTLV-I and -II with HIV is conflicting. The
experimental data presented by Sarngadharan et al., (1985), to show
extensive cross-reactivity of several proteins in the IB assay are
almost certainly mis-interpreted. However, other evidence that
demonstrates a lack of cross-reactivity between HTLV-I and HIV is more
credible (Hattori et al., 1985). Notwithstanding this, the patients
described here, and in the reports quoted above, are not in the risk
groups for these viruses.
It is, however, certainly possible that the donor who showed
reactivity with p24 and pr55, weak reactivity in the Wellcome EIA,
absent anti-"env" but very high levels of anti-"core" was infected
with HIV-2. This patient had a history of travel in Africa;
furthermore, it is been shown that there is cross-reactivity between
the gag proteins of the two viruses in the IB assay (Vittecoq et al.,
1987). In the future, it be necessary to adopt screening methods for
HIV-2 as well as HIV-1, not only for individuals who have lived in
Africa, but amongst the risk groups for HIV-1 infection. Recent data




These experiments were designed in a similar wav to those of HSV,
although in this case, there were no RIP results to corroborate the
findings. Overall the results showed good agreement about the time of
appearance of antibody, apart from the Abbott EIA. The results from
this latter test are non-specific and will not be considered further.
In two patients (no. 1 and 8), the Wellcome EIA gave an equivocal
result for a sera that was positive for antibody by the other tests.
In another, (no. 2), there was a marked discrepancy in results, with
only the IB and Abbott confirmatory assays detecting antibody in
second and third sera from the patient. The results with the other
tests for the first of these two sera were uniformly negative, while
only the Dupont assay detected antibody in the second (ie. the third
of the series). Undoubtedly, timing of samples is important; the
relatively good agreement between tests in the other patients may
simply indicate that sera were taken well away from the moment of
seroconversion. The relatively large intervals beteen the first and
second sera in the majority of patients would support this conclusion.
However, patient 2 was suffering from acute myeloid leukaemia, and the
disorders in immune function found in such patients may have led to an
abnormal antibody response to infection. Certainly, comparison of the
the bands produced in the IB assay with those produced by the other
patients shows that reactivity was virtually confined to gag proteins
and gp41 up to 176 days after the last negative serum. Other patients
showed relatively broad antibody specificies by this time, even though
the initial antibody response may have been confined to p24. The
initial antibody response may have been oligoclonal, perhaps favouring
reactivity to the critical epitopes of the IB and anti-"env" assay,
rather than those of the other tests.
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The results of testing many of the patients in the seroconversion
study and those in the haemophiliac cohort by the IB assay, showed
that antibody reactivity was confined to p24 or p24 and pl7 (figures
24; 25). Such results tended to be found in those patients with low
antibody levels by the other tests, and may indicate proximity to
seroconversion. This is not necessarily evidence that the initial
antibody response is qualitatively different from that found later in
infection. Although antibody specificity appears to broaden in the
weeks after seroconversion, this may be the result of differential
sensitivity of the test for antibody to p24 relative to other
proteins. The broadening of antibody specificity may be more apparent
than real, and the difficubtt'e-s of comparing antibody
reactivity with different proteins becomes apparent once again.
Differential sensitivity of antibody tests accounts largely for the
results of Allain et al., (1986). This study describes the testing of
sera from haemophiliacs around the time of seroconversion by the
Abbott confirmation test. Results show that antibody to the core
protein (recombinant p24) appear some time after antibody to env
(recombinant gp41) during seroconversion. The results presented in the
work described here indicate that these results may be merely an
artefact, and result from the relatively greater sensitivity of the
test for anti-"env" than anti-"core". The author found that the three
of the four sera positive for anti-"env" and negative for anti-"core"
were all reactive with p24 in the IB assay (patient 2, table 13;
patients W5 and U1, table 15). The exception (W10, table 15) failed to
develop antibody to anti-"core" or show reactivity with p24 in the IB
assay, so this was not a case of delayed appearance of antibody.
Conversely, no sera were found to be IB negative, yet reactive with
env in the Abbott confirmatory assay. Similarly, Gaines et al.,
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(1987) reported the simultaneous detection of anti-"env" antibody and
reactivity with p24 in the IB assay in patients seroconverting
following exposure to HIV. Thus, there is no evidence, yet, to
corroborate the hypothesis advanced by Allain et al. , (1986) of
differential antibody reponses on primary infection.
Several comparisons of different assays for antibody to HIV around
seroconversion have been reported. Comparisons between groups are
problematic for tests such as IB, IF and RIP assays, since the
performance of the tests may vary between laboratories, or with time
in the same laboratory as experience is gained. Gallo et al., (1986)
reported the equal sensitivity of IB and IF assays in the detection of
antibody to HIV, although this was not found in this study. Gaines et
al., (1987) has recently presented comparative data on the performance
of tests around seroconversion. This extensive study shows that IB,
RIP and the Abbott confirmatory test were substantially in agreement
about the time of seroconversion, although the targets of antibody
were different in the IB and RIP tests. As might be expected, IB
detects antibody to p24, while bands of 160, 120 and 24 KDa are found
in the RIP assay. Whether the appearance of a 120 KDa band in the
immune precipitate indicates an antibody response to gpl20 has been
discussed above. Several commercial EIAs were also used to test the
sera, and the results showed that the IF assay and the Abbott, Dupont,
Organon, Pasteur and Wellcome EIAs all detected antibody several weeks
later than the three confirmatory tests. These results were obtained
from very closely spaced sera, and do not contradict the findings made
in this study; the greater agreement in results found here may have
been related to the relative infrequency of samples from the patients.
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Marlink et al., (1986) and Ulstrup et al., (1986) reported the
seroconversion in HIV infection in small studies comprisisng two and
three patients respectively. Both studies reported the earlier
detection of antibody reactivity in the IB assay relative to a range
of commercially available ELISAs. The latter author also found the IF
assay to be significantly less sensitive than the IB assay for
HIV-specific antibody. This perhaps illustrates the problem of
comparing such tests between different laboratories, since the results
are in marked disagreement to those of Gallo et al., (1987). The
findings of Oldham et al., (1986) are more difficult to evaluate. 20
sera showing weak reactivity in a screening test for HIV antibody were
tested by a range of assays, including IB and a newly-developed
competition assay, as well as many of the commonly used commercial
ELISA tests. The results show more frequent detection of antibody
reactivity in the new assay than in the others, including IB. However,
no attempt was made to establish why some sera appeared to give
discrepant results. Proximity to seroconversion would be the most
likely cause, yet no data was presented on the testing of follow-up
samples from those patients showing initially weak reactivity in the
assays. It is questionable whether such low reactivity, not in
association with seroconversion, genuinely represents the presence of
specific antibody to HIV.
Huisman et al., (1987) presented data to suggest that the RIP assay
may detect antibody at an earlier stage of infection than IB. The
report describes the detection of antibody to p24 in the RIP assay
some weeks before the appearance of p24 reactivity in the IB assay.
These results are interesting, and may result from a greater
sensitivity of the RIP assay for antibody. However, it is possible
that the RIP may be detecting antibody in immune complexes. The
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antigenaemia that precedes seroconversion may be sufficient to absorb
the initially low levels of antibody elicited by infection. Soluble
radiolabelled antigen added during incubation with the test serum
might compete for antibody within the immune complex, and lead to a
degree of incorporation of label into the immunoprecipitate.
Subsequent analysis by SDS PAGE would reveal the presence of
radiolabelled bands, and hence give a positive result. This mechanism
relies on the antigen being in solution, and would be less likely to
occur if it were immobilised on a solid phase, such as is found in the
ELISAs and IB assay. Immune complex formation, and hence adsorption of
the early immune response to HIV, may be the reason for the generally
low rates of detection and low levels of HIV-specific IgM found in
primary infection. It is possible that the transient IgM response may
have been exhausted by the time that the antigenaemia is cleared, and
seroconversion for IgG takes place. It is not impossible, therefore,
that infection and hence the initial immune response takes place
several weeks before virus-specific IgG is detected. This would agree
with the clinical experience (see chapter 4), where the acute illness
associated with initial infection is often found to precede the
appearance of antibody by several weeks. Circumstantial evidence to
support this hypothesis comes from consideration of the serology of
HBV. Initial infection with this virus is associated with an
antigenaemia. The antigenaemia comprises predominantly surface
antigen, and while IgM to core may be readily detected in the acute
phase of the illness, IgM to surface antigen is not found.
Immunosorption of the initial immune response to HBV may be the reason
for the lack of IgM.
That reliable detection of antibody in the early stages of infection
is important is shown by local experience from the Glasgow BTS. A
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donation was negative in the standard screen (Wellcome) yet
transfusion of the blood led to seroconversion in the recipient.
Subsequent analysis of the blood revealed the presence of HIV antigen.
The serum was tested by IB and Abbott confirmatory test and found to
be negative. That there is a transient antigenaemia before
seroconversion is well established (see chapter 4), and was detected
in several of patients studied in the work described here.
Patient 2 of the seroconversion series, and 5 of 11 last negative sera
from patients in the haemophiliac cohort contained detectable antigen.
The failure to detect antigen in some patients may be related to the
frequency of sampling. While the interval between the last negative
and first positive sera in the five patients where antigen was
detected ranged from 6 to 50 days, the interval in those where antigen
was not detected was from 55 to 177 days. It is difficult to go
further than this in the statistical determination of the duration of
antigenaemia. The data has been presented to Dr R. Prescott, Medical
Statistics Department, University of Edinburgh, for analysis. No firm
conclusions have been reached at present. Not only is the data for
such an undertaking incomplete, but statistical analysis of the
results from the 11 patients brings in the assumption that a uniform
phenomenom is being studied. However, comparison between the available
data from the patients indicates that this is not so. Figure '26
indicates that the antigenaemia in patient U2 can not be longer than
33 days, while that in patient U1 could not have been shorter than 40
days.
Two sera from patients in the haemophiliac cohort showed the
simultaneous presence of antibody and antigen. Both sera showed
reactivity with p24 in the IB assay. One was negative for anti-"core"
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and positive for anti-"env". Antigen positive, anti-"core" negative
and anti-"env" positive results were found in seven sera from
haemophiliacs studied by Allain et al., (1986) around seroconversion.
However, in this study, a serum that was antigen positive and
anti-"core" positive was also found. Three such sera were also found
in the quoted study, two of which were from patients who had
previously shown the previous pattern. One serum (from patient W6) was
anti-"env" positive, anti-"core" negative and antigen negative.
Furthermore, the serum was reactive with p24 and other gag proteins in
the IB assay (figure 25). 11 such sera were found in the French study,
although not tested by IB, three of which were taken from patients who
had previously been antibody negative, antigen positive. Allain at
al., (1986) also reported an association between sampling interval and
detection of antigen. In this study, there was a 25% prevalence in the
group where the sampling interval averaged 5 months, and 50% in the
group with a mean interval between samples of 3.5 months. Similar
figures are reported by Goudsmit et al., (1986), using similar assays
(31%; 3 months mean interval). These figures indicate a similar
incidence to those reported here. The cumulative results indicate a
prevalence of 46% over 81 days mean interval. This is a very similar
figure to that reported by others. If the prevalence is multiplied by
the mean sampling interval, then an approximate duration of
antigenaemia is obtained. This elementary statistical method gives the
following results: this study, 37 days; Allain et al., (1986), 1.25
and 1.75 months (38 and 53 days); Goudsmit et al., (1986), 0.9 months
(28 days). This is a surprisingly high figure and indicates that the
prevalence of antigen carriers, who are antibody negative, may be
relatively high in the community. Assuming very approximately, an
average of 3 years for the duration of HIV infection in Britain, then
it can be seen that between 2.5% and 4.8% of individuals infected with
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HIV may be antibody negative. The high prevalence of such individuals
in the community indicates the difficulty of preventing spread of HIV
by screening blood donations for antibody. This data provides an
explanation of the findings of Salahuddin et al., (1984), who
isolated HIV from 4 out 96 seronegative samples from high-risk
patients. This study was carried out long before the development of
the antigen assay, and before the existence of a transient
antigenaemia on seroconversion was suspected.
The time to seroconversion after exposure could be studied in the
haemophiliac cohort since the source of infection was later identified
(Ludlam et al., 1985). These results are not necessarily comparable
to those of infection in other risk groups, since the route of
infection differs. Nothing is known about the early events in the
course of sexually spread infection, and there is the possibility of
local viral replication at the site of infection for considerable
lengths of time before dissemination and seroconversion. Infection
from administration of whole blood would expose the recipient to a
relatively large infectious dose, and would be expected to lead to a
rapid seroconversion.
The results from the haemophiliacs indicate that the infectious dose
may be relatively small. The prevalence of HIV infection in Edinburgh
in 1983 was very low; this was the time when blood donations that were
processed into the implicated batch of factor VIII were collected. It
is therefore possible that only one or two HIV infected samples
infected the final plasma pool of 500 donations used to prepare a
batch of factor VIII. There is, therefore, a considerable dilution of
virus compared to that found in whole blood. Lyophilisation of factor
VIII after purification has been shown to inactivate up to two logs of
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virus infactivity (MacDougal et al. , 1985), and this leads to a
further reduction in infectious dose. Circumstantial evidence for the
low dose of HIV received by the haemophiliacs comes from the
observation that, of the 34 who received the infected material, only
18 were infected. By contrast, recipients of whole blood from
seropositive donors show very high rates of infection, approaching
100%.
There appears to be some association between the numbers of bottles of
factor VIII administered and the time to seroconversion. Paricularly
notable is the relatively long interval observed in patients W4 and
Ul, who were both low users. There was no sign of infection in W4 at
least 109 days after first exposure. The detection of antigen in the
absence of antibody after 157 days in patient Ul is similar evidence
for a relatively long incubation period. Patients with relatively
higher consumption such as U2 and U8 showed a more rapid
seroconversion. It is possible that the statistical analysis currently
being carried by Dr Cuthbert and Dr Prescott may be able to show a
"significant relationship. However, it is worth pointing out at this
stage that the evidence for the infectivity of the implicated batch is
circumstantial rather than positive (Ludlam et al., 1985). Virus has
not been detected in the remaining samples of the batch on testing in
the antigen assay; similarly the material is antibody negative. These
two lines of evidence do not rule out the presence of HIV in view of
the possible low infectious dose, and because of the partial removal
of antibody from the factor VIII fraction during manufacture.
Alternatively, it is possible that the donor was antibody negative,
yet infectious, in the early stages of primary infection.
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The reportsAreviewed in chapter 4 on the incubation time between
exposure and seroconversion. In view of the different routes of
infection, it is difficult to compare the data in this work with that
of other investigators. Blood transfusion-associated infection is
relatively well documented. However, little data on the interval
between exposure and infection in haemophiliacs has been presented, in
view of the relatively early infection of haemophiliacs by factor VIII
of commercial origin. It is similarly difficult to establish the time
of exposure in the homosexual and drug-abuser risk groups. The data
presented here on the duration of antigenaemia and time to
seroconversion in haemophiliacs is therefore relatively unique.
FOLLOW-UP PERIOD
The cohort was relatively intensively followed up and the regular
supply of samples from all but one of the patients in the cohort
presented a good opportunity for the serological characterisation of
infection.
All patients show a continual rise in antibody levels to whole virus,
as determined by the Dupont EIA, and to gp41, as found by measurement
of antibody levels to env in the Abbott confirmatory assay (figure 27;
28). The quantitation of anti-"env" antibody was made difficult by the
nature of the test. While direct binding ELISAs generally show a
linear relationship between antibody concentration and optical
density, no such simple relation exists in a competitive ELISA.
Titration curves of J2 were comparable to those of other sera.
Furthermore, preliminary results showed that antibody levels
calculated from the ODs at different dilutions of test serum were
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similar, provided that the OD fell in the range 0.15 to 0.8. In
practice it proved necessary to test sequential sera from the same
patient in the same batch, since inter-test variation was significant.
In the future, it would be desirable to design a direct binding assay
using recombinant gp41 for better quantification of anti-"env" levels.
The technical problems with the test prevented testing of the mid-1987
samples, but the results of those up to 1986 showed that there were
significant rises in antibody level in the patients in the cohort.
There was, however, variation in the level of antibody finally
achieved, although this did not correl ate with clinical progression.
The final levels, and the rate of rise between the well and unwell
groups did not appear to differ significantly, even if the patients
with PGL are excluded from consideration.
The Dupont EIA uses purified virus as antigen in a direct binding
assay for antibody to HIV. Antibody reactivity to any of the HIV
proteins is therefore detected by this test. The relative amounts of
gag proteins to env available for antibody binding was not known. Some
qualifications concerning the use of OD to quantitate antibody levels
are necessary at this stage. This discussion also applies to the
quantitation of antibody levels to HSV.
The terms antibody level and antibody titre are distinct, and refer to
different measurements. Titres are determined by serial dilution of
test sera, and recording the dilution of serum at which reactivity
becomes undetectable. There are several problems with this method.
Firstly, the accuracy of the test depends on the dilution factor
between serial dilutions. If two-fold dilutions are used, then the
test can only distinguish between test sera that differ in antibody
titre by a factor of two. Furthermore, the uncertainties of
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measurement of very low ODs, and the relative arbitrariness of
assigning a cut-off point below which sera are to be considered
unreactive, leads to considerable inaccuracies in practice. The third
problem concerns the nature of the information obtained from the
titration. It can be seen that titration of sera measures the
concentration of one antibody specificity alone, ie. the most abundant
one. This may lead to problems in interpretation. For example, it was
found that the titre of HSV-2 antisera with HSV-1 and HSV-2 antigen
was similar; the explanation being that the most abundant antibody
specificity happened to cross-react with HSV-1. Equal titres to
antibody to type-homologous and heterologous is surely a
counter-intuitive result.
i !
Another method of titration would be to determine the dilution
of serum that produced an OD of 0.5, or some other easily measured
figure. The advantages would be greater accuracy, because of the
greater values of the ODs recorded relative to the experimental error.
Unfortunately, this method suffers from its inability to quantitate
antibody reactivity to relatively scarce antigens on the solid phase.
Reactivity with a minor component might be insufficient to produce the
requisite OD, even if the antibody was present in excess. In summary,
it is difficult to assign a - single numerical value to a complex
mixture of antibody of varying specificities, particularly in an ELISA
with multiple antigens.
It was observed on titration of several control sera in the Dupont
assay that there was an approximately linear relationship between
antibody concentration and OD over a relatively large range. However,
sera that lacked antibody to core proteins showed such a relation over
a much more restricted range, typically between 0 and 0.2, above which
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increasing the antibody concentration led to a less than expected
increase in OD. It is possible that predominant reactivity with pel or
env proteins, present in relatively lower amounts than gag proteins on
the solid phase, accounted for these observations. In practice, a
compromise solution was adopted. Test sera were screened at two
dilutions, and antibody levels calculated from the OD produced by
each. Where there was disagreement, and this was principally found in
sera unreactive with gag proteins, the antibody level was calculated
from the OD of the higher dilution. In plotting the graphs in figure
28, care was taken to ensure that the antibody levels of sequential
samples were calculated from the ODs at the same dilutions. This was
to ensure comparability between the results from the same patient.
However, from the previous discussion, it can be seen that it is
relatively meaningless to use these results to compare the antibody
levels of different patients. The abundances of antibody to different
proteins might vary between individuals leading to greater or lesser
reactivity with the range of proteins on the solid phase.
Antibody levels in the Dupont EIA were seen to rise steadily over the
first two years in all patients, whether well, or unwell. These results
corroborate those of the anti-"env" assay. However, testing over the
third year of infection showed significant changes between
individuals. In particular, falls in antibody level were found in four
patients, co-incLdent with the development of symptoms of ARC or AIDS.
Patient U2 showed a sustained fall in antibody level in the months
after AIDS was diagnosed. It would seem that antibody levels to whole
virus have some prognostic value, although the disease may be severe
before a fall is noted. ARC was diagnosed in U2 9 months after
infection, at a time when antibody levels were rising. Similarly,
antibody levels were seen to continue to rise after the diagnosis of
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ARC (group IVa) in U4 and U6. Three patients showed marked increases
in antibody level in the third year of infection (patients W4, W5 and
W9) . Whether this represents a favourable prognostic sign will require
prospective studies of the cohort. At present, there is no clinical
evidence to distiguish these patients from many of the others in the
well group.
Weber et al., (1987) has reported anti-"env" titres in sequential
sera of two cohorts of homosexuals infected with HIV. In contrast to
the findings here, no significant change was seen in titre in either
well or unwell patients over the three years of study. It is difficult
to account for the differences in these results with those presented
here. One difference between the studies is that the time of
seroconversion of the patients in the London cohort was not known, and
therefore many of the patients may have been seropositive for several
years before the study commenced. It is possible, therefore, that a
much later stage in HIV infection was being studied in many of the
patients. The titration method used was inaccurate, in that serial
ten-fold dilutions of sera were tested. Therefore, only relatively
large changes in antibody level could be detected by this method. In
the study presented here, ten-fold rises only took place in the first
year of infection. The proportionally smaller rises found subsequently
possibly would not be detectable by the titration method used in the
London study.
Reactivity in the IB assay, particularly with p24 showed marked
variation between patients. Reactivity with the latter protein
correlated well with reactivity of sera in the anti-"core" assay, and
substantial agreement between the two measurements was found with all
sera. However, both in the seroconversion studies, and in the
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follow-up study, the IB assay was found to be more sensitive for
antibody to core proteins than the specific ELISA. The IB results of
the first positive, mid-1985, -1986 and -1987 sera from haemophiliacs
showed that the most significant changes took place in the first year
on infection. Surprisingly, there was little change in the reactivity
of sera of most patients in subsequent years in the assay. This may be
more artefactual than real. The IB test is very sensitive for
antibody, and it requires very little antibody to produce a prominent
band on substrate development. As a result, there is likely to be
saturation of many of the bands by antibody positive sera. To compare
the reactivity of sequential sera to many of the bands, it would be
necessary to test serial dilutions in order to avoid the saturation
effect. Fortunately for this study, levels of antibody to p24 were
sufficiently low in many patients to enable comparison of reactivity
with time at a standard dilution of 1/50.
The results showed that loss of reactivity to p24 took place in many
of the patients between seroconversion and the mid-1985 sample. These
results are corroborated by measurements of anti-"core" levels (tables
16 and 17). More detailed analysis of these patients (table 19) showed
two main patterns of loss. Four patients showed loss of anti-"core"
and p24 reactivity and remained unreactive with gag proteins for the
remainder of the follow-up period. The three patients in part B of the
table showed fluctuating levels of anti-"core". Fluctuating reactivity
with p24 was also noted in the IB assay and the results of patient U4
are illustrated in figure 33. Comparison of the mid-1986 strip with
that of 1987 confirms the result of the anti-"core" ELISA
that reactivity fell away again subsequently.
Antigenaemia was found in some patients in the follow-up period,
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particularly in the last year of the study. Six of the 17 patients now
en
show persistent antigaemia, with the suspicion of antigen in two more,
on the basis of borderline, non-confirmable reactivity in the ELISA.
That this may herald the development of antigenaemia is shown by
patient U3. He showed this pattern of reactivity for 2 years before
finally becoming confirmably antigen positive in the last month of the
study. All of the patients with antigenaemia had shown previous falls
in anti-"core" levels, and reduced reactivity with p24 in the IB
assay. However, antigenaemia was found in one patient (W8) with
fluctuating anti-"core" levels; a rise in antigen level initially
ocurring against a background of rising anti-"core" levels. None of
the patients with high anti-"core" levels showed antigenaemia. The
converse holds true, with one exception. Only U6 of all the patients
showing a fall in anti-"core" levels has shown no evidence of
antigenaemia. The likely explanation for the results of patient W10,
who has shown no anti-"core" reactivity at any stage of infection, is
that the first positive sera was collected so long after
seroconversion that anti-"core" and p24 antibody reactivity had
already become undetectable. To support this hypothesis is the
observation of the relatively rapid loss of anti-"core" reactivity in
other patients after seroconversion. The first positive serum of W10
could have been collected at most 177 days after seroconversion; by
this time, significant falls in reactivity had already occurred in
patients U2 and U6. Therefore, patient W10 could perhaps be regarded
as showing the same type of immune response as those in part A of
table 19. Serum antigen was detected in this patient in mid-1987,
although he remains well.
There was a marked correlation between antigenaemia and loss of
antibody reactivity to core proteins, as can be seen from the results.
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Loss of antibody tends to occur before the appearance of antigen,
often by several years (U2, U3). Low levels of anti-"core", typically
those seen in patients with fluctuating levels, may co-exist with
antigenaemia. Finally, although sera may become completely unreactive
in the specific ELISA, very few sera become completely unreactive with
the p24 band in the IB assay. That the p24 band rarely disappears
completely was noted by Groopman et al. , (1986), although this does
not mean that p24 reactivity was the same for all patients. A large
study by Paul et al., (1987) found that 92% of sera in which antigen
was found were negative for anti-"core". Of the remaining 8%,
generally very low titres of antibody were found. Lange et al.,
(1986b; 1986c) has also presented evidence to show that loss of
reactivity to p24 in the IB and RIP assay is associated with the onset
of antigenaemia. A strong association between antigenaemia and absence
of reactivity in a specific ELISA for antibody to core proteins was
reported by Goudsmit et al., (1987a).
Further evidence to link the phenomenon of antigenaemia with loss of
gag protein reactivity comes from the detection of immune complexes in
HIV-infected patients. Morrow et al., (1986) described their
detection in patients with ARC and AIDS, and showed, by SDS-PAGE, the
presence of p25 and pr55 proteins within the complexes. However, no
data on the serological reactivity to gag proteins was presented.
Lange et al., (1987) found HIV antigen in immune complexes of HIV
infected patients, and showed its association with lack of anti-"core"
antibodies. Sera that were anti-"core" negative, and antigen negative
in the conventional assay, were shown to have contained, such immune
complexes, while they were not found in sera that were anti-"core"
positive. These findings are highly significant, and strengthen the
association between anti-"core" and circulating antigen, either free
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or complexed. They also provide some information on the mechanism of
infection. The reason for the loss of anti-"core" antibody reactivity
is not known. One suggestion is that there is clonal exhaustion of B
cells, leading to reduction in HIV-specific immunoglobulin synthesis.
A second suggestion is similar, and proposes that the continual
exposure of HIV to the immune system leads to a state of tolerance.
According to both of these theories, antigenaemia occurs as a result
of the decline in specific immunity to the virus. The third
explanation, and one supported by the findings of immune complexes, is
that core antibody production continues throughout all stages of
infection, but in some patients, there is such a rapid rate of virus
replication that immunoadsorption of antibody takes place. Initially,
immune complexes would form, but as the rate of virus replication
increases still further, free antigen would appear, and
become detectable in the conventional antigen test. The latter
explanation would predict a relatively high rate of antigen
production, and the question arises concerning the site in the body
where this could take place. It does not tally with the relatively
infrequent detection of HIV infection in T-lymphocytes, but does lend
evidence to the possibility of widespread infection In non-lymphoid
tissue, such as the brain, gut and lungs.
The relationship between antigenaemia and viraemia is not clear. The
precise composition of the serum antigen is not known. Morrow et al.,
(1986) reported the detection of gag proteins in immune complexes, but
the bands were faint, and the failure to detect other proteins may
have resulted from differential sensitivity of the IB method. Lange
et al., (1987) used an ELISA for gag protein in the analysis of the
immune complexes; thus there was no data on the possible presence of
other virion components. It is well established, on the basis of
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numerous case reports, that antigen-negative blood is infectious.
However, it is less clear whether cell-free blood products from
antigen-negative donors are also infectious. The disappearance of
antibody to p24 and other gag proteins that occurs in association with
antigenaemia or immune complex formation provided some evidence that
the antigenaemia comprises predominantly gag -encoded proteins,
although it may merely reflect the fact that the immune response to
gag proteins is relatively less effective than that to env proteins.
The fall in antibody levels in the Dupont assay found in some patients
on development of illness may reflect loss of antibody reactivity to
proteins other than gag, and the fading of the p54, p51, gp41 and p33
bands between 1985 and 1987 in patients U2 and U3 in the IB assay
smilarly supports the hypothesis that other proteins are found in the
antigenaemia. However, both patients were profoundly unwell at the
time of this loss of reactivity, and it may merely reflect HIV-induced
immunological abnormalities.
It is well known that isolations may be successful with both
antigenaemic and non-antigenaemic patients. In this laboratory (S.
Rebus, personal communication), and elsewhere (Farthing et al.,
1987), there appears to be no correlation between antigenaemia and
isolation rate. -In particular, recent attempts to isolate virus from
patient W8 have not proved successful, yet this patient has the
highest antigen level of all of the patients in the cohort (250 ng/ml,
recently recorded at 500 ng/ml). However, it was possible to isolate
from this patient at the beginning of 1986, when antigen levels were
lower (A. Lainson, personal communication). This is some evidence for
the antigenaemia not representing a true viraemia.
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CORRELATION BETWEEN SEROLOGICAL MARKERS AND CLINICAL PROGRESSION
The investigation of serological markers in cross-sectional and
prospective studies of HIV-infected patients is motivated bv the
desire to monitor the course of infection and to predict the clinical
outcome. In this study, a strong correlation between the presence of
anti-"core" and lack of disease progression was noted. This conclusion
requires the inclusion of patients with PGL (group III) in the well
group. Current evidence indicates that such inclusion is not
unjustified on clinical grounds, in that PGL does not appear to be
prodromal in many of the patients in this group (see chapter 4). The
patients with high levels of anti-"core" are W3, W4, W5, W6, W7 , W9
and U5 (PGL).
However, the converse association between progression and loss of
anti-"core" antibody does not apply. There were three well patients
who showed loss of anti-"core" and antigenaemia, as well as one with
PGL, who could also be considered to have not shown clinical
progression. All of the patients in whom ARC or AIDS was diagnosed did
show loss of anti-"core", with or without antigenaemia. A striking
feature about this study is the rapidity with which most of the
patients lost antibody to core proteins after seroconversion. Such
loss was noted in the first year of infection in all but two patients,
yet in many cases, symptoms of progression were only noted 2 years
later (U3, U4, U6). Loss of anti-"core" would appear to be more
valuable in the prediction of clinical outcome than the detection of
antigenaemia, since the appearance of the latter is often delayed for
up to two years after antibody loss (patient U2 and U3) or may remain
absent (U6). However, improved tests, such as those that detect
antigen in immune complexes, may reduce this interval (see above).
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It is possible that the three well patients and the one with PGL, who
all showed loss of anti-"core" and antigenaemia, may differ from the
unwell patients only in the time course of progression. As mentioned,
clinical progression was found in some patients up to two years after
loss of anti-"core". It is possible, therefore, that a still longer
time course of disease may be found on prospective study of those
remaining well. Only follow-up studies could establish whether there
was a difference in prognosis between these three patients and the
seven with high levels of anti-"core". Were this to be found, then the
anti-"core" and IB tests would be of major clinical and
epidemiological importance in cross-sectional studies, of infection.
Furthermore, by differentiating between those likely to progress from
those who are likely to remain well, early decisions about treatment
could be made. Drug therapy could therefore commence at an early stage
of infection, and would obviously have a better chance of success than
the current policy of treating symptomatic patients.
There have been several other reports of the association between
disease progression and anti-"core" levels or antigenaemia. Schuepbach
et al., (1985) noted a fall in the reactivity to p24 and other
gag -encoded proteins in the sera of those developing ARC or AIDS.
Biggar et al., (1985b) tested sera from a patient who died of AIDS,
and compared the results with those of HIV infected patients who
remained well. They showed that, while antibody levels to EBV and CMV
were maintained, reactivity with HIV proteins, particularly those
encoded by gag, in the IB assay fell in the patient with AIDS. Lange
et al. , (1986a) noted a fall in antibody reactivity with gag proteins
in two patients who developed AIDS, while thirteen patients who
remained well showed no such loss of reactivity. Lange et al.,
(1986b) tested sequential samples from thirteen homosexuals infected
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with HIV and showed that those from twelve of the patients, who
remained well, remained antigen negative, anti-"core" positive in the
specific ELISA and retained reactivity with p24 in the IB assay. Sera
from the patient who developed AIDS, however, showed falling levels of
anti-"core" and lost reactivity in the IB assay with p24. Antigen was
detected co-incident with the diagnosis of ARC, but at least two years
after the loss of reactivity with gag antibody reactivity. Lange at
al. , ( 1986c) reported similar findings in a cohort of nine children
with transfusion acquired HIV infection, although in this study, two
patients with antigenaemia and loss of antibody remained well.
A strong association between clinical progression and antigenaemia was
reported by Goudsmit et al., (1986), and in a further study by the
same investigators (Goudsmit et al., (1987a), similar conclusions
were reached. In this later study, nine of the eleven asymptomatic
patients had anti-"core" and were antigen negative. Two well patients
were, however, antigenaemic and anti-"core" negative. Of the eight
patients with ARC and AIDS, 5 were antigenaemic, and anti-"core"
negative. Two were antigen negative, and showed low titres of
anti-"core". However, the eighth patient (ARC) was antigen negative,
and had similar titres of anti-"core" to those of the well patients.
Pan et al., (1987) report an association between reactivity with p24
in the IB assay with lack of disesase progression in a large study of
103 individuals. Lack of reactivity with p24 in well patients was
reported, as well the finding of strong p24 reactivity in a minority
of patients with AIDS.
Paul et al., (1987) reports the prevalences of antigenaemia and
anti-"core" reactivity in a large number of patients who had AIDS, ARC
or who were asymtomatic. Antigen was detected in 69%, 46% and 19% of
- 233 -
the AIDS, ARC and well patients respectively. Anti-"core" was found in
23%, 54% and 79% of patients in these groups. The finding of high
prevalences of anti-"core" in the AIDS and ARC patients (23% and 54%)
is surprising, and differs from the current study, and those described
by the other investigators in the field. The results could have been
improved by measurement of the titre of antibody in the ELISA. Weber
et al. , (1987) showed a statistical association between titre of
anti-"core" in a specific ELISA between the well and unwell groups in
two cohorts of homosexuals. A similar association between disease
progression and reactivity with p24 in the RIP assay was also shown
for these patients. There was, in contrast, no statistically
significant difference in neutralising titres of HIV between the two
groups. In contrast, Wendler et al., (1987), on the basis of a small
study of neutralisation titres in 6 patients, three of whom had AIDS,
reported an association between fall in neutralisation titre and
progression. These, and other reports, have not resolved the issue of
whether there is an association between neutralisation and onset of
disease, and there is no information at all to indicate whether low
neutralisation titres cause progression, or whether clinical disease
causes the fall in antibody.
In summary, the studies of serological markers of progression in the
Edinburgh haemophiliac cohort have proved comparable to those of other
investigators. Follow-up has allowed a relatively intensive study of
HIV infected individuals. A particularly rapid loss of anti-"core"
antibody was seen in several patients, many of whom developed disease
some years later. Prospective studies should show whether patients
showing this pattern of loss but remaining well have a worse prognosis
than those who remained anti-"core" positive. Antigen detection
correlated less well with progression, although this may be accounted
Gy
forAits relatively delayed appearance; evidence suggests that antigen
may be in the form of immune complexes in the transition period
between loss of anti-"core" and detection of free antigen.
The observed difference in serological and clinical outcome between
the patients, in this cohort in particular, disposes of a number of
theories concerning the pathogenesis of HIV infection. The measurement
of antibody levels over a relatively long period indicates that all of
the patients were genuinely infected. The possibility that some
individuals, particularly haemophiliacs, may be immunised with
inactivated virus rather than truly infected has been often mentioned.
This study indicates that all of the patients, including all of those
who remained well, show evidence of active infection three years after
exposure. Furthermore, there was no correlation between clinical
outcome and infectious dose, although there is some evidence that this
influenced the time to seroconversion.
Another theory to explain the different outcome of infection between
individuals supposes that different strains of HIV may be more or less
pathogenic. While this may be true, the current study shows that
serological responses and clinical outcome may vary when different
patients are infected with the same strain of HIV. Similarly, the
results show that progression is not related to continual re-infection
with HIV. In all but one of the patients in the cohort, it is probable
that the implicated batch was the single source of infection.
This cohort provided the ideal opportunity to study genetic
differences in susceptibility to infection by HIV. Some connection
between clinical outcome and HLA type has been found by Dr M. Steel,
Western General Hospital, Edinburgh in this cohort. There remains the
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possibility of establishing a correlation between phenotype and the
rapid fall in antibody to anti-"core" after infection in some of the
patients, since this may be less likely to be influenced by extraneous
factors than disease progression. Eales et al., (1987) reported the
association between clinical outcome and the mobility of group
specific component, the vitamin D receptor. This has been investigated
in this cohort, both in terms of susceptibility to initial infection
and to clinical progression, but no correlation has been found with
these patients (Dr Ludlam, personal communication). At present, the
reason for these differences between patients remains unresolved.
FUTURE WORK
Monitoring trie cohort in the future using a similar range of tests as
those described above is a priority. Clinically useful information
about the course of infection may be obtained from such study, as well
as helping to select patients for treatment, and monitoring its
effect. Longer study will allow the significance of anti-"core" levels
to be more fully assessed. The evaluation of new tests for
HIV-specific antibody and antigen is facilitated by the collection of
intensively studied sera taken around seroconversion in several
individuals. That the precise time of exposure is known in many of the
patients is very valuable in establishing the specificity of new
assays. A report in press (Lelie et al., 1987a) indicates the
superiority of three new ELISA tests over their predecessors in
sensitivity and specificity. Evaluation of these tests with the range
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Detection of Antibody to Viral Proteins
Following Primary Infection With Herpes
Simplex Virus
P. Simmonds, I.W. Smith, and J.F. Peutherer
Department of Bacteriology, Edinburgh University Medical School,
Edinburgh, Scotland
Sera from patients with primary genital infection with herpes simplex virus (HSV)
were tested by immunoblotting (IB) and radioimmunoprecipitation (RIP) analysis to
determine the protein targets of antibody elicited by infection. The two tests detected
antibody to different antigens: IB primarily detected reactivity with p40, a phosphory-
lated capsid protein, and RIP detected antibody to glycoprotein B, a viral envelope
component. Furthermore, RIP detected antibody at an earlier stage of infection then
IB. A nondenaturing version of IB was developed and used to investigate the role that
the solubilisation of antigen plays in the sensitivity of each test for antibodies with
different specificities.
Key words: antibody response, antigenic targets, nondenaturing immunoblotting
INTRODUCTION
The humoral antibody response to infection with herpes simplex virus (HSV) has
been studied by a variety of serological techniques. Radioimmunoprecipitation (RIP) and
immunoblotting (IB) are two methods capable of showing the protein targets of antibody
elicited by human infection or animal inoculation with HSV. Sera from patients with
previous infection with HSV 1 or 2 contain antibodies reacting with a range of
HSV-specified proteins and glycoproteins [Eberle and Mou, 1983; Gilman et al, 1981;
Teglbjaerg et al, 1986]. However, the sera from patients with recent primary infection of
less than a month's duration contain antibodies reactive with a small subset of HSV
proteins. IB reveals predominant reactivity with p40 [Eberle et al, 1984; Bernstein et al,
1984; Eberle et al, 1985], a phosphorylated protein associated with the nucleocapsid
[Braun et al, 1984]. Other workers using RIP assays have found that the early humoral
antibody response is directed against gB, gC-1, and the major capsid protein (MCP) of
HSV 2 [Ashley and Corey, 1984; Ashley et al, 1985; Zweerink and Corey, 1982],
The different results obtained by the two methods may be accounted for by the
differing solubilisation conditions used in the preparation of the antigen for each assay.
The IB assay uses antigen solubilized in sodium dodecyl sulphate (SDS). This is a
Accepted for publication February 13, 1987.
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192Simmonds,ith,andPeutherer powerfuldeterg nthas lubilisesm joritycellularandviralproteins,b thh resultantlo sofac n ider blepropo tionthantige icde erminants.T tigef RIPassaysiproducedbmild rsolubilisationc n itionsth tpreserveot int e approachingtheirnativeconfiguration.How r,significa troportionfvi lprote ns suchastheMCPofHSV1rinsolubledetergentscommonlyus dnRIanalysi (personalobservation).RIPmethodsalsh ethdisadvantagetspuriousult y arisefromcoprecipitationfp oteinse tinartlysolubilisedaggregatesfc llular membranes[Cros ,p rso alcom unication]. Alternativesoco ventionalIBhabdescribed.Sn wd naHalliburto [1985]describetheimmunoblottingofunhea edherp spr t insrstudi serologicalr latednessofgBHSVwiththerherpvirus .Unheat drt homologouspr teinfthererpesviruseapp arbr adlycross-r ctive,inc ntt theapparents eciess ecificityodenatu dgB. AnotherapproachisthusfdetergentsotaSDS.Heleniudimo [1975]andHele iustl9r viewthnumerousd terg ntt ah eb characterised.Dewaldtl[1975]d scribt olubil sationanubseque telectropho¬ resisofmembrane-associatednzymesiTritonX-100. Theaimoftworkascompareresultste tingse apati ntsh primarygenit lHSV1a d2infectionbyo hRIPIBmeth ds.Ano denaturing versionofIBwasdevelopedandusetinvestigateheses rand rvaluath importancefthesolubilisationc nditionsHSVa t genus dt ee s.Ivi w ofthereportedcross- eactivityfabbitantis ragBHSVw hth rmem rst herpesgroup[Snowdental,1985],patientserawe elsotest df hr s ncef antibodiestvaricellazosterru(VZV),Epstein-Ba rEB dhuman cytomegalovirus(HCMV). MATERIALSANDE HOD CellsandViru VerocellsgrowninEagle'MEM(Gibco)supp ementedwith5%in tivate newborncalfs rum(Gibco)wereusediallexp rim nts;1657[Pe th r,970]nMS [Plummer,1964]wertheHSVand2strainsus dfoproductionfntigen. ControlSera Rabbitanti-HSV1nd2sera,bothpr bleedimmu ised,wer available[Peuther r,1970].Threenegativhum nseracoll ct dfromp tie ts,di toen,f rreasonsunrelatedoHSVinf ction,andp sitiveserumr mlab tory workerithrecurr ntlabialHSV1infe tioerealsoused.Thfoll wingm noclo al antibodies(mcAbs)werkigiftfromDr.ACros ,MRCVi ol gyGl sg w (specificitiesinparentheses):1892(gD-l,gD-2),246C-1),975/ 2B B 3104/23(gE-1),and5 10p ,HSV2).LP 4( D-l,gD-2)APMCP HSV1and2)weremcAbskin lysuppli dbyDr.AM son,Ca bridgeUnive s ty. PatientSera Serawereobtainedfr mpatientsatt ingthgen tourinarymedicine(GUM) clinicattheRoyalInfirmaryfEdinburghwithsymp omspr marge i lHSV infection.Attheirfirstvisitoeclinic,aserumsamplewasob ineddg al swabubmittedforHSVisolation.Thedurationfsymp mspri rtv sitw snot d.
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Thesecondrumwascollectedasubs q ntvisitthcl nic(8-18dayslater). Patientsw reconsider dth vprimaryHSVinfect onfthfir tse uwas seronegativebyimmunoblotting,thsecondrumserop sitiv ,a dHSVisol t . Isolatesweretyp dbyrestrictionenzyma lysistherwork sithlaboratory.Fiv patientsw thrimaryHSV1andfiv th2infect owersel c dfothtu y (ninefemale,oale). Immunoblotting Confluentmonolayersfveroc llswov r idith10pfu/c llHSV2 inasmallvolumefEag e'smediumorsi ilarlyockinfected.Aftbs rptionf1hou at37°C,theinoculumwasrepl cedithEagle'medi m.Ce srharv stedi hglas beadsafter20hourt37°C,pelletedycentri uga ion1,0 0gf5min t ,a washedt icithDulbe coAbuffered-saltsolution( SS).ft rr suspendinginsam l buffercontaining1%SDSa d2-mercaptoeth nol[Laemmli,1970]cell concentrationf5x106cells/ml,th lllysatewashe da1 0°Cfor3minute .Th subsequentpolyacrylamideg lelectrophor sis(PAGE)witadiscontinuousbuff systemwasperformedasdesc ibbLaem li[1970].T lofplwaa pliedt theopfa17cmwide,0%polyacrylamideseparatinggel,cross-l nkewith0.27 N,N'-methylene-bis-acrylamide.Afterelectrophoresis,tgwasblot dv rnightat 4°Cintris-glycinebuffer(0.025Mt is,0.192glycine,pH8 3)at1 5V/cmon nitrocellulosesheet(Schlei herandS u l,DassWeGermany)bytm hoof Towbinetal[1979].henitrocelluloses ew reblock di3%g latin(Sigma,G-2625 St.Louis,MO)intris-b fferedaline(0.5NaCl,0.02T is,pH7 5;BS)for3 minutes.Thisa dllsubsequ nttepsw rperformedrotemperat roarb tal shaker(Luckham,BurgessHill,UK);2.5mmstripsofnitrocellulobearingcellu arand viralproteinswerecutfromthsh tandincuba di hhumanr bbitse m(1:20 dilution)ormcAb(1:100)fo2h rs.AllantibodydilutionsweremadinTBS containing1%gela in.Stripswereashedint och ng sofTBScont in g0.05% Tween-20(BioRad,RichmondCA).Bou dantibo yasdetec ebyincuba ion horseradishp roxi a econjugatedantispeci sIgG(Sigm )tdiluti nf1:250f2 hours.Substratewa4-chl ro-l-napthol(Bi R d)p ep edaccordingt emanufactur¬ er'sinstruction . Radioimmunoprecipitation AntigenwaspreparedasfoIBiththfollowi gm difications:tserum concentrationwasreducedt0.5%,a3hourp.i.;monol yerswashedinDSSa d themediumreplacedwithEagle'sm thioninefr edium(Gibco,Pa s yScotland UK)containing50MCi/ml[3 S]methionine(Amersh m,>8 0/xCi/mMo ,Amers a , UK).Cellswereharvested20our ,washt icthDSS,ndresusp nd dc concentrationf107cells/mliRIPbuff r( %Triton,sodiudeoxy h la ein0.1M Tris-HCl,p7.5)onice;0 1mg/mlDNAaseII(Sigma,D4138and0.02M phenylmethylsulfonylfluoride(PMSF)w rpr s ntinthRIPb ff .Aft r30minut s onice,thec lllysatesw recentrifugedt100,000gfoh utremovins lubl material.Thsupernatewasaliquotedndstor d-70°C.avoicompetit onfo antigenbyIgMpresentithp tientsera,RIPanalysiswperformedi rev r , inamannerresembling"G"capturas ay.Te/dofp ti trr bbits ru5/ mcAbwasdilutedin400/dRIPbuffer:25ofa50v/vsuspensionepharos - proteinA(Sigma)inPBSwasaddedndthmixtureincubat ,keepinges ph rosi suspensionfor2h ratroomtemperature.Thsepharose-proteinAwasthensh din PBScontaining0.05%Tween-20( BST);2/dofHSVrmock-infec edc ll
194Simmonds,ithandPeutherer lysatein375jilRIPbuff rwasthenddedndincubatedfo2h urs.Thsepha ose- proteinAwasashedinPBSTnresusp n ed100lSDS-PAGEamplebuff r heatedfor3minutesI00°C.Ten/Awaremovedfrothsampletitagn spottedonaglass-fiberdi cf rliqusci tillationcounting.Threma nderft ample wasanalyzedbPAGE,forIB.Autoradiographywasperformedf10d yst-70°C onablotftheg liordertpreservehsharpnessftbanddtoi cr a eh sensitivityofdet ction.Coomassieblues ai ngfhg laf rb ottishowedtr nsferf proteinstbc mplete,aparfrv yw akb ndsfsizgre t rth n200KDa. MolecularW ightDet rmin tion Sevenmarkerproteinsw reuoSDS-PAGEg ldescr bedabovestained bycoomassielue.Th yw rafollows(m lecularw ightsinp rentheses):ca bonic anhydrase(29KD ),ovalbumin(45),b vineserummin(66KDa),lactate dehydrogenase(36.5KD ),glutamatedehydrogenase(55.4KD ),phosphorylaseB(97.4 KDa),andmacroglobulin(170K .Apl tfRv l egainstlo .molecularweight wasanapproximatest aightlineithr nge30KD120a,ndw su df r molecularweightdeterminationfv r lprote ns. NondenaturingImmunoblotting Antigenpreparationw sesse tiallyadescribedihRIPmethod,exceptthat proteinswerenotradi labeled,nd1%taurodeoxycholicaci ,sodiumlt(Sigma; TDCA)wasusedinpl ceoftheTritonandsodiumde xycholate.Elec r phoresisf TDCAsolubilisedmaterialwasadescr b dfIBiththfollowingmodif catio s:the acrylamideconcentrationwasreduc dto7%;allstepsw redoni coldr m(0-4°C); andthe0.1%SDSitg landelectrodebuff rswar plac dith0.5%TDCA(i stackinggel).Blottiwasp rformedintheabsencefde rg ntitri - ly inebuff r,pH -8.3,initiallywithnitrocellu osesh etsntanodiccath dicsidesfg l;l t proteinmigratedtow rthca hode,islat rprecautionsdiscont ued.Co mas ie bluestainingofthg lafterblottishowedtr nsferprot insbess tiallyc mplete. Duringdevelopmentfth smethod,therd terg sw reusi lacefTDCA.t n X-100and3-[(3-cholamidopropyl)-dimethylammonio]-l-propane-sulfonate(CHAPS) weretestedusinghameprotocolsde crib dab ve.Tht tingfrawithbl t d antigenwascarri doutdesc ibedithIBsection. HCMV,EBVandVZAntibodyMeasurement HCMVantibodieswerestimat dbyanindirectELISAechnique,usinggl c ne extractedCMV-infectedcellsastig n.Ace one-fixedR jic llsw reui immunofluorescent(IF)techniquef rdetectionfEBVgGantibody.VZ antibodieswermeasuredi st ndardcomplementfixat ost. RESULTS SpecificityofIBandRIPAssays Therewasnosignificantre tivityofanythserawi hm ck-infectedat r al eitherassay(datanotsh wn).Tspecificityotwom thodssa ses edbe ting preimmuneandimmu izedrabbita tis rannegat vepositiveh ansew th type-homologousHSVanti enbythme h ds(TableI,Figs.1,2)B thpreimmune
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'Countsliq idscintillationc i gf1/0 himmunepre pitate. bNameofproteingiv ,rMWinKDaftidentified. cProminentbandsiboldfac . rabbitserafail dtoreactineitherm t op odu ngdetect leb ds(F g.1,lan s3 11;Fig.2,lanes0)andosignificantact vi yosci tillatiocou ing.Allthre negativehum ns rawe eu r activeagainstHSV1d2antigen(Fi .,la5 Fig.2,lanes3-5,12-14).Bycontrast,thimmunisedrabbitseraddult convalescentserumprod cedel tedc untsintheRIPassaydumeroba d bothIBandRIPssays,reflectingbroadpolypeptides eci icities(Fig.1,lan s462; Fig.2,lanes,6,11). IdentificationofPr teinsithRIPAss y Figure1,lanes7-10,13,showsthreactionofmcAbiRIPsay;gD-1(l 7)andgD-2(notshown)bothappearsbr adanfapproximateMW66KD ,nd thebandisdistort dylargmountsofco igratingIgG.Theialsow akerb ndf MW121KDainlane7,probablytheresultofc precipitationgC-1.Richmanel [1986]showedt atamcAb,LP10,precipit tedgG-1roducingbanofsi lar mobilityandappearancetgD-1inth irRIPass y.Biwasu dcros -linkerit PAGEanalysisoftheprecipitate.Ther for ,bandsit iacann tpos tively identifiedaseith rgD-1orG-1theRIPandIBassaysu eiwork,dllb referredtoasgD/gG.C-1(lane8)ppearssprominentbandoMW121,with weakerbandst75Knd4 ;gB-1(l e9)h stwopromin ntbandsfsiz118K 112K,witht olo ermoleculareightbandsf56Kand0.Thesprobablyrepre en cleavageproducts.gB-2(lane13)h smajorbanof10Kdsimilarlow rmolecul r weightbands;g£-1anotdetect bleithRIPssayu ingm Ab3104/23.McAb5 10 (p40)producedweakban sofMW47.5,452.5KDithHSV1antigen(la0), andnobandswithHSV2.AP2(MCP)producefaib n sofapparentMW158KD withHSV1and2(d tanotshown).
196Simmonds,ith,andPeutherer 170-
9101123
Fig.1.Reactionofcontrolseraintheradioimmunopr cipitation( IP)a say.La snd2,st da dprotei (molecularw ightsinbrackets),c omassielustain;la1,c rbon canhydra e(29kilod lt n(KDa)), ovalbumin(45KDa),bovineserumalbumin(66KD );lane2,lactatdehydrogenas(3 .5KD ),glut m te dehydrogenase(55.4KDa),phosphorylase(97.4K a),andmacrogl bulin(1 0D );lanes3-1 ,re tionof controlserawi hherpessimplexv rusty1(HSV)antig niRIPa say;lanes3d4,preble dHSV immunisedrabbitanti ra;lane5a d6,egativco v lescentad lthu ns r ;lan7,m noc o al antibody(mcAb)1892(gD);lane8.246( C);l9.2975/22(gB);lan10,5010p4 );lanes11-13,reaction ofcontrolserawi hHSV2antigen;lan s11nd2,prebleedaHSVimmunisr b tanti ra;la13, mcAb2975/22(gB). IdentificationofPr teinsithIBAss y OnlyLP10(gD),2462(gC-1)a d5010werereactivei hdenatureprote nith IBassay.gD-1(Fig.2,lane7)andgD-2(notshown)appe rb ndsofp roximateMW 57KDa.McAb010reactswithp4ofb thHSV1and2(lanes9,6),wh re s24 2 (gC)producesban sof102,0d9KDa(la e8).Itcanes eth tpr einshav differentapparenMWsinthwosystem . TDCAIB Preliminaryexperime tsw rcarr edoutinord rtfisuitablde e gent. Figure3,lane1showstresolutionac iev dbyele trophoresisofc llu apro eininth presenceofTDCA.ritoandCHAPScausesm aringfpr t insandwer ,ther fore, notusedfurther.Allsubsequenexperimentsdescrib dinthictionsTDCA. Water-solublemarkerp oteinsdn tfrac ionats le yothb sisfs zithig system,unlikeSDS-PAGE.Carbonicanh dras(29KD )hRfv lueo0.7, ovalbumin(45KDa)hadnRfva e0.31,nbo ineserumalbumin(66KD )h d valueof0.72(d tanotshown).Therefor ,ba dscanncribedmolecu arweigh ,s arereferredtobyh irRfv lues.Lan2-8,Figu3s wtresultsotestingh variouscontrolserabythismethod.T ereact nofcon lescentadults r mwiHSV-1
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Fig.4.Reactionoffirstandse ondp tienterainimmunoblo tinga say.La s1-4,hersimplexviruty
1(HSV)antigen;lanes5-8,HSV2a tigen;l d,firstseconderaofpati nt;lan s3d4s ra ofpatient5;lanesand6,patient9lane78pati nt. AntibodyResponseiPatientW hPrimaryGe it lHSVInfec Theser sultsarpr ent dinTablII.Nonftfirstse ah ddetectable antibodybyIB(Fig.4,lanes1,3,5,7),us xoutftewerepositiveyRIPdTDCA IB(althoughpatients9and10g veconflictingresultsbytl terwom h ds).Th countsdetectableinthemmunprecipitateobta n dfr mw klyposi ives rdn correlatewithdetectionfbandsySDS-PAGE.Tht rg totib dyinefirss a, asmeasuredbyRIP,w sgB(Fig.5,lane3);iadditiontyp2nfectionselicitedant body toanotherpr teinofMW130K(Fig.5,lan7).TDCAIBreveal da tibody specificitytogBinhixpositivefir tsera(Fig.6,la s37).TwopatientsthHSV1 infectionalsodevelopedantib dytpro einofRv lu0.03( an tshown). Allsecondrawe epositivfoant bo ytHSVbyllthr ete t .S awer




Fig.6.Reactionofpatients' eraithetaurodeoxycholicidimm obl ttingsa .Leg nsforFi u4. weaklyreactiveinthises .Tfi ts rromt ixpat entsw thsymptomfou daysormo ewerllp sitivbRIP,ndfiv fthsixwerep sitivTDCAIB. DISCUSSION Thepreimmunisedrabb ts raandtthnegativhums rhoweli tl detectablenonspecificreact vityithIBa dRIPass ys.Nonspecificrea ions RIPassayrecommonlyobserv dwithglyc proteins[Zwee inkandCor y,1981;r personalcommunication].Inparticul r,detergent-sol bilisedEhb shownave Fcbindingact vity[Bau kendSpear,1979].Nonspecif cbi d ngactivitym yh ve beenavoidedythdiffer ntm tho ologyoftRIPassaydescribeh .Allantiboi attachedbytheFregionopr t iAduringinc ba ionwiHSVanti ,ossibly preventingthunwantedreactiowithgE.Treasoforthslig tacti nfe negativehum ns rawithgBitheTDCAIBass ynocl rpre nt.
202Simmonds,ith,andPeutherer McAbsofknownspecificityw reomhelpitheidentificationbandt threeassays.Th ylsorev aledt tseveralHSVp ot insappearedmoton band,complicatingthesubsequentanalysis.gB-1pp arswomafMW112 and118KDa.Theserprobablythprecursormaturefo msofpolypeptide, respectively.Thetwolo rmolecularightbandsf56and0K( lsoob rvedt gB-2)areprobablycleavagepr ducts,sinceth ynotobserv diRIPa saf Ashleyeta[1985],whoperform dlincubations4C.40ndthM Pappears faintbandsitheRIPassayonreactionwi hppropriatemcAbs,r b blyrefl cting thelowsolubilityft eseprot insindete g ntmploy d.McAallowh identificationofp40,gC-1andDtheIBssay.b thHSV12re ctedwi h mcAb5010,producingacomplexfveryromin ntbands.gDndC-1hdifferen apparentmolecularweightsinRIPndIBassays.Thlo erpp rentMWfgDt IBassaymaybeaccountedforythebse cefcomigr tinggGatdist st ndi theRIPassay.T121KDformofgC-1undit saynotdetectedIB assay;insteadth rerlowermolecularightf rms.Treasonsidiffer ncea unclearatpres nt.Th rewasslighcoprecipi tionfgC-1by1892( D),uverall, proteinsappearedtprecipitateinde end ntlynhRIPssay.Tide tific iof proteinsisfurthercomplicatedbythan malousmigr tionfglycoproteinsSDS- PAGE.Theirmigrationisnfluencedbytcross-linkeru ethg lsy t m.F example,gG-2hasnapparentMWof92KwhBiisused[ r d ntl,1984], whereasexperim ntersusingdiallyltartardiamidefingG-2oh vMWf130 [Roizmanetal,1985;Olofsso86].Forthisrea on,itdif icultco pare resultsobtainedbydiff rentinvestig tor . Detergentsforimmunoblottingsh uldb fl wmice arzeallowr igra ion ofdetergent-solubilisedmater alith l,bsol blhr ughoutngfpHvalu s usedindiscontinuousg lbuff rsystems,aitowidera gfpr tein .Thes propertiesaretbfoundinTDCA,whichh shdvan agev rmorcommonly useddeoxycholica iinbeingfr lysolubleel wpH7.Icontrasttrit n,TDCAha micellarsizemiltoSDS,andher fo e,houldn tr strictm bilityfs lubi ised proteinsduri gelectrophoresis.PAGEwithTDCAs lubilisedmaterialg vm d ate resolutionofseveralc ll l randviraprot ins.Whbl tsuchg lw eusediIB assay,severalvirantigenscouldbdet ctythrabbitra.Twoft esel identifiedasgBndDbymcAbs.AlthoughTDCAsegativelychar ed,oeot causefractionationfproteinsr lynsizbas s,hexperim ntw thm k r proteinsshows.TlowmigrationrateofgBn7%acryl midel(Rv u1.5(HSV 1)and.3(HSV2))suggeststhagBipres ntnoli omericfothisy t m, perhapssimilartohedimericforobse vedbySn wdenandHalliburton,[1985]t i modificationfIB.Theseauthorsr p tthecr ss-reactivitygB-1,2nd homologouspr teinfEHV-1andBMV.Thlackcorrelationbetw etibody HCMV,EBandVZVantibodytogBi nyfourthreessamethodsdisc nt thepossibilityfcros -speciesantibodeact vitinfluen ingurl s. RIPandconventionalIBmethodsusedifferenteterg ntsolub lisehan ig . SDS,usedinIB,solubilisesalmost)!protein,b tdisr pthe t arystructuref proteins,leadi gtossofp port onoss bleepit pes.RIPas aygen rallyu milderdetergentshap eserveantigenicd rmina tsfor dbytertiarystructu eof theprotein;however,solubilisat onfvir lp insinc mplete,andysubs proteinscabstudied.Thisdifferenceinol b lisationun oubtedlyc ntr butesth differencenresultsoftheIBa dRIPm thodsfou ispaper.H wever,t rr
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severalmethodologicaldiffer ncesbetwe nthassaytylcontribute. Dependingothem thod,antig nisith rolu iorbounolphase.It RIPmethod,thesensitivityofesiafunctionp cificradi activit antigen,whereasiIBssay ,thsensitivitydep dsoamountftigenvailabl forreactionandthese sitivityfseconantib dyndubstra edet ctb antibody.CoprecipitationfproteinsithRIPssaycau enonspecificityat irrelevanttoIB.Proteinsincorpor teradio ctivityw thdiff i geffic enciesurh labelingprocedurerequiredfothRIPassay.Fexampl ,Ashl yt[1985]oun thatgGw slabeledpoorlyby[35S]m thi nine,andn ibodticouln tdetect theirRIPassay. TDCAIBismethodologicallysimilartoconventi nal;h ydiffer ceb i thechoiceofdetergent.It,her fore,giv saopp rtunityass simp tan solubilisationcond tionsftheantigenindependentlyloth rconsiderati ns.B hRIP andTDCAIBdetectedgBntibodyis veralofthfirster ,whereasllen gative bySDSIB.Allsecondrawe epositiveyathre s,utargediff r nt. Serat stedbyDSIBshowemajorre ctivitywithp40,e k randrvariable reactionwi hotherprote ns,articularlyitgD( rossiblyG-1)andpr fMW 107K.Secondserafrompatientsw thHSVinf onbyRIPhadn ibodytgBnd onecastgC,whereasyp2sere ctedi hB-2MCPandh130Kprotein.A thisstageeidentityof130KDaprot inca notbascertained.gG-2woul expectedtoappearar und90-100KsinceB swasus dcros -linker.ICP8h apparentMWof128K,ndthisispossiblecandidat .TDCAIBdetectedpr dom ¬ nantlygBre ctivityithes co dra.Ov r ll,IBcontrastswithRIPa dTDCA intsdetectionofan bodyp40,ndifailuretd tectntibodygB.Thef il r RIPandTDCAIBtodetectntibodyp40mayresultfromorsolu ilitfi ild detergents(asshownbytweakreactioofmcAb5010inhRIPs aynd nonreactivityithTDCAIBassay).epitopesfgBrpre umablysen itive denaturationbySDS,l d gtohefail reofIBtd tectgBantib dyi ny firstsera.Over ll,ther ultsofRIPandTDCAIBrinagreementcontraswith thoseofc nventionalIB.Therefore,edis pancyiSDSa dRIPresultsobs rved inthispaperandbyprev ousworkersstudyingantibodyrespons st imaHSV infectionmaybeac ountedforythesolubil s tioncond ti nsfta t ge ,dn theoth rmethodologicaldiffer ncesbe we ntassays. Thereisapossibleobjectiont isconclus n.Pr t nAusedRIPaydo notreactwithIgG3,whereastenzyme-linkeda tihumanus dihBs y wouldbeexpectetr actithalhsubtyp sofhum nIgG.T sayle d detectionofiff rentapparentntibodyspe if citiesir fut d,fi s ,bythevid ncf Eberleta[1985],whoobtainedsim larresu sinIBithproteinAndantihumgG conjugate,a dsecond,bythedetecti nofgBantibodiesTDCAIBus gam conjugateasusediconventionalIB. ThedetectionofantibodyitfirstserabyRIPndDCAIBas aysw s dependentonthuratiofsympt msri rtatte dingGUMcli ic.Thfirstra fromthewopatientsthsymptomf rnlythredaysw enega ivebRIPssand nomorethanweaklyp sitivbyTDCAIB,whereass rfrompati ntsthymp om offourmoredaysurationwerreactivintheRIPssay(fiv tfsixpo ib TDCAIB).Secondseratakenfromwopatie ts(nos5nd9t1921d ysft r onsetfsymptoms)hadbroaderpolypep ides ecifici sinthIBaTDCAtests highercountsthanseco deratakefromt rixpatw thsympt mfr
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Routine testing of all blood donations for antibody to LAV/HTLV-III was
introduced throughout the United Kingdom on 14 October 1985, using scre¬
ening tests manufactured by Wellcome Diagnostics (UK) and Organon-
Teknika Ltd. In England and Wales, confirmatory testing was undertaken
by several centres of the Public Health Laboratory Services, which used
a varying range of confirmatory tests. In Scotland two regional virology
laboratories undertake all confirmatory work for the Blood Transfusion
Service using immunoblotting as the primary confirmatory procedure.
SCREENING PROGRAMME RATIONALE
The intentions of the donor assessment protocol are to ensure that no donor
is informed of a positive test result until this has been confirmed by a positive
immunoblot, and secondly to ensure the immediate and permanent removal
of any suspect donation from the blood supply. In addition, we feel it is vital
to have such a schema to ensure that no donor is left in an 'unclassified'
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position due to an unconfirmed positive screening test result. This latter
situation could lead to repeated calls to donate followed by immediate
discarding of the blood, which is clearly not an acceptable position.
RESULTS
Table 1 summarizes the United Kingdom donor testing results from October
1985 to the end of February 1986. This emphasizes the very low prevalence
in the United Kingdom overall. The prevalence of LAV/HTLV-III antibody
in the West of Scotland is identical to that in the UK as a whole. However,
in the East (accounted for by four different blood collecting centres) the
prevalence is six times higher. It is important, therefore, to determine
whether these substantial differences can be explained by factors related to
the performance of screening or confirmatory testing, or whether they are
due to donor factors such as a high prevalence of infection in the community,
or a tendency for donors in high-risk groups to disregard the prohibition on
blood donation.




Tested 1,052,086 122,667 63,370 59,297
Confirmed positive 19 8 7 1
Prevalence 1 in 55,372 1 in 15,333 1 in 9,053 1 in 59,297
With respect to Scotland, the evidence favours the interpretation that the
differences between East and West are due to the large difference in preva¬
lence of infection between certain parts of the country. Sixty-five per cent
of intravenous drug abusers (IVDA) in the East are LAV/HTLV-III anti¬
body test positive, in contrast to 4.5% of IVDA in the West.2 Eight antibody-
positive donors in Scotland were found to be IVDA.
In the Scottish Blood Transfusion Services experience to date, the Well¬
come competitive ELISA has yielded no repeatably positive results other
than those which have eventually been confirmed by immunoblotting. Thus
our two reference laboratories have received referred samples from eight
donors and all have been strongly immunoblot-positive. This has led to a
level of concern about the sensitivity of the screening test, and we have
therefore concentrated in the past few months on assessing the relative
sensitivity of various screening ELISAs and of our immunoblot confirmation
procedure to try and determine whether greater sensitivity is needed to
reduce any risk of false-negative results. Initial studies on about 10,000
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donors and on high-risk patients indicated, as have other reports, that the
Wellcome screening assay is at least as sensitive as other screening tests. We
have recently concentrated on the serological events which occur around the
time of seroconversion, as it is here that we feel the risk of a failure in a
donor screening test may be greatest, either because the initial response may
contain very low levels of antibody or because the specificity of the early
antibody response could be very restricted. For example, if the very earliest
antibody response is to a large envelope glycoprotein, certain assays could
fail to detect this.
The immunoblot procedure which has been used throughout this work is
based on the methods of Laemmli3 and Towbin et al,4 We are aware of a
number of modifications which are likely to increase sensitivity and these are
being assessed. Tables 2 and 3 illustrate some of the results obtained from
serial samples from donors and transfusion recipient. Table 2 includes the
two subjects in whom, on one or more occasions the immunoblot was clearly
positive when the screening ELISAs were equivocal or non-reactive. In the
case of the blood donor, at the time the blot became positive there was
detectable reactivity in the Wellcome assay, but this was only noted by the
use of a more critical method of interpreting the results than that which is
recommended by the manufacturer. In the case of the blood (platelet)
recipient, there is a series of samples consistently positive by immunoblot
(reacting only in the pl9 and p25 region) and consistently non-reactive by
the ELISA tests.
Table 3 shows a similar study on two recipients of coagulation factor
products. In each of these subjects, reactivity observable in the screening
assay at the same stage as antibody was detected by the immunoblot. These
early data show that reactivity are no grounds to be complacent about the
performance of either donor screening or confirmatory testing methods.
DEVELOPMENT OF IMPROVED TESTS
Some possible lines of future technical development include improved immu-
noblots, radioimmune precipitin assays (RIPA), competitive immunoassays
(capture or competition) and flow cytometry detection of viral coded cell
surface antigens. We believe it is important that more work be done on
optimizing the immunoblot procedure and in particular to compare it directly
with the RIPA, since there is evidence from various sources that the RIPA
tests perform better in detecting antibodies to the high molecular weight
components of the envelope. It is important to know if and when these
antibodies may be missed by the immunoblot, since without this information
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Secondly, the appearance of alternative competition immunoassays using
well-characterized core and envelope antigens produced by recombinant
DNA methods or by synthesis will provide an excellent tool for investigating
the fine specificity of antibodies detected by other methods; and by using a
range of antigens and monoclonal antibody probes, competitive assays will
probably help to define a small number of epitopes which are essential
for screening tests. Eventually such assays are likely to become routine
confirmatory procedures, or indeed largely remove the need for secondary
tests.
We should be preparing to respond to a growing need to give additional
information about infectivity of blood donors who are found to be antibody-
positive. While direct antigen assays on body fluids probably may not for
some time be sufficiently sensitive for this application, it is desirable to pursue
rapid improvements in immunoassay methods for detecting virally coded
antigens. It may prove very useful to have a 'user-friendly' system which
permits the establishment of a short-term culture of whole blood in the
presence of a suitable lymphocyte stimulant, followed by a simple procedure
to detect antigen or other viral product in the supernatant.
Finally, the safety of blood and blood products will only be assured by a
combination of technical excellence and good management. I wish to
conclude by suggesting that there is a continued need for national and inter¬
national agreement about what confirmatory procedures are of most value,
about which laboratories should do them, and about how the results should
be interpreted. Additionally, there should be an effective system of national
quality assessment of testing laboratories and of commercially produced
test kits for screening and confirmation. Perhaps most important, individual
laboratories should operate and report daily QA schemes which are correctly
designed to test the overall performance of the whole testing facility. There
must be properly established ways for the results of these activities to be
reported, and to make sure that effective corrective action is taken when
things are not going right.
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DISCUSSION
Dr Deinhardt
Regarding the plea of Dr McClelland, I wanted to mention that at the last
meeting of the WHO collaborating centres on AIDS exactly the same plea
for standardization of reagents, of sera and of methodology was made. In
the meantime one standard reference serum containing antibodies against
the major viral antigens was provided by the USA, and 10,000 ampoules
of a reference serum have been prepared and lyophilized for the German
Association against Viral Diseases by Dr Habermehl in the Federal Republic
of Germany. In addition, a standard antigen for immunoblots as well as
immunoblot strips has been prepared, and can be obtained for standardiz¬
ation in limited amounts. These reagents have been evaluated by more than
20 laboratories both in Europe and the USA. This is obviously only a small
beginning, but you should know that these materials are already available.
Dr McClelland
May I just enquire about the contact and access to these materials. Would
that be through yourself Professor Deinhardt?
Dr Deinhardt
Yes, or through Dr Assaad or Dr Petricciani at WHO.
